



(43) International Publication Date  
21 April 2016 (21.04.2016)

- (51) International Patent Classification:  
*A61K 38/08* (2006.01) *C07K 14/47* (2006.01)  
*A61K 48/00* (2006.01)
- (21) International Application Number:  
PCT/US2015/055380
- (22) International Filing Date:  
13 October 2015 (13.10.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
62/063,909 14 October 2014 (14.10.2014) US
- (71) Applicant: RIPTIDE BIOSCIENCE, INC. [US/US]; 941 Railroad Avenue, Vallejo, California 94592 (US).
- (72) Inventors: JAYNES, Jesse M.; Riptide Bioscience, Inc., 941 Railroad Avenue, Vallejo, California 94592 (US). LOPEZ, Henry W.; Riptide Bioscience, Inc., 941 Railroad Avenue, Vallejo, California 94592 (US). MARTIN, George R.; Riptide Bioscience, Inc., 941 Railroad Avenue, Vallejo, California 94592 (US). YATES, Clayton; Riptide Bioscience, Inc., 941 Railroad Avenue, Vallejo, California 94592 (US). GARVIN, Charles E.; Riptide Bioscience, Inc., 941 Railroad Avenue, Vallejo, California 94592 (US).

(74) Agent: SCHERER, David C.; 1900 University Avenue, Suite 200, East Palo Alto, California 94303 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PEPTIDES HAVING ANTI-INFLAMMATORY PROPERTIES

Figure 1



(57) Abstract: Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.

## **PEPTIDES HAVING ANTI-INFLAMMATORY PROPERTIES**

### **CROSS-REFERENCE TO RELATED APPLICATIONS**

[0001] Pursuant to 35 U.S.C. § 119 (e), this application claims the benefit of priority to United States Provisional Patent Application Serial No. 62/063,909, filed October 14, 2014, the disclosure of which application is hereby incorporated by reference herein in its entirety.

### **FIELD OF THE INVENTION**

[0002] Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.

### **BACKGROUND OF THE INVENTION**

[0003] Under normal conditions, inflammation is a process that helps an animal recover from injury. Acute inflammation is the initial response of a tissue to harmful stimuli. It involves a complex, highly regulated process that begins when cells present in the injured tissue, including macrophages, dendritic cells, histiocytes, Kupffer cells, and mastocytes, sense molecules associated with the injury and become activated. Upon activation, these cells release inflammatory mediators, such as vasodilators. The vasodilators induce increased blood flow and permeability of the blood vessels in the vicinity of the injury. This, in turn, results in the increased movement of plasma and leukocytes (including neutrophils and macrophages) from the blood into the injured tissue. Because inflammatory mediators are, in general, rapidly degraded, acute inflammation requires constant stimulation in order to be sustained. As a result, acute inflammation ends once the harmful stimulus is removed.

[0004] Various agents, including but not limited to bacteria, viruses, physical injury, chemical injury, cancer, chemotherapy, and radiation therapy, can, depending on the specific agent and the genetic makeup of the animal exposed to it, cause prolonged and excessive inflammation. Such inflammation, known as chronic inflammation, is believed to be a contributing factor to many widespread and debilitating diseases, including heart disease, cancer, respiratory disease, stroke, neurological diseases such as Alzheimer's disease, diabetes, and kidney disease. The result of chronic inflammation is the destruction of normal tissue and its replacement with collagen-rich connective tissue. Collagen-rich connective tissue, also known as scar tissue, exhibits

diminished tissue function as compared to normal tissue. Persistent and prolonged formation of scar tissue, in turn, leads to fibrosis. Fibrosis is among the common symptoms of diseases affecting the lungs, skin, liver, heart, and bone marrow, and is a critical factor in diseases such as idiopathic pulmonary fibrosis, scleroderma, keloids, liver cirrhosis, myocardial fibrosis, diabetic kidney disease, myelodysplastic syndrome, and other disorders.

[0005] Studies of chronic inflammation and fibrosis have indicated that, regardless of the activating agent and the tissue affected, a common network of signaling proteins tend to function together to establish the pro-inflammatory state. This network of signaling proteins includes a number of different cytokines, cytokine receptors, transcription factors, and micro RNAs, including TGF $\beta$ , TGF $\beta$ RII, and miRNA19b.

[0006] Despite growing knowledge about conditions that involve excessive inflammation, such as chronic inflammation and fibrosis, treatments for such conditions remain elusive. Many drugs and other substances have been shown to have anti-inflammatory activity, either *in vitro* or *in vivo*, but for many indications caused or potentiated by inflammation, there are still no therapies. In addition, many anti-inflammatory therapies are associated with harmful side effects. Thus, there remains a critical need to identify therapeutic agents that reduce inflammation without harmful side effects.

## SUMMARY OF THE INVENTION

[0007] The present invention is based, in part, on the discovery of novel peptides that have powerful anti-inflammatory activities *in vitro* and *in vivo*. The present invention is also based, in part, on the discovery that peptides of the invention specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins. The present invention is also based, in part, on the discovery that the peptides of the invention are sufficiently stable in the circulation to allow for intravenous administration.

[0008] Accordingly, in one aspect, the invention provides a composition comprising an anti-inflammatory polypeptide. In certain embodiments, the anti-inflammatory polypeptide is 3 to 24 amino acids residues in length and includes a striapathic region consisting of alternating hydrophobic and hydrophilic modules. In certain embodiments, each hydrophilic module is made up of a sequence of one or more (e.g., 1-5, 1-4, 1-3) hydrophilic amino acid residues. In

certain embodiments, each hydrophobic module is made up of a sequence of one or more (e.g., 1-5, 1-4, 1-3) hydrophobic amino acid residues.

**[0009]** In certain embodiments, the striapathic region of an anti-inflammatory peptide includes m hydrophilic modules and n hydrophobic modules, with m and n each being a positive integer. For example, in certain embodiments, the striapathic region includes two hydrophilic modules and two hydrophobic modules (2:2), two hydrophilic modules and three hydrophobic modules (2:3), three hydrophilic modules and two hydrophobic modules (3:2), three hydrophilic modules and three hydrophobic modules (3:3), three hydrophilic modules and four hydrophobic modules (3:4), or four hydrophilic modules and three hydrophobic modules (4:3).

**[0010]** In certain embodiments, the striapathic region of an anti-inflammatory polypeptide is at least 5, 6, 7, 8, 9, or 10 amino acid residues in length. In preferred embodiments, the length of the striapathic region is between 7 and 12 amino acid residues. In certain embodiments, the striapathic region makes up at least 25% of the length of the polypeptide. For example, in certain embodiments, the striapathic region comprises at least 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the length of the polypeptide.

**[0011]** In certain embodiments, the striapathic region of an anti-inflammatory polypeptide adopts a helical secondary structure. Examples of helical secondary structures include  $3_{10}$ -helices,  $\alpha$ -helices,  $\pi$ -helices, and poly-proline helices. In other embodiments, the striapathic region of an anti-inflammatory polypeptide adopts a beta-strand secondary structure. In preferred embodiments, the striapathic region of an anti-inflammatory polypeptides has an amphipathic conformation.

**[0012]** In certain embodiments, an anti-inflammatory polypeptide comprises, consists essentially of, or consists of a striapathic region having a sequence that conforms to any one of the structural formulas disclosed herein (e.g., any one of Formulas I-LIII). In certain embodiments, the anti-inflammatory polypeptide is one of the polypeptides listed in Tables 3-9. In other embodiments, the anti-inflammatory polypeptide has at least 70%, 80%, or 90% homology with any one of the polypeptides disclosed in Tables 3-9.

**[0013]** In certain embodiments, an anti-inflammatory polypeptide binds to at least one signaling protein. In preferred embodiments, the anti-inflammatory polypeptide binds to at least one signaling protein *in vitro* and/or *in vivo*, with sufficient affinity to modulate the activity of the signaling protein. Examples of signaling proteins that the anti-inflammatory polypeptides bind



to include proteins that function as pro-inflammatory cytokines, proteins that inhibit macrophage activity, or protein that regulate histone function. In certain embodiments, the anti-inflammatory polypeptide binds to a protein target selected from the group consisting of NFkB class II proteins (e.g., Rel A, Rel B, cRel, NF-kB1, and NF-kB2), TGFβ, Notch receptors (e.g., Notch1), Wnt receptors (e.g., Wnt8R), TRAIL, EGFR, interleukin receptors (e.g., IL6R, IL10R), cyclin dependent kinases (e.g., CDK6), CD47, SIRP-α, transglutaminases (e.g., TGM2), LEGUMAIN, CD209, FAS, programmed cell death protein 1 (PD-1/CD279), mitogen-activated protein kinase kinase 7 (MKK7), ribonucleotide reductase (RNR), and histone methyl transferase. In preferred embodiments, the anti-inflammatory polypeptide binds to two, three, four, or more such signaling proteins. For example, in certain embodiments, an anti-inflammatory polypeptide binds to an NF-kB Class II protein (e.g., RelB) and at least one other signaling protein that functions as a pro-inflammatory cytokine, an inhibitor of macrophage activity, or a regulator of histone function. In preferred embodiments, the anti-inflammatory polypeptide binds to the NF-kB Class II protein and at least one other protein target, with sufficient binding affinity to each target to modulate the activity of both targets *in vivo*. In preferred embodiments, an anti-inflammatory polypeptide binds to the dimerization site of an NFkB Class II protein (e.g., RelB).

**[0014]** In certain embodiments, an anti-inflammatory polypeptides binds to a carrier protein in the blood (e.g., serum albumin).

**[0015]** In certain embodiments, an anti-inflammatory polypeptide is modified to include, for example, a linker, a carbohydrate, a lipid, or a polymer (e.g., PEG). In certain embodiments, a first anti-inflammatory polypeptide is linked to a second anti-inflammatory polypeptide so as to form a multimer, such as a dimer. In certain embodiments, the dimer is a homodimer. In other embodiments, the dimer is a heterodimer. In certain embodiments, the linker is a peptide linker. In preferred embodiments, the peptide linker forms a peptide bond with the C-terminus of the first anti-inflammatory polypeptide and a peptide bond with the N-terminus of the second anti-inflammatory polypeptide. In certain embodiments, the linker is a biodegradeable linker. In certain embodiments, the linker is a disulfide bond. In certain embodiments, the disulfide linkage is formed by a pair of cysteine residues (e.g., one cysteine residue from each of the polypeptides being linked).

**[0016]** In certain embodiments, the anti-inflammatory polypeptide is linked to a molecule other than another anti-inflammatory polypeptide. For example, the anti-inflammatory polypeptide

can be linked to a label or a chemotherapeutic agent. In certain embodiments, the linker is a biodegradable linker. In certain embodiments, the linker is a di-sulfide bond (e.g., involving the sulfhydryl group of a cysteine residue located at the C-terminus or N-terminus of the anti-inflammatory polypeptide).

**[0017]** In another aspect, the invention provides pharmaceutical compositions that comprise an anti-inflammatory polypeptide and a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition comprises a single type of anti-inflammatory polypeptide. In other embodiments, the pharmaceutical composition comprises a combination of two or more anti-inflammatory polypeptides. In preferred embodiments, the pharmaceutical composition is substantially free of blood proteins and/or metabolites found in the blood. In other embodiments, the pharmaceutical composition includes serum albumin (e.g., human serum albumin). In preferred embodiments, any serum albumin present in a pharmaceutical composition is recombinantly produced and/or substantially free of other blood proteins and/or metabolites found in the blood. In certain embodiments, the pharmaceutical composition comprises 1 mg to 1000 mg (e.g., 10 to 400 mg, 20 to 300 mg, or about 25 to 250 mg) of an anti-inflammatory polypeptide.

**[0018]** In another aspect, the invention provides methods of treating a subject by administering to the subject a composition (e.g., a pharmaceutical composition) comprising an anti-inflammatory polypeptide. In certain embodiments, the subject is an animal, such as a mammal (e.g., a human). In certain embodiments, the subject has elevated levels of inflammatory cytokines, is suffering from a chronic inflammatory condition, or is likely to develop a chronic inflammatory condition. In certain embodiments, the chronic inflammatory condition can be irritable bowel disease, ulcerative colitis, colitis, Crohn's disease, fibrosis, idiopathic pulmonary fibrosis, asthma, keratitis, arthritis, osteoarthritis, rheumatoid arthritis, an auto-immune disease, a feline or human immunodeficiency virus (FIV or HIV) infection, or cancer. In certain embodiments, the cancer is colon cancer, breast cancer, leukemia, lymphoma, ovarian cancer, prostate cancer, liver cancer, lung cancer, testicular cancer, cervical cancer, bladder cancer, endometrial cancer, kidney cancer, melanoma, or a cancer of the thyroid or brain. In certain embodiments, the composition is administered in combination with a chemotherapeutic agent, immunotherapeutic agent, and/or radiation therapy.

[0019] These and other features and advantages of the compositions and methods of the invention will be set forth or will become more fully apparent in the description that follows and in the appended claims. For example, suitable anti-inflammatory polypeptides may be identified by use of the Structural Algorithm described herein. Furthermore, features and advantages of the described compositions and methods may be learned by practicing the methods or will be obvious from the description.

### **BRIEF SUMMARY OF THE DRAWINGS**

[0020] Figure 1 depicts a structural model of human RelB, an NF- $\kappa$ B Class II protein.

[0021] Figure 2 depicts a structural model of human RelB bound by RP-182.

[0022] Figure 3 depicts a structural model of human RelB bound by RP-166.

[0023] Figure 4 depicts a structural model of human RelB bound by RP-113.

[0024] Figure 5 depicts a structural model of human RelB bound by RP-387.

[0025] Figure 6 depicts a structural model of human RelB bound by RP-289.

[0026] Figure 7 depicts a structural model of human RelB bound by NF-Contr2.

[0027] Figure 8 depicts a structural model of human RelB bound by NF-Contr3.

[0028] Figure 9 depicts structural models of polypeptides RP-182, RP-166, RP-113, and RP-289, with each model showing the polar and non-polar facial arc associated with the helices formed by the polypeptides.

[0029] Figure 10 depicts structural models of polypeptides RP-387, NF-Contr2, and NF-Contr3, with each model showing the polar and non-polar amino acid residues. The facial arc associated with the helix formed by RP-387 is also shown.

[0030] Figure 11 depicts a structural model of the binding pocket of the RelB dimerization domain.

[0031] Figure 12 depicts a structural model of the binding pocket of the RelB dimerization domain bound by RP-183.

[0032] Figure 13 depicts a structural model of histone methyl transferase enzyme bound by RP-182.

[0033] Figure 14 depicts structural models of a CD47 dimer (left panel) and a CD47 dimer bound by RP-183.

[0034] Figure 15 depicts structural models of a SIRP- $\alpha$  dimer (left panel) and a SIRP- $\alpha$  dimer bound by RP-183.

[0035] Figure 16 depicts structural models of CD206 (left side) and CD206 bound by RP-182 (right side).

[0036] Figure 17 depicts structural models of TGM2 (left side) and TGM2 bound by RP-182 (right side).

[0037] Figure 18 depicts a structural model of human serum albumin bound by RP-183.

[0038] Figure 19 shows PD-1-stained tumor cells from p53/KRAS mice treated with vehicle only (left panel) or treated with RP-182 (right panel). PD-1 expression is reduced in RP-182 treated mice.

[0039] Figure 20 shows PD-L1-stained (left panels) and PD-L2-stained (right panels) tumor cells from p53/KRAS mice treated with vehicle only (top panel in each set) or treated with RP-182 (bottom panel in each set). PD-L1 and PD-L2 expression is reduced in RP-182 treated mice.

[0040] Figure 21 shows MDA-MB-231 tumor volume in four cohorts of mice over time. Cohort 1: vehicle; Cohort 2: Gemcitabine treated; Cohort 3: RP-182 treated; Cohort 4: RP-182 + Gemcitabine treated.

[0041] Figure 22 shows C42B tumor volume in four cohorts of mice over time. Cohort 1: vehicle; Cohort 2: Docetaxel treated; Cohort 3: RP-182 treated; Cohort 4: RP-182 + Docetaxel treated.

## DETAILED DESCRIPTION OF THE INVENTION

[0042] The following description supplies specific details in order to provide a thorough understanding of the present invention. That said, to avoid obscuring aspects of the described anti-inflammatory polypeptides and related methods of treating a subject, well-known structures, materials, processes, techniques, and operations are not shown or described in detail. Additionally, the skilled artisan will understand that the described anti-inflammatory polypeptides and related methods of treating a subject can be implemented and used without employing these specific details. Indeed, the described anti-inflammatory polypeptides and methods can be placed into practice by modifying the illustrated polypeptides, compositions, and methods, and can be used in conjunction with other treatments, apparatuses, and techniques conventionally used in the industry.

[0043] As discussed above, the invention disclosed herein relates to immune-modulatory polypeptides, particularly peptides that have immunosuppressive properties, and methods of administering such immune-modulatory polypeptides to a subject, particularly a subject suffering from a medical condition associated with persistent inflammation or at risk developing such a medical condition.

[0044] The invention provides anti-inflammatory polypeptides, sometimes referred to as “RP peptides,” that satisfy the requirements of the Structural Algorithm described below. The invention also provides anti-inflammatory polypeptides that share a minimum degree of homology with any of the exemplary RP peptides disclosed herein. Thus, a peptide or polypeptide of the invention is an anti-inflammatory polypeptide that satisfies the Structural Algorithm described below or shares a minimum degree of homology with any of the exemplary RP peptides disclosed herein (e.g., in Tables 3-9).

[0045] The terms “peptide” and “polypeptide” are used synonymously herein to refer to polymers constructed from amino acid residues.

[0046] The term “amino acid residue,” as used herein, refers to any naturally occurring amino acid (L or D form), non-naturally occurring amino acid, or amino acid mimetic (such as a peptoid monomer).

[0047] The “length” of a polypeptide is the number of amino acid residues linked end-to-end that constitute the polypeptide, excluding any non-peptide linkers and/or modifications that the polypeptide may contain.

[0048] The term “striapathic region,” as used herein, refers to an alternating sequence of hydrophobic and hydrophilic modules. A “hydrophobic module” is made up of a peptide sequence consisting of one to five hydrophobic amino acid residues. Likewise, a hydrophilic module is made up of a peptide sequence consisting of one to five hydrophilic amino acid residues.

[0049] Hydrophobic amino acid residues are characterized by a functional group (“side chain”) that has predominantly non-polar chemical properties. Such hydrophobic amino acid residues can be naturally occurring (L or D form) or non-naturally occurring. Alternatively, hydrophobic amino acid residues can be amino acid mimetics characterized by a functional group (“side chain”) that has predominantly non-polar chemical properties. Conversely, hydrophilic amino acid residues are characterized by a functional group (“side chain”) that has predominantly polar

(charged or uncharged) chemical properties. Such hydrophilic amino acid residues can be naturally occurring (L or D form) or non-naturally occurring. Alternatively, hydrophilic amino acid residues can be amino acid mimetics characterized by a functional group (“side chain”) that has predominantly polar (charged or uncharged) chemical properties. Examples of hydrophilic and hydrophobic amino acid residues are shown in Table 1, below. Suitable non-naturally occurring amino acid residues and amino acid mimetics are known in the art. See, e.g., Liang et al. (2013), “An Index for Characterization of Natural and Non-Natural Amino Acids for Peptidomimetics,” PLoS ONE 8(7):e67844.

[0050] Although most amino acid residues can be considered as either hydrophobic or hydrophilic, a few, depending on their context, can behave as either hydrophobic or hydrophilic. For example, due to their relatively weak non-polar characteristics, glycine, proline, and/or cysteine can sometimes function as hydrophilic amino acid residues. Conversely, due to their bulky, slightly hydrophobic side chains, histidine and arginine can sometimes function as hydrophobic amino acid residues.

**Table 1: Hydrophobic and Hydrophilic Amino Acid Residues**

<b>Hydrophilic Residues (X)</b>	<b>Hydrophobic Residues (Y)</b>
Arginine	Tryptophan
Histidine	Phenylalanine
Lysine	Tyrosine
Aspartic Acid	Isoleucine
Glutamic Acid	Leucine
Asparagine	Valine
Glutamine	Methionine
Pyrrolysine	Cysteine
	Threonine
	Serine
	Alanine
	Proline
	Glycine
	Selenocysteine
	N-formylmethionine
	Norleucine
	Norvaline

[0051] The term “anti-inflammatory property,” as used herein, refers to any property of a polypeptide that can be evaluated *in silico*, *in vitro*, and/or *in vivo*, that reduces or inhibits, or

would be expected to reduce or inhibit, a pro-inflammatory signal mediated by a protein target and/or reduces or inhibits inflammation in a subject.

**[0052]** Structural Algorithm

**[0053]** In its most basic form, the Structural Algorithm requires an anti-inflammatory peptide to have the following characteristics:

**[0054]** a length of 3 to 24 amino acid residues;

**[0055]** a striapathic region that comprises at least 25% of the length of the polypeptide; and

**[0056]** at least one anti-inflammatory property.

**[0057]** The anti-inflammatory peptide and/or its striapathic region can have a length that is greater than 3 amino acid residues and/or less than 24 amino acid residues. Thus, the requisite length of the polypeptide can be, for example, 3 to 20, 3 to 18, 3 to 16, 3 to 14, 3 to 12, 4 to 20, 4 to 18, 4 to 16, 4 to 14, 4 to 12, 5 to 20, 5 to 18, 5 to 16, 5 to 14, 5 to 12, 6 to 20, 6 to 18, 6 to 16, 6 to 14, 6 to 12, 7 to 20, 7 to 18, 7 to 16, 7 to 14, or in certain embodiments 7 to 12 amino acid residues. For an anti-inflammatory polypeptide that is longer than 12 amino acid residues, it can be advantageous to design a kink in the secondary structure (e.g., such as produced by a proline residue) such that the polypeptide has a striapathic region that is 12 or fewer amino acid residues in length. The striapathic region of an anti-inflammatory peptide can comprise at least 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the length of the polypeptide.

**[0058]** An anti-inflammatory polypeptide can have a striapathic region that includes at least two hydrophobic modules and one or more (e.g., two or three) hydrophilic modules. Alternatively, an anti-inflammatory polypeptide can have a striapathic region that includes at least three hydrophobic modules and two or more (e.g., three or four) hydrophilic modules; a striapathic region that includes at least two hydrophilic modules and one or more (e.g., two or three) hydrophilic modules; or a striapathic region that includes at least three hydrophilic modules and two or more (e.g., three or four) hydrophobic modules.

**[0059]** As discussed above, a striapathic region consists of alternating hydrophilic ( $X_m$ ) and hydrophobic ( $Y_n$ ) modules. In this context, the subscripts  $m$  and  $n$  are positive integers that identify different modules. Each  $X_m$  module consists of a sequence according to the formula  $X_{ma}-X_{mb}-X_{mc}-X_{md}-X_{me}$ .  $X_{ma}$  is selected from the group consisting of a naturally occurring hydrophilic amino acid, a non-naturally occurring hydrophilic amino acid, and a hydrophilic

amino acid mimetic; and  $X_{mb}$ ,  $X_{mc}$ ,  $X_{md}$  and  $X_{me}$  are each individually absent or selected from the group consisting of a naturally occurring hydrophilic amino acid, a non-naturally occurring hydrophilic amino acid, and a hydrophilic amino acid mimetic. Each  $Y_n$  module consists of a sequence according to the formula  $Y_{na}-Y_{nb}-Y_{nc}-Y_{nd}-Y_{ne}$ .  $Y_{na}$  is selected from the group consisting of a naturally occurring hydrophobic amino acid, a non-naturally occurring hydrophobic amino acid, and a hydrophobic amino acid mimetic;  $Y_{nb}$ ,  $Y_{nc}$ ,  $Y_{nd}$ , and  $Y_{ne}$  are each individually absent or selected from the group consisting of a naturally occurring hydrophobic, a non-naturally occurring hydrophobic amino acid, and a hydrophobic amino acid mimetic.


**[0060]** In certain anti-inflammatory polypeptides, each  $X_m$  module consists of a sequence according to the formula  $X_{ma}-X_{mb}-X_{mc}-X_{md}$  or  $X_{ma}-X_{mb}-X_{mc}$ . Similarly, in certain anti-inflammatory polypeptides, each  $Y_n$  module consists of a sequence according to the formula  $Y_{na}-Y_{nb}-Y_{nc}-Y_{nd}$  or  $Y_{na}-Y_{nb}-Y_{nc}$ .

**[0061]** Anti-inflammatory peptides can include a striapathic region corresponding to a formula selected from the group consisting of:

- |   |                 |
|---|-----------------|
| $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}$                      | (Formula I);    |
| $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}-X_{2a}-Y_{3a}-X_{3a}$ | (Formula II);   |
| $X_{2a}-Y_{3a}-X_{3a}-Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}$ | (Formula III);  |
| $X_{1a}-X_{1b}-X_{1c}-Y_{2a}-X_{2a}-X_{2b}-X_{2c}$                      | (Formula IV);   |
| $Y_{1a}-X_{1a}-X_{1b}-X_{1c}-Y_{2a}-X_{2a}-X_{2b}-X_{2c}-Y_{3a}-X_{3a}$ | (Formula V);    |
| $X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}$                             | (Formula VI);   |
| $Y_{1a}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}$               | (Formula VII);  |
| $Y_{1a}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}-Y_{3b}-X_{3a}$ | (Formula VIII); |
| $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}-Y_{3b}$ | (Formula IX);   |
| $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}-X_{3a}$ | (Formula X);    |
| $X_{1a}-Y_{1a}-X_{2a}-X_{2b}-Y_{2a}-Y_{2b}-X_{3a}-X_{3b}-Y_{3a}-Y_{3b}$ | (Formula XI);   |
| $X_{1a}-Y_{1a}-Y_{1b}-X_{2a}-X_{2b}-Y_{2a}-Y_{2b}-X_{3a}-X_{3b}-Y_{3a}$ | (Formula XII);  |
| $Y_{1a}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-X_{2c}-Y_{3a}-Y_{3b}$ | (Formula XIII); |
| $X_{1a}-X_{1b}-X_{1c}-Y_{1a}-Y_{1b}-X_{2a}-X_{2b}-Y_{2a}-Y_{2b}-Y_{2c}$ | (Formula XIV);  |
| $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-X_{2c}$ | (Formula XV);   |
| $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-X_{1c}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}$ | (Formula XVI);  |
| $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}$                             | (Formula XVII); |



$X_{1a}-Y_{1a}-Y_{1b}-X_{2a}-X_{2b}-Y_{2a}-Y_{2b}-X_{3a}$	(Formula XVIII);
$Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-Y_{3a}-Y_{3b}-X_{3a}$	(Formula XIX);
$X_{1a}-Y_{1a}-Y_{1b}-X_{2a}-Y_{2a}-Y_{2b}-X_{3a}-X_{3b}-Y_{3a}-Y_{3b}$	(Formula XX);
$Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-X_{2a}-X_{2b}-Y_{3a}-Y_{3b}$	(Formula XXI);
$X_{1a}-Y_{1a}-Y_{1b}-X_{2a}-X_{2b}-X_{2c}-Y_{2a}-X_{3a}-Y_{3a}-Y_{3b}$	(Formula XXII);
$Y_{1a}-Y_{1b}-X_{1a}-Y_{2a}-X_{2a}-X_{2b}-X_{2c}-Y_{3a}-Y_{3b}-X_{3a}$	(Formula XXIII);
$X_{1a}-X_{1b}-Y_{1a}-X_{2a}-Y_{2a}-X_{3a}-X_{3b}$	(Formula XXIV);
$Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1b}-Y_{2a}-X_{2a}-Y_{3a}-X_{3a}-X_{3b}$	(Formula XXV);
$X_{1a}-X_{1b}-Y_{1a}-X_{2a}-Y_{2a}-X_{3a}-X_{3b}-Y_{3a}-Y_{3b}-Y_{3c}$	(Formula XXVI);
$X_{1a}-X_{1b}-X_{1c}-Y_{1a}-Y_{1b}-Y_{1c}$	(Formula XXVII);
$X_{1a}-X_{1b}-X_{1c}-X_{1d}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}$	(Formula XXVIII);
$Y_{1a}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-Y_{2a}-Y_{2b}-Y_{2c}-Y_{2d}-X_{2a}$	(Formula XXIX);
$X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}$	(Formula XXX);
$Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-X_{1c}-Y_{2a}-Y_{2b}-Y_{2c}-X_{2a}-X_{2b}$	(Formula XXXI);
$X_{1a}-Y_{1a}-X_{2a}-Y_{2a}-X_{3a}-X_{3b}-X_{3c}-Y_{3a}-Y_{3b}-Y_{3c}$	(Formula XXXII);
$Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1b}-X_{1c}$	(Formula XXXIII);
$Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-X_{1a}-X_{1b}-X_{1c}-X_{1d}$	(Formula XXXIV);
$X_{1a}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-X_{2a}-X_{2b}-X_{2c}-X_{2d}-Y_{2a}$	(Formula XXXV);
$Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}$	(Formula XXXVI);
$X_{1a}-X_{1b}-Y_{1a}-Y_{1b}-Y_{1c}-X_{2a}-X_{2b}-X_{2c}-Y_{2a}-Y_{2b}$	(Formula XXXVII);
$Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1a}-X_{1c}-Y_{2a}-X_{2a}-Y_{3a}-X_{3a}$	(Formula XXXVIII);
$Y_{1a}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}$	(Formula XXXIX);
$Y_{1a}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}-Y_{2b}-Y_{2c}-Y_{2d}$	(Formula XL);
$Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}-Y_{2b}-Y_{2c}$	(Formula XLI);
$Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}-Y_{2b}$	(Formula XLII);
$Y_{1a}-Y_{1b}-Y_{1c}-Y_{1e}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}$	(Formula XLIII);
$X_{1a}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{2a}$	(Formula XLIV);
$X_{1a}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{2a}-X_{2b}-X_{2c}-X_{2d}$	(Formula XLV);
$X_{1a}-X_{1b}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{2a}-X_{2b}-X_{2c}$	(Formula XLVI);
$X_{1a}-X_{1b}-X_{1c}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{2a}-X_{2b}$	(Formula XLVII);
$X_{1a}-X_{1b}-X_{1c}-X_{1d}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{2a}$	(Formula XLVIII);



**[0062]** Typically, the striapathic region (or a portion thereof) of an anti-inflammatory polypeptide will have an amphipathic conformation (e.g., under physiological conditions). To be considered amphipathic, the striapathic region (or portion thereof) need not be in the amphipathic conformation at all times. Rather, it is sufficient that the amphipathic conformation be present at least 50%, 60%, 70%, 80%, or more of the time, or when the anti-inflammatory polypeptide is binding to a target molecule, such as an NF-kB Class II protein (e.g., Rel B). Often, the amphipathic conformation will be associated with a particular secondary structure, such as a helical structure. Thus, the striapathic region (or a portion thereof) of the anti-inflammatory polypeptide can have an amphipathic  $3_{10}$ -helical conformation, an amphipathic  $\alpha$ -helical conformation, an amphipathic  $\pi$ -helical conformation, or an amphipathic poly-proline helical conformation. Alternatively, the striapathic region (or a portion thereof) of the anti-inflammatory polypeptide can have an amphipathic  $\beta$ -strand conformation.

**[0063]** For anti-inflammatory peptides that comprise a striapathic region that includes or has an amphipathic helical conformation (e.g.,  $3_{10}$ -helical,  $\alpha$ -helical,  $\pi$ -helical, or polyproline helical conformation), the hydrophobic surface ("side") can have a facial arc of at least  $100^\circ$ . In certain embodiments, the facial arc of the hydrophobic surface or side is at least  $125^\circ$ ,  $150^\circ$ ,  $175^\circ$ ,  $200^\circ$ ,  $225^\circ$ ,  $250^\circ$ ,  $275^\circ$ , or  $300^\circ$ .

**[0064]** Anti-inflammatory polypeptides in certain embodiments have a striapathic region that has a relatively large hydrophobic volume. Accordingly, the striapathic region can optimally contain hydrophobic amino acid residues having a total side-chain volume of at least 600 cubic angstroms. In certain embodiments, the hydrophobic amino acid residues of the striapathic region have a hydrophobic side-chain volume of at least 650, 700, 750, 800, 850, 900, 950, 1000, or more cubic angstroms. Alternatively, or in addition, the striapathic region can be characterized by a ratio of the sum of the side-chain volume of hydrophobic amino acid residues

to the sum of the side-chain volume of hydrophilic amino acid residues, wherein the ratio is at least 0.75 or higher. For example, the ratio can be at least 0.8, 0.85, 0.9, 0.95, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, or greater.

**[0065]** Because of the desirability of a striapathic region having a relatively large hydrophobic side-chain volume, it is generally preferable to include one or more (e.g., 2, 3, 4, 5, or more) large hydrophobic amino acid residues in the sequence of the striapathic region. Conversely, it is generally preferable to have two or fewer (e.g., 1 or 0) small hydrophobic amino acid residues in the sequence of the striapathic region. Examples of large hydrophobic amino acid residues include tryptophan, phenylalanine, and tyrosine. In addition, under certain circumstances, histidine or arginine can be considered a large hydrophobic amino acid residue. Examples of small hydrophobic residues include glycine, alanine, serine, cysteine, valine, threonine, and proline. Accordingly, an anti-inflammatory polypeptide can have a striapathic region that includes one or more (e.g., 2, 3, 4, 5, or more) hydrophobic residues selected from the group consisting of tryptophan, phenylalanine, and tyrosine. Alternatively, the anti-inflammatory polypeptide can have a striapathic region that includes one or more (e.g., 2, 3, 4, 5, or more) hydrophobic residues selected from (i) the group consisting of tryptophan, phenylalanine, tyrosine, and histidine, or (ii) the group consisting of tryptophan, phenylalanine, tyrosine, and arginine. In certain embodiments, the anti-inflammatory polypeptide has a striapathic region that includes two or fewer (e.g., 1 or 0) hydrophobic residues selected from the group consisting of glycine, alanine, serine, cysteine, valine, threonine, and proline. Alternatively, the anti-inflammatory polypeptide can have a striapathic region that includes no more than one hydrophobic residue selected from the group consisting of glycine, alanine, serine, cysteine, valine, threonine, and proline. In other alternatives, the anti-inflammatory polypeptide can have a striapathic region that includes no glycine residues, no alanine residues, no serine residues, no cysteine residues, no valine residues, no threonine residues, and/or no proline residues.

**[0066]** It is also preferable that an anti-inflammatory polypeptide have a striapathic region characterized by a moderate level of cationicity (i.e., a striapathic region that does not contain an excessive number of amino acid residues having positively charged side chains). Examples of amino acid residues having positively charged side groups (assuming physiological conditions) includes lysine, typically arginine, and sometimes histidine. Examples of amino acid residues having negatively charged side chains (assuming physiological conditions) include aspartic acid


and glutamic acid. Examples of hydrophilic amino acid residues having uncharged side chains (assuming physiological conditions) include asparagine and glutamine. Accordingly, an anti-inflammatory polypeptide can have a striapathic region that includes five or fewer (e.g., 4, 3, 2) lysine residues. Alternatively, an anti-inflammatory polypeptide can have a striapathic region that includes five or fewer (e.g., 4, 3, 2) amino acid residues selected from the group consisting of lysine and arginine. In other alternatives, an anti-inflammatory polypeptide can have a striapathic region that includes five or fewer (e.g., 4, 3, 2) amino acid residues selected from the group consisting of lysine, arginine, and histidine. For anti-inflammatory polypeptides that have a striapathic region that includes one or more (e.g., two or more) positively charged amino acid residues, it can be advantageous for the striapathic region to also include some negatively charged or polar, uncharged amino acid residues. For example, the anti-inflammatory polypeptide can have a striapathic region that includes both positively and negatively charged amino acid residues, such that the net charge on the polypeptide is no more than +2 or +1 (e.g., the number of positively charged amino acid residues does not exceed the number of negatively charged amino acid residues by more than one or two). Alternatively, the anti-inflammatory polypeptide can have a striapathic region that includes both positively charged and polar, uncharged amino acid residues, such that the net charge on the polypeptide is no more than +2 or +1 (e.g., the number of positively charged amino acid residues does not exceed one or two). In other alternatives, the anti-inflammatory polypeptide can have a striapathic region that includes both positively charged, negatively charged, and hydrophilic uncharged charged amino acid residues, such that the net charge on the polypeptide is no more than +2.

**[0067]** To avoid certain undesired interactions between RP peptides and other molecules (whether another RP peptide, a metal ion, etc.) it can be advantageous to limit the number of certain types of amino acid residues in the polypeptide. For example, because cysteine residues form di-sulfide bonds under certain conditions (e.g., oxidative environments), it can be useful to limit the number of cysteine residues in a polypeptide of the invention to no more than one or two, or even none. Because histidine residues chelate metals under certain conditions (e.g., alkaline environments), it can be useful to limit the number of histidine residues in a polypeptide of the invention to no more than one or two, or even none. In addition, because proline residues tend to introduce kinks into secondary structure elements (e.g.,  $\alpha$ -helices and  $\beta$ -strands), it can

be useful exclude proline residues in the striapathic region of a polypeptide of the invention, or limit their number to no more than one.

**[0068]** Class I Polypeptides

**[0069]** An anti-inflammatory polypeptide of the invention can be a Class I polypeptide. Class I polypeptides comprise, consist essentially of, or consist of a striapathic region that includes a sequence selected from the group of sequences defined by Formula I:



**[0070]** Each of amino acid residues  $Y_{1a}$ ,  $Y_{1b}$ ,  $Y_{1c}$ ,  $Y_{2a}$ ,  $Y_{2b}$ , and  $Y_{2c}$  in Formula I can be selected from the group consisting of Phe (F), Trp (W), Tyr (Y), His (H), Leu (L), Cys (C), Met (M), Val (V), Ile (I), Pro (P), Thr (T), Ser (S), Ala (A), and Gly (G). In certain embodiments, at least 3, 4, 5, or 6 of amino acid residues  $Y_{1a}$ ,  $Y_{1b}$ ,  $Y_{1c}$ ,  $Y_{2a}$ ,  $Y_{2b}$ , and  $Y_{2c}$  in Formula I are selected from the group consisting of Phe (F), Trp (W), Tyr (Y), His (H), and Leu (L). In certain embodiments, at least 3, 4, 5, or 6 of amino acid residues  $Y_{1a}$ ,  $Y_{1b}$ ,  $Y_{1c}$ ,  $Y_{2a}$ ,  $Y_{2b}$ , and  $Y_{2c}$  in Formula I are selected from the group consisting of Phe (F), Trp (W), and Tyr (Y). In certain embodiments, less than two (and in certain embodiments 1 or none) of amino acid residues  $Y_{1a}$ ,  $Y_{1b}$ ,  $Y_{1c}$ ,  $Y_{2a}$ ,  $Y_{2b}$ , and  $Y_{2c}$  in Formula I are selected from the group consisting of Pro (P), Thr (T), Ser (S), Ala (A), and Gly (G).



**[0071]** The module  $Y_{1a}-Y_{1b}-Y_{1c}$  in Formula I can have a sequence selected from the group consisting of Phe-Phe-Phe (FFF), Trp-Trp-Trp (WWW), Tyr-Tyr-Tyr (YYY), Leu-Leu-Leu (LLL), Cys-Cys-Cys (CCC), Met-Met-Met (MMM), Val-Val-Val (VVV), Ile-Ile-Ile (III). Alternatively, the module  $Y_{1a}-Y_{1b}-Y_{1c}$  in Formula I can have a sequence selected from the group consisting of Pro-Pro-Pro (PPP), Thr-Thr-Thr (TTT), and Ala-Ala-Ala (AAA). In certain embodiments, module  $Y_{1a}-Y_{1b}-Y_{1c}$  in Formula I has a sequence selected from the group consisting of Phe-Phe-Phe (FFF), Trp-Trp-Trp (WWW), Tyr-Tyr-Tyr (YYY), and combinations thereof (e.g., Phe-Phe-Trp (FFW), Phe-Trp-Trp (FWW), Trp-Phe-Trp (WFW), Trp-Trp-Phe (WWF), Phe-Phe-Tyr (FFY), Phe-Tyr-Tyr (FYY), Tyr-Phe-Tyr (YFY), Tyr-Tyr-Phe (YYF), Trp-Trp-Tyr (WWY), Trp-Tyr-Tyr (WYY), Tyr-Trp-Tyr (YWY), Tyr-Tyr-Trp (YYW), Phe-Trp-Tyr (FWY), Phe-Tyr-Trp (FYW), Trp-Phe-Tyr (WFY), Trp-Tyr-Phe (WYF), Tyr-Trp-Phe (YWF), or Tyr-Phe-Trp (YFW)).

**[0072]** The module  $Y_{2a}-Y_{2b}-Y_{2c}$  in Formula I can have a sequence selected from the group consisting of Phe-Phe-Phe (FFF), Trp-Trp-Trp (WWW), Tyr-Tyr-Tyr (YYY), Leu-Leu-Leu

(LLL), Cys-Cys-Cys (CCC), Met-Met-Met (MMM), Val-Val-Val (VVV), and Ile-Ile-Ile (III). Alternatively, the module  $Y_{2a}-Y_{2b}-Y_{2c}$  in Formula I can have a sequence selected from the group consisting of Pro-Pro-Pro (PPP), Thr-Thr-Thr (TTT), and Ala-Ala-Ala (AAA). In certain embodiments, module  $Y_{2a}-Y_{2b}-Y_{2c}$  in Formula I has a sequence selected from the group consisting of Phe-Phe-Phe (FFF), Trp-Trp-Trp (WWW), Tyr-Tyr-Tyr (YYY), and combinations thereof (e.g., Phe-Phe-Trp (FFW), Phe-Trp-Trp (FWW), Trp-Phe-Trp (WFW), Trp-Trp-Phe (WWF), Phe-Phe-Tyr (FFY), Phe-Tyr-Tyr (FYY), Tyr-Phe-Tyr (YFY), Tyr-Tyr-Phe (YYF), Trp-Trp-Tyr (WWY), Trp-Tyr-Tyr (WYY), Tyr-Trp-Tyr (YWY), Tyr-Tyr-Trp (YYW), Phe-Trp-Tyr (FWY), Phe-Tyr-Trp (FYW), Trp-Phe-Tyr (WFY), Trp-Tyr-Phe (WYF), Tyr-Trp-Phe (YWF), or Tyr-Phe-Trp (YFW)).

**[0073]** Thus, a Class I anti-inflammatory polypeptide can comprise, consist essentially of, or consist of a striapathic region having a sequence selected from the group consisting of FFF- $X_{1a}$ -FFF (SEQ ID NO: 1), WWW- $X_{1a}$ -WWW (SEQ ID NO: 2), YYY- $X_{1a}$ -YYY (SEQ ID NO: 3), and combinations thereof. Alternatively, a Class I anti-inflammatory polypeptide can comprise, consist essentially of, or consist of a striapathic region having a sequence selected from the group consisting of LLL- $X_{1a}$ -LLL (SEQ ID NO: 4), CCC- $X_{1a}$ -CCC (SEQ ID NO: 5), MMM- $X_{1a}$ -MMM (SEQ ID NO: 6), VVV- $X_{1a}$ -VVV (SEQ ID NO: 7), and III- $X_{1a}$ -III (SEQ ID NO: 8). In such peptides,  $X_{1a}$  can be selected from the group consisting of Arg (R), His (H), and Lys (K); or  $X_{1a}$  can be selected from the group consisting of Glu (E), Gln (Q), Asn (N), and Asp (D).

**[0074]** A Class I anti-inflammatory polypeptide can comprise, consist essentially of, or consist of a striapathic region having a sequence selected from the group of sequences defined by Formula II or the group of sequences defined by Formula III:



**[0075]** The  $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}$  sequences defined by Formulas II and III can be any of the sequences described above in connection with Formula I.  $X_{2a}$  and  $X_{3a}$  in Formulas II and III can be each individually selected from the group consisting of Arg (R), His (H), Lys (K), Glu (E), Gln (Q), Asn (N), and Asp (D). Alternatively,  $X_{2a}$  and  $X_{3a}$  in Formulas II and III can be each individually selected from the group consisting of Arg (R), His (H), and Lys (K). In other alternatives,  $X_{2a}$  and  $X_{3a}$  in Formulas II and III can be each individually selected from the group consisting of Arg (R), His (H), Lys (K), and Gln (Q). In other alternatives,  $X_{2a}$  and  $X_{3a}$  in


Formulas II and III can be each individually selected from the group consisting Glu (E), Gln (Q), Asn (N), and Asp (D). In other alternatives,  $X_{2a}$  in Formulas II and III can be selected from the group consisting of Arg (R), His (H), and Lys (K), and  $X_{3a}$  in Formulas II and III can be selected from the group consisting of Glu (E), Gln (Q), Asn (N), and Asp (D).  $Y_{3a}$  in Formulas II and III can be selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), and Ile (I). In certain embodiments,  $Y_{3a}$  in Formulas II and III is selected from the group consisting of Phe (F), Trp (W), Tyr (Y), and Leu (L).

**[0076]** The modules  $X_{2a}-Y_{3a}-X_{3a}$  in Formulas II and III can be selected from the group consisting of EFQ, EFE, EFN, EFD, NFQ, NFE, NFN, NFD, QFQ, QFE, QFN, QFD, DFQ, DFE, DFN, DFD, EWQ, EWE, EWN, EWD, NWQ, NWE, NWN, NWD, QWQ, QWE, QWN, QWD, DWQ, DWE, DWN, DWD, EYQ, EYE, EFN, EYD, NYQ, NYE, NYN, NYD, QYQ, QYE, QYN, QYD, DYQ, DYE, DYN, DYD, ELQ, ELE, ELN, ELD, NLQ, NLE, NLN, NLD, QLQ, QLE, QLN, QLD, DLQ, DLE, DLN, DLD, RFR, RFQ, RFE, RFN, RFD, RWR, RWQ, RWE, RWN, and RWD.

**[0077]** A Class I anti-inflammatory polypeptide can comprise, consist essentially of, or consist of a striapathic region comprising, consisting essentially of, or consisting of a sequence selected from the group of sequences listed in Table 3, e.g., RP394, RP108-RP123, RP125-131, RP133, RP135-RP141, RP143-RP146, RP148-RP150, RP152-RP165, RP179, RP395, RP211, RP230, RP232, RP258, RP267, RP268, RP271, RP273, RP280-281, and RP287 (i.e., SEQ ID NOs: 33-98, respectively). In certain embodiments, the Class I anti-inflammatory polypeptide can comprise, consist essentially of, or consist of a striapathic region that comprises, consists essentially of, or consists of a sequence selected from the group of sequences consisting of RP113 (SEQ ID NO: 39), RP118 (SEQ ID NO: 44), and RP394 (SEQ ID NO: 33).

**[0078]** Class II Polypeptides

**[0079]** An anti-inflammatory polypeptide of the invention can be a Class II polypeptide. Class II anti-inflammatory polypeptides can comprise, consist essentially of, or consist of a striapathic region that includes a sequence selected from the group of sequences defined by Formula VII:



**[0080]** Amino acid residue  $Y_{2a}$  in Formula VII can be selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), Ile (I), Pro (P), Thr (T), Ser (S), Ala (A), and Gly (G). In certain embodiments, amino acid residue  $Y_{2a}$  in Formula VII is selected

from the group consisting of Phe (F), Trp (W), and Tyr (Y). Alternatively, amino acid residue Y<sub>2a</sub> in Formula VII can be selected from the group consisting of Leu (L), Cys (C), Met (M), Val (V), Ile (I).

**[0081]** Amino acid residue Y<sub>2b</sub> in Formula VII can be selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), Ile (I), Pro (P), Thr (T), Ser (S), Ala (A), and Gly (G). In certain embodiments, amino acid residue Y<sub>2b</sub> in Formula VII is selected from the group consisting of Phe (F), Trp (W), and Tyr (Y). Alternatively, amino acid residue Y<sub>2b</sub> in Formula VII can be selected from the group consisting of Leu (L), Cys (C), Met (M), Val (V), Ile (I).

**[0082]** Amino acid residue X<sub>1b</sub> in Formula VII can be selected from the group consisting of Arg (R), Lys (K), and His (H). Alternatively amino acid residue X<sub>1b</sub> in Formula VII can be selected from the group consisting of Asn (N), Gln (Q), Asp (D), and Glu (E).

**[0083]** Amino acid residue X<sub>2a</sub> in Formula VII can be selected from the group consisting of Arg (R), Lys (K), and His (H). Alternatively, amino acid residue X<sub>2a</sub> can be selected from the group consisting of Asn (N), Gln (Q), Asp (D), and Glu (E).

**[0084]** The sequence X<sub>1b</sub>-Y<sub>2a</sub>-Y<sub>2b</sub>-X<sub>2a</sub> in Formula VII can be selected from the group consisting of Lys-Phe-Phe-Lys (KFFK; SEQ ID NO: 386), Lys-Trp-Trp-Lys (KWWK; SEQ ID NO: 387), Lys-Tyr-Tyr-Lys (KYYK; SEQ ID NO: 388), Lys-Phe-Trp-Lys (KFWK; SEQ ID NO: 389), Lys-Trp-Phe-Lys (KWFK; SEQ ID NO: 390), Lys-Phe-Tyr-Lys (KFYK; SEQ ID NO: 391), Lys-Tyr-Phe-Lys (KYFK; SEQ ID NO: 392), Lys-Trp-Tyr-Lys (KWYK; SEQ ID NO: 393), and Lys-Tyr-Trp-Lys (KYWK; SEQ ID NO: 394). Alternatively, the sequence X<sub>1b</sub>-Y<sub>2a</sub>-Y<sub>2b</sub>-X<sub>2a</sub> in Formula VII can be selected from the group consisting of Arg-Phe-Phe-Arg (RFFR; SEQ ID NO: 395), Arg-Trp-Trp-Arg (RWWR; SEQ ID NO: 396), Arg-Tyr-Tyr-Arg (RYYR; SEQ ID NO: 397), Arg-Phe-Trp-Arg (RFWR; SEQ ID NO: 398), Arg-Trp-Phe-Arg (RWFR; SEQ ID NO: 399), Arg-Phe-Tyr-Arg (RFYR; SEQ ID NO: 400), Arg-Tyr-Phe-Arg (RYFR; SEQ ID NO: 401), Arg-Trp-Tyr-Arg (RWYR; SEQ ID NO: 402), and Arg-Tyr-Trp-Arg (RYWR; SEQ ID NO: 403). In other alternatives, the sequence X<sub>1b</sub>-Y<sub>2a</sub>-Y<sub>2b</sub>-X<sub>2a</sub> in Formula VII can be selected from the group consisting of His-Phe-Phe-His (HFFH; SEQ ID NO: 404), His-Trp-Trp-His (HWWH; SEQ ID NO: 405), His-Tyr-Tyr-His (HYYH; SEQ ID NO: 406), His-Phe-Trp-His (HFWH; SEQ ID NO: 407), His-Trp-Phe-His (HWFH; SEQ ID NO: 408), His-Phe-Tyr-His



(HFYH; SEQ ID NO: 409), His-Tyr-Phe-His (HYFH; SEQ ID NO: 410), His-Trp-Tyr-His (HWYH; SEQ ID NO: 411), and His-Tyr-Trp-His (HYWH; SEQ ID NO: 412).

**[0085]** Amino acid residue  $X_{1a}$  in Formula VII can be selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E). In certain embodiments, amino acid residue  $X_{1a}$  is selected from the group consisting of Arg (R) and Gln (Q). In certain embodiments, amino acid residue  $X_{1a}$  in Formula VII is Arg (R). Alternatively, amino acid residue  $X_{1a}$  in Formula VII can be selected from the group consisting of Lys (K), Gln (Q), Glu (E), and Asn (N).

**[0086]** Amino acid residue  $X_{2b}$  in Formula VII can be selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E). In certain embodiments, amino acid residue  $X_{2b}$  is selected from the group consisting of Arg (R) and Gln (Q). In certain embodiments, amino acid residue  $X_{2b}$  in Formula VII is Arg (R). Alternatively, amino acid residue  $X_{2b}$  in Formula VII can be selected from the group consisting of Lys (K), Gln (Q), Glu (E), and Asn (N).

**[0087]** Amino acid residue  $Y_{1a}$  in Formula VII can be selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), Ile (I), Thr (T), Pro (P), Ser (S), Ala (A), and Gly (G). In certain embodiments, amino acid residue  $Y_{1a}$  in Formula VII is selected from the group consisting of Phe (F), Trp (W), and Tyr (Y). Alternatively, amino acid residue  $Y_{1a}$  in Formula VII can be selected from the group consisting of Leu (L), Cys (C), Met (M), Val (V), Ile (I).

**[0088]** Amino acid residue  $Y_{3a}$  in Formula VII can be selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), Ile (I), Thr (T), Pro (P), Ser (S), Ala (A), and Gly (G). In certain embodiments, amino acid residue  $Y_{3a}$  in Formula VII is selected from the group consisting of Phe (F), Trp (W), and Tyr (Y). Alternatively, amino acid residue  $Y_{3a}$  in Formula VII can be selected from the group consisting of Leu (L), Cys (C), Met (M), Val (V), Ile (I).

**[0089]** Thus, a Class II anti-inflammatory polypeptide can comprise, consist essentially of, or consist of a striapathic region having a sequence selected from the group consisting of F- $X_{1a}$ - $X_{1b}$ -FF- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 9), F- $X_{1a}$ - $X_{1b}$ -FF- $X_{2a}$ - $X_{2b}$ -W (SEQ ID NO: 10), W- $X_{1a}$ - $X_{1b}$ -FF- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 11), F- $X_{1a}$ - $X_{1b}$ -FW- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 12), F- $X_{1a}$ - $X_{1b}$ -WF- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 13), F- $X_{1a}$ - $X_{1b}$ -WW- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 14), W- $X_{1a}$ - $X_{1b}$ -WW- $X_{2a}$ - $X_{2b}$ -

F (SEQ ID NO: 15), F-X<sub>1a</sub>-X<sub>1b</sub>-WW-X<sub>2a</sub>-X<sub>2b</sub>-W (SEQ ID NO: 16), W-X<sub>1a</sub>-X<sub>1b</sub>-WW-X<sub>2a</sub>-X<sub>2b</sub>-W (SEQ ID NO: 17), F-X<sub>1a</sub>-X<sub>1b</sub>-FF-X<sub>2a</sub>-X<sub>2b</sub>-Y (SEQ ID NO: 18), Y-X<sub>1a</sub>-X<sub>1b</sub>-FF-X<sub>2a</sub>-X<sub>2b</sub>-F (SEQ ID NO: 19), F-X<sub>1a</sub>-X<sub>1b</sub>-FY-X<sub>2a</sub>-X<sub>2b</sub>-F (SEQ ID NO: 20), F-X<sub>1a</sub>-X<sub>1b</sub>-YF-X<sub>2a</sub>-X<sub>2b</sub>-F (SEQ ID NO: 21), F-X<sub>1a</sub>-X<sub>1b</sub>-YY-X<sub>2a</sub>-X<sub>2b</sub>-F (SEQ ID NO: 22), Y-X<sub>1a</sub>-X<sub>1b</sub>-YY-X<sub>2a</sub>-X<sub>2b</sub>-F (SEQ ID NO: 23), F-X<sub>1a</sub>-X<sub>1b</sub>-YY-X<sub>2a</sub>-X<sub>2b</sub>-Y (SEQ ID NO: 24), and Y-X<sub>1a</sub>-X<sub>1b</sub>-YY-X<sub>2a</sub>-X<sub>2b</sub>-Y (SEQ ID NO: 25), Y-X<sub>1a</sub>-X<sub>1b</sub>-YY-X<sub>2a</sub>-X<sub>2b</sub>-W (SEQ ID NO: 26), W-X<sub>1a</sub>-X<sub>1b</sub>-YY-X<sub>2a</sub>-X<sub>2b</sub>-Y (SEQ ID NO: 27), Y-X<sub>1a</sub>-X<sub>1b</sub>-YW-X<sub>2a</sub>-X<sub>2b</sub>-Y (SEQ ID NO: 28), Y-X<sub>1a</sub>-X<sub>1b</sub>-WY-X<sub>2a</sub>-X<sub>2b</sub>-Y (SEQ ID NO: 29), Y-X<sub>1a</sub>-X<sub>1b</sub>-WW-X<sub>2a</sub>-X<sub>2b</sub>-Y (SEQ ID NO: 30), W-X<sub>1a</sub>-X<sub>1b</sub>-WW-X<sub>2a</sub>-X<sub>2b</sub>-Y (SEQ ID NO: 31), and Y-X<sub>1a</sub>-X<sub>1b</sub>-WW-X<sub>2a</sub>-X<sub>2b</sub>-W (SEQ ID NO: 32). Amino acid residues X<sub>1a</sub>, X<sub>1b</sub>, X<sub>2a</sub>, and X<sub>2b</sub> in the foregoing sequences can be selected as discussed above.

**[0090]** A Class II anti-inflammatory polypeptide can comprise, consist essentially of, or consist of a striapathic region that further includes a first additional amino acid residue directly bound to amino acid residue Y<sub>1a</sub> of Formula VII. The first additional amino acid residue can be a hydrophobic amino acid residue (e.g., a residue selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), Ile (I), Thr (T), Pro (P), Ser (S), Ala (A), and Gly (G)); a residue selected from the group consisting of Phe (F), Trp (W), and Tyr (Y); a residue selected from the group consisting of Phe (F), Trp (W), Tyr (Y), and Leu (L); or, a residue selected from the group consisting of Leu (L), Cys (C), Met (M), Val (V), and Ile (I)). Alternatively, the first additional amino acid residue can be a hydrophilic amino acid residue (e.g., a residue selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E)); a residue selected from the group consisting of Arg (R), Lys (K), and His (H); a residue selected from the group consisting Arg (R), Lys (K), His (H), and Gln (Q); or a residue selected from the group consisting of Asn (N), Gln (Q), Asp (D), and Glu (E)).

**[0091]** A Class II anti-inflammatory polypeptide can comprise, consist essentially of, or consist of a striapathic region that further includes a first additional amino acid residue directly bound to amino acid residue Y<sub>3a</sub> of Formula VII. The first additional amino acid residue can be a hydrophobic amino acid residue (e.g., a residue selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), Ile (I), Thr (T), Pro (P), Ser (S), Ala (A), and Gly (G)); a residue selected from the group consisting of Phe (F), Trp (W), and Tyr (Y); a residue selected from the group consisting of Phe (F), Trp (W), Tyr (Y), and Leu (L); or, a residue selected from the group consisting of Leu (L), Cys (C), Met (M), Val (V), and Ile (I)).


Alternatively, the first additional amino acid residue can be a hydrophilic amino acid residue (e.g., a residue selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E); a residue selected from the group consisting of Arg (R), Lys (K), and His (H); a residue selected from the group consisting Arg (R), Lys (K), His (H), and Gln (Q); or a residue selected from the group consisting of Asn (N), Gln (Q), Asp (D), and Glu (E)).

**[0092]** A Class II anti-inflammatory polypeptide can comprise, consist essentially of, or consist of a striapathic region that further includes a first additional amino acid residue directly bound to amino acid residue Y<sub>1a</sub> of Formula VII and a second additional amino acid residue directly bound to amino acid residue Y<sub>3a</sub> of Formula VII. The first additional amino acid residue can be a hydrophobic amino acid residue and the second additional amino acid residue can be a hydrophilic amino acid residue. Alternatively, the first additional amino acid residue can be a hydrophilic amino acid residue and the second amino acid residue can be a hydrophobic amino acid residue. Regardless, the additional hydrophobic amino acid residue can be selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), Ile (I), Thr (T), Pro (P), Ser (S), Ala (A), and Gly (G); and in certain embodiments from the group consisting of Phe (F), Trp (W), and Tyr (Y); and in additional embodiments from the group consisting of Phe (F). The additional hydrophilic amino acid residue can be selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E); and in certain embodiments, a residue selected from the group consisting of Arg (R), Lys (K), and His (H); or a residue selected from the group consisting of Asn (N), Gln (Q), Asp (D), and Glu (E).

**[0093]** A Class II anti-inflammatory polypeptide can comprise, consist essentially of, or consist of a striapathic region comprising, consisting essentially of, or consisting of a sequence selected from the group of sequences listed in Table 5, e.g., RP124, RP132, RP134, RP142, RP147, RP151, RP166-RP172, RP175, RP177, RP182, RP183, RP185, RP186, RP 424, RP190, RP194, RP198, RP199-RP202, RP204, RP206, RP207, RP209, RP210, RP212-RP216, RP218, RP219, RP425, RP225, RP227, RP233-RP239, RP398, RP241-RP247, RP250-RP256, RP426, RP427, RP285, and RP387 (i.e., SEQ ID NOs: 106-173, respectively). In certain embodiments, the Class II anti-inflammatory polypeptide comprises, consists essentially of, or consists of a striapathic region comprising, consisting essentially of, or consisting of a sequence selected from the group consisting of RP124 (SEQ ID NO: 106), RP166 (SEQ ID NO: 112), RP182 (SEQ ID NO: 121), and RP183 (SEQ ID NO: 122).

**[0094]** Class XII Polypeptides

**[0095]** An anti-inflammatory polypeptide of the invention can be a Class XII polypeptide. Class XII anti-inflammatory polypeptides can comprise, consist essentially of, or consist of a striapathic region that includes a sequence selected from the group of sequences defined by Formula XLIX:



**[0096]** Amino acid residues  $Y_{1a}$ ,  $Y_{2a}$ , and  $Y_{3a}$  of Formula XLIX can be each independently selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Ile (I), Cys (C), Met (M), Val (V), Pro (P), Thr (T), Ser (S), Ala (A), and Gly (G). In certain embodiments, amino acid residues  $Y_{1a}$ ,  $Y_{2a}$ , and  $Y_{3a}$  of Formula XLIX are each independently selected from: the group consisting of Phe (F), Trp (W), and Tyr (Y); the group consisting of Phe (F), Trp (W), Tyr (Y), and Leu (L); or the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Ile (I), Cys (C), Met (M), Val (V), and Ala (A).

**[0097]** Amino acid residues  $X_{1a}$ ,  $X_{2a}$ , and  $X_{3a}$  of Formula XLIX can be each independently selected from the group consisting of Arg (R), Lys (K), His (H), Gln (Q), Glu (E), Asn (N), and Asp (D). In certain embodiments, amino acid residues  $X_{1a}$ ,  $X_{2a}$ , and  $X_{3a}$  are each independently selected from the group consisting of Arg (R), Lys (K), and His (H). Alternatively, amino acid residues  $X_{1a}$ ,  $X_{2a}$ , and  $X_{3a}$  are each independently selected from the group consisting of Arg (R), Lys (K), His (H), and Gln (Q).

**[0098]** A Class XII anti-inflammatory polypeptide can comprise, consist essentially of, or consist of a striapathic region that further includes a first additional amino acid residue. The first additional amino acid residue can be a hydrophilic amino acid residue directly bound to amino acid residue  $Y_{1a}$  of Formula XLIX. Thus, the first additional amino acid residue can be, for example, a residue selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E); a residue selected from the group consisting of Arg (R), Lys (K), and His (H); a residue selected from the group consisting Arg (R), Lys (K), His (H), and Gln (Q); or a residue selected from the group consisting of Asn (N), Gln (Q), Asp (D), and Glu (E)). Alternatively, the first amino acid residue can be a hydrophobic amino acid residue directly bound to amino acid residue  $X_{3a}$  of Formula XLIX. Thus, the first additional amino acid residue can be, for example, a residue selected from the group consisting of Phe (F), Trp (W), and Tyr (Y); a residue selected from the group consisting of Phe (F), Trp (W), Tyr (Y), and Leu (L); or a

residue selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Ile (I), Cys (C), Met (M), Val (V), and Ala (A)).

**[0099]** A Class XII anti-inflammatory polypeptide can comprise, consist essentially of, or consist of a striapathic region that further includes first and second additional amino acid residues. The first additional amino acid residue can be a hydrophilic amino acid residue, as discussed above, which is directly bound to amino acid residue  $Y_{1a}$  of Formula XLIX. The second additional amino acid residue can be directly bound to the first additional amino acid residue. Thus, the second additional amino acid residue can be a hydrophobic amino acid residue, e.g., a residue selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), Ile (I), Thr (T), Pro (P), Ser (S), Ala (A), and Gly (G); a residue selected from the group consisting of Phe (F), Trp (W), and Tyr (Y); a residue selected from the group consisting of Phe (F), Trp (W), Tyr (Y), and Leu (L); or, a residue selected from the group consisting of Leu (L), Cys (C), Met (M), Val (V), and Ile (I)). Alternatively, the second additional amino acid residue can be a hydrophobic amino acid residue directly bound to amino acid residue  $X_{3a}$  of Formula XLIX, as discussed above.

**[00100]** A Class XII anti-inflammatory polypeptide can comprise, consist essentially of, or consist of a striapathic region that further includes first, second, and third additional amino acid residues. The first additional amino acid residue can be a hydrophilic amino acid residue which is directly bound to amino acid residue  $Y_{1a}$  of Formula XLIX and the second additional amino acid residue can be a hydrophobic amino acid residue which is directly bound to the first additional amino acid residue, as discussed above. The third additional amino acid residue can be a hydrophilic amino acid residue that is directly bound to the second additional amino acid residue. Thus, the third additional amino acid residue can be, for example, a residue selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E); a residue selected from the group consisting of Arg (R), Lys (K), and His (H); a residue selected from the group consisting Arg (R), Lys (K), His (H), and Gln (Q); or a residue selected from the group consisting of Asn (N), Gln (Q), Asp (D), and Glu (E)). Alternatively, the third amino acid residue can be a hydrophobic amino acid residue directly bound to amino acid residue  $X_{3a}$  of Formula XLIX. Thus, the third additional amino acid residue can be, for example, a residue selected from the group consisting of Phe (F), Trp (W), and Tyr (Y); a residue selected from the group consisting of Phe (F), Trp (W), Tyr (Y), and Leu (L); or a residue selected from the group

consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Ile (I), Cys (C), Met (M), Val (V), and Ala (A)).

**[00101]** A Class XII anti-inflammatory polypeptide can comprise, consist essentially of, or consist of a striapathic region that further includes four, five, six, or more additional amino acid residues. The additional amino acid residue can be added in a manner that continues the alternating pattern of a hydrophobic amino acid residue followed by a hydrophilic amino acid residue followed by a hydrophobic amino acid residue, as shown in Formula XLIX. In this manner, Class XII anti-inflammatory polypeptides can be expanded to comprise, consist essentially of, or consist of a striapathic region having 10, 11, 12, or more amino acid residues.

**[00102]** An anti-inflammatory polypeptide of Class XII can comprise, consist essentially of, or consist of a striapathic region comprising, consisting essentially of, or consisting of a sequence selected from the group consisting of RP393, RP391, PR392, RP390, and RP389 (i.e., SEQ ID NOs: 253-257, respectively).

**[00103]** Class XIV Polypeptides

**[00104]** An anti-inflammatory polypeptide of the invention can be a Class XIV polypeptide. Class XIV anti-inflammatory polypeptides can comprise, consist essentially of, or consist of a striapathic region that includes a sequence selected from the group of sequences defined by any one of Formulas LI through LIV:

$X_{1a}-X_{1b}-Y_{1a}-Y_{1b}-X_{2a}-Y_{2a}-Y_{2b}-Y_{2c}-Y_{2d}$  (Formula LI);

$Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-X_{1a}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}$  (Formula LII);

$Y_{1a}-Y_{1b}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}-X_{2b}-Y_{3a}-X_{3a}-Y_{4a}$  (Formula LIII); and

$Y_{1a}-X_{1a}-Y_{2a}-X_{2a}-Y_{3a}-Y_{3b}-Y_{3c}-X_{3a}-Y_{4a}-Y_{4b}$  (Formula LIV).

**[00105]** The striapathic region of a Class XIV polypeptide can include at least 3 (e.g., 3 to 6) proline amino acid residues. For example, amino acid residues  $Y_{1a}$ ,  $Y_{2a}$ , and  $Y_{2b}$  in Formula LI can be proline amino acid residues. Alternatively, amino acid residues  $Y_{1c}$ ,  $Y_{1d}$ , and  $Y_{2b}$  in Formula LII can be proline amino acid residues. In other alternatives, amino acid residues  $Y_{1a}$ ,  $Y_{2a}$ ,  $Y_{2b}$ ,  $Y_{2c}$ ,  $Y_{3a}$ , and  $Y_{4a}$  in Formula LIII can be proline amino acid residues. In still other alternatives, amino acid residues  $Y_{1a}$ ,  $Y_{2b}$ ,  $Y_{3a}$ ,  $Y_{3b}$ ,  $Y_{3c}$ , and  $Y_{4b}$  in Formula LIV can be proline amino acid residues.

**[00106]** Hydrophobic amino acid residues (e.g.,  $Y_{1a}$ ,  $Y_{1b}$ ,  $Y_{1c}$ ,  $Y_{1d}$ ,  $Y_{2a}$ ,  $Y_{2b}$ ,  $Y_{2c}$ ,  $Y_{2d}$ ,  $Y_{3a}$ ,  $Y_{3b}$ ,  $Y_{3c}$ ,  $Y_{4a}$ , and  $Y_{4b}$ ) not designated as proline residues in Formulas LI through LIV can be

each individually selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), Ile (I), Thr (T), Pro (P), Ser (S), Ala (A), and Gly (G). In certain embodiments, such hydrophobic amino acid residues are each individually selected from: the group consisting of Phe (F), Trp (W), and Tyr (Y); the group consisting of Phe (F), Trp (W), Tyr (Y), and Leu (L); or, the group consisting of Leu (L), Cys (C), Met (M), Val (V), and Ile (I).

**[00107]** Hydrophilic amino acid residues in Formulas LI through LIV (e.g., X<sub>1a</sub>, X<sub>1b</sub>, X<sub>2a</sub>, X<sub>2b</sub>, and X<sub>3a</sub>) can be each individually selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E). In certain embodiments, such hydrophilic amino acid residues are each individually selected from the group consisting of Arg (R), Lys (K), and His (H). Alternatively, such hydrophilic amino acid residues are each individually selected from: the group consisting of Arg (R), Lys (K), His (H), and Gln (Q); or the group consisting of Asn (N), Gln (Q), Asp (D), and Glu (E).

**[00108]** An anti-inflammatory polypeptide of Class XIV can comprise, consist essentially of, or consist of a striapathic region that comprises, consists essentially of, or consists of a sequence selected from the group consisting of RP449, RP450, RP448, RP447, RP452, RP451, RP444, RP441, RP446, RP445, RP442, and RP443 (i.e., SEQ ID NOs: 258-269, respectively).

**[00109]** Other Classes of Polypeptides

**[00110]** An anti-inflammatory polypeptide of the invention can be from any of Classes II through XI and XIII. Such anti-inflammatory polypeptides can comprise, consist essentially of, or consist of a striapathic region that includes a sequence selected from the group of sequences defined by any one of Formulas IV through XLVIII and L.

**[00111]** Hydrophobic amino acid residues in Formulas IV through XLVIII and L (e.g., Y<sub>1a</sub>, Y<sub>1b</sub>, Y<sub>1c</sub>, Y<sub>1d</sub>, Y<sub>1e</sub>, Y<sub>2a</sub>, Y<sub>2b</sub>, Y<sub>2c</sub>, Y<sub>2d</sub>, Y<sub>2e</sub>, Y<sub>3a</sub>, Y<sub>3b</sub>, Y<sub>3c</sub>, Y<sub>4a</sub>, and Y<sub>4b</sub>) can be each individually selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), Ile (I), Thr (T), Pro (P), Ser (S), Ala (A), and Gly (G). In certain embodiments, such hydrophobic amino acid residues are each individually selected from: the group consisting of Phe (F), Trp (W), and Tyr (Y); the group consisting of Phe (F), Trp (W), Tyr (Y), and Leu (L); or, the group consisting of Leu (L), Cys (C), Met (M), Val (V), and Ile (I).

**[00112]** Hydrophilic amino acid residues in Formulas IV through XLVIII and L (e.g., X<sub>1a</sub>, X<sub>1b</sub>, X<sub>1c</sub>, X<sub>1d</sub>, X<sub>2a</sub>, X<sub>2b</sub>, X<sub>2c</sub>, X<sub>2d</sub>, X<sub>3a</sub>, X<sub>3b</sub>, X<sub>3c</sub>, X<sub>4a</sub>, and X<sub>4b</sub>) can be each individually selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E).

In certain embodiments, such hydrophilic amino acid residues are each individually selected from the group consisting of Arg (R), Lys (K), and His (H). Alternatively, such hydrophilic amino acid residues are each individually selected from: the group consisting of Arg (R), Lys (K), His (H), and Gln (Q); or the group consisting of Asn (N), Gln (Q), Asp (D), and Glu (E).

**[00113]** An anti-inflammatory polypeptide of any one of Formulas IV through XLVIII and L can comprise, consist essentially of, or consist of a striapathic region that further includes a first additional amino acid residue directly bound to the first amino acid residue of the Formula (e.g., Y<sub>1a</sub> or X<sub>1a</sub>) or to the last amino acid residue in the formula. The first additional amino acid residue can be a hydrophilic amino acid residue (e.g., a residue selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E); a residue selected from the group consisting of Arg (R), Lys (K), and His (H); a residue selected from the group consisting Arg (R), Lys (K), His (H), and Gln (Q); or a residue selected from the group consisting of Asn (N), Gln (Q), Asp (D), and Glu (E)). Alternatively, the first additional amino acid residue can be a hydrophobic amino acid residue (e.g., a residue selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), Ile (I), Thr (T), Pro (P), Ser (S), Ala (A), and Gly (G); a residue selected from the group consisting of Phe (F), Trp (W), and Tyr (Y); a residue selected from the group consisting of Phe (F), Trp (W), Tyr (Y), and Leu (L); or, a residue selected from the group consisting of Leu (L), Cys (C), Met (M), Val (V), and Ile (I)).

**[00114]** An anti-inflammatory polypeptide of any one of Formulas IV through XLVIII and L can comprise, consist essentially of, or consist of a striapathic region that further includes first and second additional amino acid residues, with the first additional amino acid residue directly bound to the first amino acid residue of the Formula (e.g., Y<sub>1a</sub> or X<sub>1a</sub>) or the last amino acid residue in the formula, and the second additional amino acid residue directly bound to the first amino acid residue in the formula, the last amino acid residue in the formula, or the first additional amino acid residue. The first additional amino acid residue can be a hydrophilic or hydrophobic amino acid residue, as discussed above. The second additional amino acid residue likewise can be a hydrophilic or hydrophobic amino acid residue, as discussed above.

**[00115]** An anti-inflammatory polypeptide of any one of Formulas IV through XLVIII and L can comprise, consist essentially of, or consist of a striapathic region that comprises, consists essentially of, or consists of a sequence selected from the group consisting of RP396, RP405,



RP174, RP176, RP178, RP180-181, RP184, RP408, RP187, RP416, RP188, RP189, RP388, RP417, RP191-RP193, RP404, RP196, RP397, RP197, RP402, RP203, RP409, RP205, RP208, RP217, RP220-RP224, RP226, RP229, RP231, RP240, RP248, RP249, RP415, RP257, RP259-RP266, RP269, RP272, RP274, RP277-RP279, RP282, RP283, RP286, RP289, and RP414 (i.e., SEQ ID NOs: 174-233, respectively).

**[00116]**      Variant Polypeptides

**[00117]**      The exemplary anti-inflammatory polypeptide sequences shown in Tables 3-9 (below) are merely examples and are not the only anti-inflammatory polypeptides provided herein. Indeed, fragments and variants of the sequences of the disclosed peptides are within the scope of the invention.

**[00118]**      A “fragment” of the invention includes at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous amino acid residues of a polypeptide disclosed herein (or up to one less than the number of amino acid residues in the subject polypeptide) and retains at least one anti-inflammatory property of the subject polypeptide. Thus, fragments of the invention include polypeptides that are missing one, two, three, four, or more amino acids from the N-terminus and/or the C-terminus relative to a polypeptide disclosed herein.

**[00119]**      A “variant” of the invention is a polypeptide that is substantially similar to a polypeptide disclosed herein and retains at least one anti-inflammatory property of the subject polypeptide. Variants can include deletions (i.e., truncations) of one or more amino acid residues at the N-terminus or the C-terminus of a subject polypeptide disclosed herein; deletion and/or addition of one or more amino acid residues at one or more internal sites in the subject polypeptide disclosed herein; and/or substitution of one or more amino acid residues at one or more positions in the subject polypeptide disclosed herein. For subject polypeptides that are 12 amino acid residues in length or shorter, variant polypeptides can include three or fewer (e.g., two, one, or none) deleted amino acid residues, whether located internally, at the N-terminal end, and/or at the C-terminal end.

**[00120]**      Accordingly, the invention further provides anti-inflammatory polypeptides that are at least 50% identical (e.g., at least 60%, 70%, 80%, 90%, or more) to any one of the anti-inflammatory polypeptides disclosed in Tables 3-9 and still retain at least one anti-inflammatory property. For example, the invention provides anti-inflammatory polypeptides that are 3 to 24 amino acids residues in length and comprise, consist essentially of, or consist of a striapathic

region sharing at least 50% identity (e.g., at least 60%, 70%, 80%, 90%, or more identity) with a Class I anti-inflammatory polypeptide (e.g., any one of the sequences of Table 3). Such identity can be shared, for example, with RP-394 (SEQ ID NO: 33), RP-108 (SEQ ID NO: 34), RP-113 (SEQ ID NO: 39), RP-118 (SEQ ID NO: 44), RP-129 (SEQ ID NO: 54), or RP-179 (SEQ ID NO: 86). Alternatively, the invention provides anti-inflammatory polypeptides that are 3 to 24 amino acid residues in length and comprise, consist essentially of, or consist of a striapathic region sharing at least 50% identity (e.g., at least 60%, 70%, 80%, 90%, or more identity) with a Class II, Sub-class 1 anti-inflammatory polypeptide (e.g., any one of the sequences of Table 5). Such identity can be shared, for example, with RP-124 (SEQ ID NO: 106), RP-134 (SEQ ID NO: 108), RP-166 (SEQ ID NO: 112), RP-168 (SEQ ID NO: 114), RP-182 (SEQ ID NO: 121), or RP-183 (SEQ ID NO: 122). In other alternatives, the invention provides anti-inflammatory polypeptides that are 3 to 24 amino acid residues in length and comprise, consist essentially of, or consist of a striapathic region sharing at least 50% identity (e.g., at least 60%, 70%, 80%, 90%, or more identity) with any Class II through Class IX or Class XIII anti-inflammatory polypeptide (e.g., any one of the sequences of Table 6). In other alternatives, the invention provides anti-inflammatory polypeptides that are 3 to 24 amino acid residues in length and comprise, consist essentially of, or consist of a striapathic region sharing at least 50% identity (e.g., at least 60%, 70%, 80%, 90%, or more identity) with any Class VIII to Class XI anti-inflammatory polypeptide (e.g., any one of the sequences of Table 7). In other alternatives, the invention provides anti-inflammatory polypeptides that are 3 to 24 amino acid residues in length and comprise, consist essentially of, or consist of a striapathic region sharing at least 50% identity (e.g., at least 60%, 70%, 80%, 90%, or more identity) with a Class XII or Class XIV anti-inflammatory polypeptide (e.g., any one of the sequences of Table 8). In still other alternatives, the invention provides anti-inflammatory polypeptides that are 3 to 24 amino acid residues in length and comprise, consist essentially of, or consist of a striapathic region sharing at least 50% identity (e.g., at least 60%, 70%, 80%, 90%, or more identity) with any one of the combination sequences of Table 9.

**[00121]** The differences between the striapathic region of a homologous anti-inflammatory polypeptide and any one of the anti-inflammatory polypeptides of Tables 3-9 can include deletions, additions, and/or substitutions of amino acid residues, as discussed above. Substituted amino acid residues can be unrelated to the amino acid residue being replaced (e.g.,

unrelated in terms of hydrophobicity/hydrophilicity, size, charge, polarity, etc.), or the substituted amino acid residues can constitute similar, conservative, or highly conservative amino acid substitutions. As used herein, “similar,” “conservative,” and “highly conservative” amino acid substitutions are defined as shown in Table 2, below. The determination of whether an amino acid residue substitution is similar, conservative, or highly conservative is based exclusively on the side chain of the amino acid residue and not the peptide backbone, which may be modified to increase peptide stability, as discussed below.

**Table 2: Classification of Amino Acid Substitutions**

<b>Amino Acid in Subject Polypeptide</b>	<b>Similar Amino Acid Substitutions</b>	<b>Conservative Amino Acid Substitutions</b>	<b>Highly Conservative Amino Acid Substitutions</b>
Glycine (G)	A,S,N	A	n/a
Alanine (A)	S,G,T,V,C,P,Q	S,G,T	S
Serine (S)	T,A,N,G,Q	T,A,N	T,A
Threonine (T)	S,A,V,N,M	S,A,V,N	S
Cysteine (C)	A,S,T,V,I	A	n/a
Proline (P)	A,S,T,K	A	n/a
Methionine (M)	L,I,V,F	L,I,V	L,I
Valine (V)	I,L,M,T,A	I,L,M	I
Leucine (L)	M,I,V,F,T,A	M,I,V,F	M,I
Isoleucine (I)	V,L,M,F,T,C	V,L,M,F	V,L,M
Phenylalanine (F)	W,L,M,I,V	W,L	n/a
Tyrosine (Y)	F,W,H,L,I	F,W	F
Tryptophan (W)	F,L,V	F	n/a
Asparagine (N)	Q	Q	Q
Glutamine (Q)	N	N	N
Aspartic Acid (D)	E	E	E
Glutamic Acid (E)	D	D	D
Histidine (H)	R,K	R,K	R,K
Lysine (K)	R,H	R,H	R,H
Arginine (R)	K,H	K,H	K,H

[00122] In certain embodiments, a variant polypeptide of the invention binds to two or more targets (e.g., pro-inflammatory targets). In some embodiments, a variant polypeptide binds to three, four, five, or more pro-inflammatory targets. For example, a variant polypeptide can bind to any combination of targets disclosed herein (e.g., an NF-kB Class II protein and human serum albumin (HSA)), as discussed below. Such binding can be based on *in silico*, *in vitro*, or *in vivo* data.

[00123] Modeling Polypeptide Binding to Target Molecules

[00124] The determination of whether a polypeptide has anti-inflammatory properties can be performed *in silico*. For example, the binding of a polypeptide (e.g., a polypeptide that has a length of 3 to 24 amino acid residues and includes a striapathic region comprising at least 25% of the length of the polypeptide) to a putative target molecule can be modeled *in silico*, using any of the numerous molecular modeling and docking platforms available in the art, to thereby assess whether the polypeptide is an anti-inflammatory polypeptide. The on-line ClusPro™ algorithm, version 2.0 (developed at Boston University) is particularly useful for modeling the conformation of polypeptides and their binding to target molecules, such as signaling proteins, as described in the Examples set forth below. Modeling algorithms, such as the ClusPro™ algorithm, that allow for docking of polypeptides on target molecules can be used, for example, to predict the binding energy associated with the polypeptide-target interaction. Such predictions provide reasonable estimates for the binding energies, but they are not necessarily equal to the binding energies that would be calculated by testing the polypeptides and protein targets *in vitro*. In that regard, the binding energies identified herein were all generated using the ClusPro™ algorithm. Accordingly, absent indication to the contrary, any numerical reference to the binding energy associated with a peptide binding to a particular target is a reference to a binding energy determined by modeling the interaction using the ClusPro™ algorithm.

[00125] As detailed in the Examples below, the exemplary RP peptides have been shown to interact with various signaling molecules associated with inflammation, including NF-kB Class II subunit RelB, TGFβ, Notch1, Wnt8R, TRAIL, IL6R, IL10R, EGFR, and CDK6, as well as other membrane associated signaling molecules, including CD206, CD47 and SIRP-α, translational modification protein transglutaminase 2 (TGM2), and histone modification enzyme histone methyl transferase (HMT). Upon folding of these protein targets to their normal 3-

dimensional conformations, an amphipathic cleft is often generated that has high affinity for the immune-modulating peptides herein described.

**[00126]** For modeling interactions between potential anti-inflammatory polypeptides and NF-kB Class II subunits, any Class II subunit sequence can be used (e.g., RelA, RelB, cRel, NF-kB1, or NF-kB2). In certain embodiments, the Class II subunit sequence folds into a functional Class II subunit or a functional fragment thereof. The particular Class II subunit used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human NF-kB Class II subunit is selected if the intended subject is a human, a bovine NF-kB Class II subunit is selected if the intended subject is a cow, etc.). The NF-kB Class II subunit sequence used for modeling can be the human RelB sequence (NCBI Accession No. NP-006500), which is as follows:

MLRSGPASGPSVPTGRAMPSRRVARPPAAPELGALGSPDLSSLSLAVSRSTDELEIIDEYIKENG  
FGLDGGQPGPGEGLPRLVSRGAASLSTVTLGVPAPPATPPPWGCPLGRLVSPAPGPGPQPHLVIT  
EQPKQRGMRFRYECEGRSAGSILGESSTEASKTLPAIELRDCGGLREVEVTACLWWDWPHRVHP  
HSLVGKDCTDGI CRVRLRPHVSPRHSFNNLGIQCVRKKEIEAAIERKIQLGIDPYNAGSLKNHQE  
VDMNVVRICFQASYRDQQGQMRMDPVLSEPVYDKKSTNTSELRICRINKESGPCTGGEELYLLC  
DKVQKEDISVVFSRASWEGRADFSQADVHRQIAIVFKTPPYEDLEIVEPVTNVNVLQRLTDGVCS  
EPLPFTYLPRDHDSYGVDKKRKRGMPPDVLGELNSSDPHGIESKRRKKKPAILDHFLPNHSGSPFL  
PPSALLPDPDFSGTVSLPGLEPPGGPDLLDDGFAYDPTAPTFLTMLDLLPPAPPHASAVVCSGG  
AGAVVGETPGPEPLTLD SYQAPGPGDGGTASLVGSNMFPNHYREAAFGGGLLSPGPEAT (SEQ  
ID NO: 367).

**[00127]** The underlined sequence in human RelB (above) has been identified as the dimerization domain. The highlighted amino acid residues (Tyr-300, Leu-302, and His-332) are believed to be particularly important in the dimerization interaction.

**[00128]** An anti-inflammatory polypeptide can be identified based on its ability to bind (e.g., *in silico*) to the dimerization pocket of the Class II subunit and/or interfere with or block the ability of the Class II subunit to dimerize. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human RelB (SEQ ID NO: 367) selected from the group consisting of Leu-281, Ile-283, Cys-284, Glu-298, Tyr-300, Leu-301, Leu-302, Cys-303, Ile-311, Ser-312, Ala-329, Asp-330, Val-331, His-332, Gln-334, and Leu-371, or the equivalent amino acid residue(s) in a different human NF-kB Class II protein or an NF-kB Class II protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one

amino acid residue of human RelB (SEQ ID NO: 367) selected from the group consisting of Glu-298, Tyr-300, Leu-302, Asp-330, Gln-334, and Leu-371 or the equivalent amino acid residue(s) in a different human NF-kB Class II protein or an NF-kB Class II protein of another species.

**[00129]** In certain embodiments, an anti-inflammatory polypeptide binds to human RelB (SEQ ID NO: 367) with an affinity of at least -650 kcal/mol, and in certain embodiments at least -700, -750, -800, -850, -900, -925, -950, -975, -1000, -1025, -1050, -1075, -1100, -1125, -1150, -1200 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00130]** For modeling interactions between potential anti-inflammatory polypeptides and TGFβ, any TGFβ protein sequence can be used. The TGFβ sequence generally folds into a functional TGFβ protein or a functional fragment thereof. The TGFβ protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human TGFβ is selected if the intended subject is a human, a bovine TGFβ is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human TGFβ sequence (NCBI Acc. No. NP\_000651.3), which is as follows:

MPPSGLRLLPLLLPLLWLLVLTTPGRPAAGLSTCKTIDMELVKRKRIEAI RQILSKLRLA  
 SPSPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEI  
 YDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSWR  
 YLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFT  
 TGRRGDLATI HGMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYI  
 DFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNP GASAAPCCVPQA  
 LEPLPIVYYVGRKPKVEQLSNMIVRSCKCS (SEQ ID NO: 368).

**[00131]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the receptor binding site on TGFβ and/or interfere with or block the ability of TGFβ to bind to its receptor. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human TGFβ (SEQ ID NO: 368) selected from the group consisting of Arg-25, Gly-29, Trp-30, Lys-31, Trp-32, Ile-33, His-34, Tyr-91, Val-92, Val-93, Gly-94, Arg-95, Lys-96, and Pro-97, or the equivalent amino acid residue(s) in a TGFβ protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human TGFβ (SEQ ID NO: 368) selected from the group consisting of Leu-20, Ile-22,

Phe-24, Asp-27, Leu-28, Trp-30, Trp-32, Tyr-39, Phe-43, Pro-80, Leu-83, Leu-101 and Ser-112, or the equivalent amino acid residue(s) in a TGF $\beta$  protein of another species. In other alternatives, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human TGF $\beta$  (SEQ ID NO: 368) selected from the group consisting of Asp-27, Leu-28, Trp-30, and Trp-32, or the equivalent amino acid residue(s) in a TGF $\beta$  protein of another species.

**[00132]** In certain embodiments, an anti-inflammatory polypeptide can bind to human TGF $\beta$  (SEQ ID NO: 368) with an affinity of at least -650 kcal/mol, and in certain embodiments at least -700, -750, -800, -850, -900, -925, -950, -975, -1000, -1025, -1050 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00133]** For modeling interactions between potential anti-inflammatory polypeptides and Notch1, any Notch1 protein sequence can be used. The Notch1 sequence used for modeling generally folds into a functional Notch1 protein or a calcium-binding fragment thereof. The Notch1 sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human Notch1 is selected if the intended subject is a human, a bovine Notch1 is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human Notch1 sequence (GenBank Acc. No.

AAG33848.1), which is as follows:

```
MPPLLAPLLCLALLPALAARGPRCSQPGETCLNGGKCEAANGTEACVCGGAFVGPRCQDP
NPCLSTPCKNAGTCHVVDRRGVADYACSCALGFSGPLCLTPLDNACLTNPCRNGGTCDLL
TLTEYKCRCPGWSGKSCQQADPCASNPCANGGQCLPFEASYICHCPPSFHGPTCRQDVN
ECGQKPRLCRHGGTCHNEVGSYRCVCRATHGTGPNCEPHYVPCSPSPCQNGGTCRPTGDVT
HECACLPGFTGQNCEENIDDCPGNNCKNGGACVDGVNTYNCPCPPEWTGQYCTEDVDECQ
LMPNACQNGGTCHNTHGGYNCVVCVNGWTGEDCSENIDDCASAACFHGATCHDRVASFYCE
CPHGRTGLLCHLNDACISNPCNEGSNCDTNPVNGKAICTCPSGYTGPACSQDVDECSLGA
NPCEHAGKCINTLGSFECQCLQGYTGPRCEIDVNECVSNPCQNDATCLDQIGEFQCMCMP
GYEGVHCEVNTDECASSPCLHNGRCLDKINEFQCECPTGFTGHLQYDVDECASTPCKNG
AKCLDGPNTYTCVCTEGYTGTGTHCEVDIDECDDPDPCHYGSCCKDGVATFTCLCRPGYTGHHC
ETNINECSSQPCRLRGTCQDPDNAYLCFCLKGTTGPNCEINLDDCASSPCDSGTCLDKID
GYECACEPGYTGSMCNSNIDECAGNPCHNGGTCEDEINGFTCRCPEGYHDPCLSEVNEC
NSNPCVHGACRDSLNGYKCDGPGWSGTNCDINNNECESNPCVNGGTCKDMTSGIVCTCR
EGFSGPNCQTNINECASNPCLNKGTCIDDVAGYKCNCLLPYTGATCEVVLAPCAPSPCRN
```

GGECRQSEDIYESFSCVCPTAGAKGQTCEVDINECVLSPCRHGASCQNTGXYRCHCQAGY  
 SGRNCETDIDDCRPNPCHNGGSCDTGINTAFCDCLPGFRGTFCCEEDINECASDPCRNGAN  
 CTDVDSYTCCTCPAGFSGIHCENNTPDCTESSCFNGGTCVDGINSFTCLCPPGFTGSYCQ  
 HVVNECDSRPCLLGGTCQDGRGLHRCTCPQGYTGPNQCQNLVHWCDSSPCKNGGKCWQTHT  
 QYRCECPSGWTGLYCDVPSVSCEVAAQRQGVDVARLCQHGGLCVDAGNTHHCRCQAGYTG  
 SYCEDLVDECSPSPCQNGATCTDYLGGYSCKCVAGYHGVNCSEEIDECLSHPCQNGGTCL  
 DLPNTYKCSCPRGTTQGVHCEINVDDCNPPVDPVSRSPKCFNNGTCVDQVGGYSCTCPPGF  
 VGERCEGDVNECLSNPCDARGTQNCVQVRVNDHFCECRAGHTGRRCESVINGCKGKPKCKNG  
 GTCAVASNTARGFICKCPAGFEGATCENDARTCGSLRCLNNGGTCISGPRSPTCLCLGPFT  
 GPECQFPASSPCLGGNPCYNQGTCEPTSESPFYRCLCPAKFNGLLCHILDYSFGGGAGRD  
 IPPPLIEEACELPECQEDAGNKVCSLQCNNHACGWDGGDCSLNFNDPWKNCTQSLQCWKY  
 FSDGHCDSDQNSAGCLFDGFDQRAEGQCNPLYDQYCKDHFSDGHCDQGCNSAECEWDGL  
 DCAEHVPERLAAGTLVVVVLMPPEQLRNSSFHFLRELSRVLHTNVVFKRDAHQQMIFPY  
 YGREEELRKHPKRAAEGWAAPDALLGQVKASLLPGGSEGGRRRRELDPM DVRGSI VYLE  
 IDNRQCVQASSQCFQSATDVAAFLGALASLGSLNIPYKIEAVQSETVEPPPPAQLHFMYV  
 AAAAFVLLFFVGCGLLSRKRRRQHGQLWFPEGFKVSEASKKKRREPLGEDSVGLKPLKN  
 ASDGALMDDNQNEWGDEDLETKKFRFEEPVLDPDLDQTDHRQWTQQHLDAADLRMSAMA  
 PTPPQGEVDADCMDVNVVRGPDGFTPLMIASCSGGGLETGNSSEEEEDAPAVISDFIYQGAS  
 LHNQTDRTGETALHLAARYSRSDAAKRLLEASADANIQDNMGRTPHLHAAVSADAQGVFQI  
 LIRNRATDL DARMHDGTTPLILAAARLAVEGMLEDLINSHADVNAVDDLKKSALHWAAAVN  
 NVDAAVVLLKNGANKDMQNNREETPLFLAAREGSYETAKVLLDHFANRDI TDHMDRLPRD  
 IAQERMHHDIVRLLEYNLVRSPQLHGAPLGGTPTLSPPLCSPNGYLGSLKPGVQGGKVR  
 KPSSKGLACGSKEAKDLKARRKKSQDGKGCLLDSSGMLSPVDSLES PHGYLS DVASPPLL  
 PSPFQQSPSVPLNHLPGMPDTHLGIGHLNVAAPKEMAALGGGRLAFETGPPRLSHLPVA  
 SGTSTVLGSSSGGALNFTVGGSTSLNGQCEWLSRLQSGMVPNQYNPLRGSVAPGPLSTQA  
 PSLQHGMVGPLHSSLAASALSQMMSYQGLPSTRLATQPHLVQTQQVQPQNLQMQQQNLQP  
 ANIQQQQSLQPPPPPPQPHLGVSSAASGHLGRSFLSGEPSQADVQPLGPSSLAVHTILPQ  
 ESPALPTSLPSSLVPPVTAAQFLTPPSQHSYSSPVDNTPSHQLQVPEHPFLTPSPESPQDQ  
 WSSSSPHSNVSDWSEGVSSPPTSMQSQIARIPEAFK (SEQ ID NO: 369).

**[00134]** An anti-inflammatory polypeptide can be identified based on its ability to bind to the calcium-binding site on Notch1 and/or interfere with or block the ability of Notch1 to bind to calcium. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human Notch1 (SEQ ID NO: 369) selected from the group consisting of Phe-1520, Gln-1523, Arg-1524, Glu-1526, Ala-1553, Glu-1556, Trp-1557, Cys-1562, His-1602, Arg-1684,



Gln-1685, Cys-1686, Ser-1691, Cys-1693, Phe-1694, and Phe-1703, or the equivalent amino acid residue(s) in a Notch1 protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human Notch1 (SEQ ID NO: 369) selected from the group consisting of Phe-1520, Trp-1557, Cys-1562, and Phe-1703, or the equivalent amino acid residue(s) in a Notch1 protein of another species.

**[00135]** In certain embodiments, a polypeptide of the invention binds to human Notch1 (SEQ ID NO: 369) with an affinity of at least -650 kcal/mol, and in certain embodiments at least -700, -750, -800, -850, -900, -925, -950, -975, -1000, -1025, -1050, -1075 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00136]** For modeling interactions between potential anti-inflammatory polypeptides and Wnt8R, any Wnt8R protein sequence can be used. The Wnt8R sequence used for modeling generally folds into a functional Wnt8R protein or a Wnt8-binding fragment thereof. The Wnt8R protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human Wnt8R is selected if the intended subject is a human, a bovine Wnt8R is selected if the intended subject is a cow, etc.). The sequence used for modeling can be, for example, the bovine Wnt8R sequence (NCBI Acc. No. XP\_005214377.1), which is as follows:

```
MEWGYLLEVTSLAALALLQRSSGAAASAKELACQEITVPLCKGIGYNYTYMPNQFNHD
TQDEAGLEVHQFWPLVEIQCSFDLKFFLCMYTPICLEDYKKPLPPCRSVCERAKAGCAP
LMRQYGFAPDRMRCDRLEPQGNPDITLCMDYNRTDLTTAASSVDGDPVAGICYVGNQSLD
NLLGFVLAPLVIYLFITGMFLLAGFVSLFRIRSVIKQQGGPTKTHKLEKLMIRLGLFTVL
YTVPAAVVVACLFIYEQHNRPWEATHNCPCLRDLPDQARRPDYAVFMLKYFMCLVVGIT
SGVWVWSGKTLESWRALCTRCCWASKGAGAAGAGAAGGGPGGGGPGAGGGGGPGAGGAGS
LYSDVSTGLTWRSGTASSVSYPKQMPLSQV (SEQ ID NO: 370).
```

**[00137]** An anti-inflammatory polypeptide can be identified based on its ability to bind to a Wnt ligand-binding site on Wnt8R and/or interfere with or block the ability of Wnt8R to bind to a Wnt ligand (e.g., Wnt8). For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of bovine Wnt8R (SEQ ID NO: 370) selected from the group consisting of Tyr-52, Gln-56, Phe-57, Asn-58, Met-91, Tyr-100, Lys-101, Pro-103, Pro-105, Pro-106, Arg-137 and Asp-145, or the equivalent amino acid residue(s) in a Wnt8R protein of

another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of bovine Wnt8R (SEQ ID NO: 370) selected from the group consisting of Tyr-52, Phe-57, Tyr-100, and Asp-145, or the equivalent amino acid residue(s) in a Wnt8R protein of another species.

**[00138]** In certain embodiments, a polypeptide of the invention binds to bovine Wnt8R (SEQ ID NO: 370) with an affinity of at least -600 kcal/mol, and in certain embodiments at least -650, -700, -750, -800, -850, -875, -900, -925, -950, -975 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00139]** For modeling interactions between potential anti-inflammatory polypeptides and TRAIL, any TRAIL protein sequence can be used. The TRAIL sequence used for modeling in certain embodiments folds into a function TRAIL protein or a functional fragment thereof. The TRAIL protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human TRAIL is selected if the intended subject is a human, a bovine TRAIL is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human TRAIL sequence (GenBank Acc. No. EAW78466.1), which is as follows:

KEKQQNISPLVREGRGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSF  
LSNLHLRNGELVIEHKGFFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLM  
KSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG (SEQ ID  
NO: 371).

**[00140]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the receptor binding site on TRAIL and/or interfere with or block the ability of TRAIL to bind to its receptor. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human TRAIL (SEQ ID NO: 371) selected from the group consisting of Arg-130, Arg-158, Ser-159, Gly-160, His-161, Phe-163, Tyr-189, Arg-189, Gln-193, Glu-195, Glu-236, Tyr-237, Leu-239, Asp-267, Asp-269, His-270, and Glu-271, or the equivalent amino acid residue(s) in a TRAIL protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human TRAIL (SEQ ID NO: 371) selected from the group consisting of Ala-123, His-161, Ser-162, Phe-163, Tyr-183,

Tyr-185, Tyr-243, His-270, Glu-271, Phe-274, Phe-278, Leu-279, and Val-280, or the equivalent amino acid residue(s) in a TRAIL protein of another species. In other alternatives, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human TRAIL (SEQ ID NO: 371) selected from the group consisting of Phe-163, Tyr-243, Glu-271, and Phe-278, or the equivalent amino acid residue(s) in a TRAIL protein of another species.

**[00141]** In certain embodiments, an anti-inflammatory polypeptide can bind to human TRAIL (SEQ ID NO: 371) with an affinity of at least -650 kcal/mol, and in certain embodiments at least -700, -750, -800, -850, -900, -925, -950, -975, -1000, -1025, -1050 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00142]** For modeling interactions between potential anti-inflammatory polypeptides and IL6R, any IL6R protein sequence can be used. The IL6R sequence used for modeling generally folds into a functional IL6R protein or a IL6-binding fragment thereof. The IL6R protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human IL6R is selected if the intended subject is a human, a bovine IL6R is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human IL6R sequence (NCBI Acc. No. NP\_786943.1), which is as follows:

```
MLTLQTWLVQALFIFLTTESTGELLDPGCIISPESPVVQLHSNFTAVCVLKEKCMQDYFHV
NANYIVWKTNHFTIPKEQYTIINRTASSVTFTDIASLNIQLTCNILTFGQLEQNVYGITII
ISGLPPEKPKNLS CIVNEGKMRCEWDGGRETHLETNFTLKSEWATHKFADCKAKRDTPT
SCTVDYSTVYFVNIEVWVEAENALGKVTSDHINFDPVYKVKPNPPHNLSVINSEELSSIL
KLTWTNPSIKSVIILKYNIQYRTKDASTWSQIPPEDTASTRSSFTVQDLKPFTEYVFRIR
CMKEDGKGYWSDWSEEASGITYEDNIA SF (SEQ ID NO: 372).
```

**[00143]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the IL6-binding site on IL6R and/or interfere with or block the ability of IL6R to bind to its ligand, IL6. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human IL6R (SEQ ID NO: 372) selected from the group consisting of Glu-163, Gly-164, Phe-168, Gln-190, Phe-229, Tyr-230, Phe-279 and Gln-281, or the equivalent amino acid residue(s) in a IL6R protein of another species. Alternatively, the anti-inflammatory

polypeptide can bind to at least one amino acid residue of human IL6R (SEQ ID NO: 372) selected from the group consisting of Leu-108, Glu-140, Pro-162, Phe-229, Tyr-230, and Phe-279, or the equivalent amino acid residue(s) in a IL6R protein of another species. In other alternatives, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human IL6R (SEQ ID NO: 372) selected from the group consisting of Glu-140, Phe-229, Tyr-230, Phe-279, or the equivalent amino acid residue(s) in a IL6R protein of another species.

**[00144]** In certain embodiments, an anti-inflammatory polypeptide can bind to human IL6R (SEQ ID NO: 372) with an affinity of at least -600 kcal/mol, and in certain embodiments at least -650, -700, -750, -800, -850, -900, -925, -950, -975, -1000, -1025, -1050 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00145]** For modeling interactions between potential anti-inflammatory polypeptides and IL10R, any appropriate IL10R protein sequence can be used. The IL10R sequence used for modeling generally folds into a functional IL10R protein or a IL10-binding fragment thereof. The IL10R protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human IL10R is selected if the intended subject is a human, a bovine IL10R is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human IL10R sequence (NCBI Acc. No. NP\_001549.2), which is as follows:

```
MLPCLVLLAALLSLRLGSDAHGTELPSPPSVWFEEFFHHILHWTPIPNQSESTCYEVA
LLRYGIESWNSISNCSQTLSDLTAVTLDLYHSNGYRARVRVDGSRHSNWTVTNTRFSV
DEVTLTVGSVNLEIHNGFILGKIQLPRPKMAPANDTYESIFSHFREYEIAIRKVPGNFTF
THKKVKHENFSLTSGEVGEFCVQVKPSVASRSNKGMSKEECISLTRQYFTVTNVIIF
AFVLLLSGALAYCLALQLYVRRRKKLPSVLLFKKPSPFIFISQRPSPETQDTIHPLDEEA
FLKVSPPELKNLDLHGSTDGSGFGSTKPSLQTEEPQFLLPDHPQADRTLGNREPPVLGDSC
SSGSSNSTDSGICLQEPSLSPSTGPTWEQQVGSNSRGQDDSGIDLQNSEGRAGDTQGG
ALGHHSPPEPEVPGEEDPAAVAFQGYLRQTRCAEEKATKTGCLEESPLTDGLGPKFGRC
LVDEAGLHPPALAKGYLKQDPLEMTLASSGAPTQWNQPTTEEWSLLALSSCSDLGISDWS
FAHDLAPLGCVAAPGGLLGSFNSDLVTLPLISSLQSSE (SEQ ID NO: 373).
```

**[00146]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the IL10-binding site on IL10R and/or interfere with or block the ability of

IL10R to bind to its ligand, IL10. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human IL10R (SEQ ID NO: 373) selected from the group consisting of Tyr-43, Ile-45, Glu-46, Asp-61, Asn-73, Arg-76, Asn-94, Arg-96, Phe-143, Ala-189, Ser-190, and Ser-191, or the equivalent amino acid residue(s) in a IL6R protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human IL10R (SEQ ID NO: 373) selected from the group consisting of Leu-41, Arg-42, Tyr-43, Ile-45, Glu-46, Ser-47, Trp-48, Arg-76, and Arg-78, or the equivalent amino acid residue(s) in a IL10R protein of another species. In other alternatives, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human IL10R (SEQ ID NO: 373) selected from the group consisting of Tyr-43, Ile-45, Glu-46, Trp-48, or the equivalent amino acid residue(s) in a IL10R protein of another species.

**[00147]** In certain embodiments, an anti-inflammatory polypeptide can bind to human IL10R (SEQ ID NO: 373) with an affinity of at least -600 kcal/mol, and in certain embodiments at least -650, -700, -750, -775, -800, -825, -850, -875, -900 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00148]** For modeling interactions between potential anti-inflammatory polypeptides and EGFR, any EGFR protein sequence can be used. The EGFR sequence used for modeling generally folds into a functional EGFR protein or a ligand-binding fragment thereof. The EGFR protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human EGFR is selected if the intended subject is a human, a bovine EGFR is selected if the intended subject is a cow, etc.).

Alternatively, the sequence used for modeling can be the drosophila EGFR sequence (GenBank Acc. No. AAR85273.1), which is as follows:

```
KICIGTKSRLSVPSNKEHHYRNLRDRYTNCTYVDGNLELTWLPNENLDLSFLDNIREVTG
YILISHVDVKKVVF PKLQIIRGRTLFSLSVEEEKYALFVTYSKMYTLEIPDLRDVLNGQV
GFHNNYNLCHMRTIQWSEIVSNGTDAYNYDFTAPERECPKCHESCTHGCWGE GPKNCQK
FSKLT CSPQCAGGRCYGP KPRECCHLFCAGGCTGPTQKDCIACKNFFDEGVCKEECPMR
KYNPTTYVLETNPEGKYAYGATCVKECPGHL LRDNGACVRSCPQDKMDKGGE CVPCNGPC
PKT CPGVTVLHAGNIDSFRNCTVIDGNIRILDQTFSGFQDVYANYTMGPRIPLDPERLE
VFSTVKEITGYLNIEGTHPQFRNLSYFRNLETIHGRQLMESMFAALAIVKSSLYSLEMRN
```

LKQISSGSVVIQHNRLCYVSNIRWPAIQKEPEQKVWVNENLRADLCEKNGTICSDQCNE  
 DGCWGAGTDQCLNCKNFNFNGTCIADCGYISNAYKFDNRTCKICHPECRTCNGAGADHCQ  
 ECVHVRDGQHCVSECPKNKYNDRGVCRECHATCDGCTGPKDTIGIGACTTCNLAIINND  
 TVKRCLLKDDKCPDGYFWEYVHPQEQQSLKPLAGRAVCRKCHPLCELCTNYGYHEQ (SEQ ID  
 NO: 374).

**[00149]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the ligand-binding site on EGFR and/or interfere with or block the ability of at least one ligand to bind to EGFR. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of drosophila EGFR (SEQ ID NO: 374) selected from the group consisting of Leu-10, Thr-40, Trp-41, Asp-48, Phe-51, Leu-63, His-66, Asp-68, Leu-88, and Tyr-101, or the equivalent amino acid residue(s) in a EGFR protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of drosophila EGFR (SEQ ID NO: 374) selected from the group consisting of Trp-41, Asp-48, Phe-51, Asp-68, and Tyr-101, or the equivalent amino acid residue(s) in a EGFR protein of another species.

**[00150]** In certain embodiments, an anti-inflammatory polypeptide can bind to drosophila EGFR (SEQ ID NO: 374) with an affinity of at least -650 kcal/mol, and in certain embodiments at least -700, -750, -800, -850, -900, -925, -950, -975, -1000, -1025, -1050 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00151]** For modeling interactions between potential anti-inflammatory polypeptides and CDK6, any CDK6 protein sequence can be used. The CDK6 sequence used for modeling generally folds into a functional CDK6 protein or a functional fragment thereof. The CDK6 protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human CDK6 is selected if the intended subject is a human, a bovine CDK6 is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human CDK6 sequence (NCBI Acc. No. NP\_001250.1), which is as follows:

MEKDGLCRADQQYECVAEIGEGAYGKVFKARDLKNNGRFVALKRVRVQTGEEGMPLSTIR  
 EVAVLRHLETFEHPNVVRLFDVCTVSRTDRETKLTLVFEHVDQDLTTYLDKVPEPGVPTE

TIKDMMFQLLRGLDFLHSHRVVHRDLKPQNILVTSSGQIKLADFGLARIYSFQMALTSVV  
 VTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMFRRKPLFRGSSDQDLGKILDVIGLPGE  
 EDWPRDVALPRQAFHSKSAQPIEFVTDIDELGKDLLLKCLTFNPAKRISAYSALSHPYF  
 QDLERCKENLDShLPPSQNTSELNTA (SEQ ID NO: 375).

**[00152]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the active site on CDK6 and/or interfere with or block the kinase activity of CDK6 or the ability of CDK6 to phosphorylate one or more CDK6 substrates. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human CDK6 (SEQ ID NO: 375) selected from the group consisting of Val-142, Arg-144, Asp-145, Ser-171, Val-180, Val-181, Leu-183, Arg-186, Val-190, Gln-193, Tyr-196, and Val-200, or the equivalent amino acid residue(s) in a CDK6 protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human CDK6 (SEQ ID NO: 375) selected from the group consisting of Asp-145, Val-180, and Tyr-196, or the equivalent amino acid residue(s) in a CDK6 protein of another species.

**[00153]** In certain embodiments, an anti-inflammatory polypeptide can bind to human CDK6 (SEQ ID NO: 375) with an affinity of at least -600 kcal/mol, and in certain embodiments at least -650, -700, -750, -800, -850, -900, -925, -950, -975, -1000, -1025, -1050 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00154]** For modeling interactions between potential anti-inflammatory polypeptides and histone methyl transferase (HMT), any HMT protein sequence can be used. The HMT sequence used for modeling generally folds into a functional HMT protein or a functional fragment thereof. The HMT protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human HMT is selected if the intended subject is a human, a bovine HMT is selected if the intended subject is a cow, etc.). The sequence used for modeling can be, for example, the *Paramecium bursaria* Chlorella virus 1 HMT sequence (NCBI Acc. No. NP\_048968.1), which is as follows:  
 MFNDRVIVKKSPLGGYGVFARKSFEEKGELVEECLCIVRHNDWDGTALEDYLF SRKNMSAM  
 ALGFGAIFNHSKDPNARHELTAGLKRMRIFTIKPIAIGEEITISYGDDYWLSRPRLTQN (SEQ ID NO: 376).

**[00155]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the active site on HMT and/or interfere with or block the methyl transferase activity of HMT or the ability of HMT to methylate histone substrates. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of *Paramecium bursaria* HMT (SEQ ID NO: 376) selected from the group consisting of Asn-69, His-70, Ser-71, Lys-72, Asp-73, Pro-74, and Asn-75, or the equivalent amino acid residue(s) in a HMT protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of *Paramecium bursaria* HMT (SEQ ID NO: 376) selected from the group consisting of Tyr-16, Glu-48, Tyr-50, Leu-51, Phe-52, and Asn-69, or the equivalent amino acid residue(s) in a HMT protein of another species.

**[00156]** In certain embodiments, an anti-inflammatory polypeptide can bind to *Paramecium bursaria* HMT (SEQ ID NO: 376) with an affinity of at least -600 kcal/mol, and in certain embodiments at least -650, -700, -750, -800, -850, -900, -925, -950, -975, -1000, -1025, -1050 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00157]** For modeling interactions between potential anti-inflammatory polypeptides and CD47, any CD47 protein sequence can be used. The CD47 sequence used for modeling generally folds into a functional CD47 protein or a SIRP- $\alpha$ -binding portion thereof. The CD47 protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human CD47 is selected if the intended subject is a human, a bovine CD47 is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human CD47 sequence (NCBI Acc. No. XP\_005247966.1), which is as follows:

MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKF  
KGRDIYTFDGLNKS TVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELT  
REGETIIELKYRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIAL  
VAGLVITVIVIVGAILFVPGEYS LKNATGLGLIVTSTGILILLHYVVFSTAIGLTSFVIA  
ILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQLLGLVYMKFVE (SEQ ID NO:  
377).



**[00158]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the SIRP- $\alpha$ -binding site on HMT and/or interfere with or block the binding of CD47 to SIRP- $\alpha$ . For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of CD47 (SEQ ID NO: 377) selected from the group consisting of Glu-29, Ala-30, Glu-35, Val-36, Tyr-37, Lys-39, Thr-49, Asp-51, Glu-97, Thr-99, Leu-101, Thr-102, Arg-103, Glu-104, and Glu-106, or the equivalent amino acid residue(s) in a CD47 protein of another species. In certain embodiments, the anti-inflammatory polypeptide can bind to at least one amino acid residue of CD47 (SEQ ID NO: 377) selected from the group consisting of Glu-29, Glu-35, Lys-39, Glu-97, Leu-101, Thr-102, Arg-103, Glu-104, and Glu-106, or the equivalent amino acid residue(s) in a CD47 protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human CD47 (SEQ ID NO: 377) selected from the group consisting of Tyr-16, Glu-48, Tyr-50, Leu-51, Phe-52, and Asn-6 Tyr-37, Thr-49, Phe-50, Asp-51, Ala-53, Glu-97, Val-98, Glu-100, Leu-101, Thr-102, Glu-104, Glu-106, Gly-107, or the equivalent amino acid residue(s) in a CD47 protein of another species. In certain embodiments, the anti-inflammatory polypeptide can bind to at least one amino acid residue of CD47 (SEQ ID NO: 377) selected from the group consisting of Tyr-37, Glu-97, Glu-100, Leu-101, Glu-104, Glu-106, or the equivalent amino acid residue(s) in a CD47 protein of another species.

**[00159]** In certain embodiments, an anti-inflammatory polypeptide can bind to human CD47 (SEQ ID NO: 377) with an affinity of at least -550 kcal/mol, and in certain embodiments at least -600, -650, -675, -700, -725, -750, -775, -800 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00160]** For modeling interactions between potential anti-inflammatory polypeptides and SIRP- $\alpha$ , any SIRP- $\alpha$  protein sequence can be used. The SIRP- $\alpha$  sequence used for modeling generally folds into a functional SIRP- $\alpha$  protein or a CD47-binding fragment thereof. The SIRP- $\alpha$  protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human SIRP- $\alpha$  is selected if the intended subject is a human, a bovine SIRP- $\alpha$  is selected if the intended subject is a cow, etc.). The

sequence used for modeling can be the human SIRP- $\alpha$  sequence (GenBank Acc. No. AAH26692.1), which is as follows:

```
MEPAGPAPGRLGPLLCLLLAASCAWSGVAGEEELQVIQPDKSVSVAAGESAILHCTVTSL
IPVGP IQWFRGAGPARELIYNQKEGHFPRVTTVSESTKRENMDFSISISNITPADAGTYY
CVKFRKGS PDTEFKSGAGTELSVRAKPSAPVVSGPAARATPQHTVSFTCESHGFSPRDIT
LKWFKN GNELSDFQTNVDPVGESVSYSIHSTAKVVLTREDVHSQVICEVAHVTLQGDPLR
GTANLSE TIRVPPTLEVTQQPVRAENQVNVT CQVRKFYPQRLQLTWLENGNVSR TETAST
VTENKDG TYNWMSWLLVNVSAHRDDVKLT CQVEHDGQPAVSKSHDLKVS AHPKEQGSNTA
AENTGSN ERNIYIVGVVCTLLVALLMAALYLVRIRQKKAQGSTSSTR LHEPEKNAREIT
QVQSLDT NDITYADLNL PKGKKPAPQAAEPNNHTEYASIQTSPQPA SEDTLTYADLDMVH
LNRTPKQ PAPKPEPSFSEYASVQVPRK (SEQ ID NO: 378).
```

**[00161]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the HMT-binding site on SIRP- $\alpha$  and/or interfere with or block the binding of SIRP- $\alpha$  to HMT. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of SIRP- $\alpha$  (SEQ ID NO: 378) selected from the group consisting of Leu-30, Gln-37, Gln-52, Lys-53, Ser-66, Thr-67, Arg-69, Met-72, Phe-74, Lys-96 and Asp-100, or the equivalent amino acid residue(s) in a SIRP- $\alpha$  protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human SIRP- $\alpha$  (SEQ ID NO: 378) selected from the group consisting of Tyr-50, Gln-52, Pro-58, Ser-66, Thr-67, and Ser-77, or the equivalent amino acid residue(s) in a SIRP- $\alpha$  protein of another species. In certain embodiments, the anti-inflammatory polypeptide can bind to at least one amino acid residue of SIRP- $\alpha$  (SEQ ID NO: 378) selected from the group consisting of Tyr-50, Gln-52, Ser-66, and Thr-67, or the equivalent amino acid residue(s) in a SIRP- $\alpha$  protein of another species.

**[00162]** In certain embodiments, an anti-inflammatory polypeptide can bind to human SIRP- $\alpha$  (SEQ ID NO: 378) with an affinity of at least -600 kcal/mol, and in certain embodiments at least -650, -700, -750, -800, -825, -850, -875, -900, -925, -950, -975, -1000 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00163]** For modeling interactions between potential anti-inflammatory polypeptides and CD206, any CD206 protein sequence can be used. The CD206 sequence used for modeling

generally folds into a functional CD206 protein or a mannose-binding fragment thereof. The CD206 protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human CD206 is selected if the intended subject is a human, a bovine CD206 is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human CD206 sequence (NCBI Acc. No. NP\_002429.1), which is as follows:

```
MRLPLLLVFASVIPGAVLLLDTRQFLIYNEDHKRCVDAVSPSAVQTAACNQDAESQKFRW
VSESQIMSVAFKLCGLVPSKTDWVAITLYACDSKSEFQKWECKNDTLLGIKGEDLFFNYG
NRQEKNIMLYKGSGLWSRWKIYGTDDNLCSRGYEAMYTLLGNANGATCAFPFKFENKWYA
DCTSAGRSDGWLWCCTTTDYDTDKLFGYCPLKFEGSESLWNKDPLTSVSYQINSKSALTW
HQARKSCQQQNAELLSITEIHEQTYLTGLTSSLTSGLWIGLNSLSFNQSGWQWSDRSPFRY
LNWLPGSPSAEPGKSCVSLNPGKNKAKWENLECVQKLGYICKKGNTTLNSFVIPSESDVPT
HCPSQWWPYAGHCYKIHRDEKKIQRDALTTCKRKEGGDLTSIHTIEELDFIISQLGYEPND
ELWIGLNDIKIQMYFEWSDGTPVTFTKWLRGEPHENNRQEDCVVMKGKDGWADRGCEW
PLGYICKMKSRSQGPEIVEVEKGCRCGWKKHHFYCYMIGHTLSTFAEANQTCNNENAYLT
TIEDRYEQAFLTSTFVGLRPEKYFWTGLSDIQTKGTFQWTIEEEVRFTHWNSDMPGRKPGC
VAMRTGIAGGLWDVLKCDKAKFVCKHWAEGVTHPPKPTTTPEPKCPEDWGASSRTSLCF
KLYAKGKHEKKTWFESRDFCRALGGDLASINNKEEQQTIIWRLITASGSYHKLFWLGLTYG
SPSEGFTWSDGSPVSYENWAYGEPNNYQNV EYCGELKGDPTMSWNDINCEHLNNWICQIQ
KGQTPKPEPTPAPQDNPPVTEDGWVIYKDYQYYFSKEKETMDNARAFCKRNFGLVLSIQS
ESEKKFLWKYVNRNDAQSAYFIGLLISLDKKFAWMDGSKVDYVSWATGEPN FANEDENCV
TMYSNSGFWN DINCYPNAFICQRHNSSINATTVMPTMPSVPSGCKEGWNFYSNKCFKIF
GFMEERKNWQEAR KACIGFGGNLVS IQNEKEQAF LTYHMKDSTFSAWTGLNDVNSEHTF
LWTDGRGVHYTNWKGKYPGGRRSSLSYEDADCVVIIGGASNEAGKWMDDTCD SKRGYICQ
TRSDPSLTNPPATIQT DGFVKY GKSSYSLMRQKFQWHEAETYCKLHNSLIASILDPYSNA
FAWLQMETSNERNVWIALNSNLTDNQYTWT DKWRVRYTNWAADEPKLKSACVYLDLDGYWK
TAHCNESFYFLCKRSDEIPATEPPQLPGRCPESDHTAWIPFHGH CYIIESSYTRNWGQAS
LECLRMGSSSLVSIESAAESSFLSYRVEPLKSKTNFWIGLFRNVEGTW LWINNSPVSFVNW
NTGDPSGERNDCVALHASSGFWSNIHCSSYKGYICKRPKIIDAKPTHELLTTKADTRKMD
PSKPSSNVAGVVIIVILLILT GAGLAAYFFYKKRRVHLPQEGAFENTLYFNSQSSPGTSD
MKDLVGNI EQNEHSVI (SEQ ID NO: 379).
```

**[00164]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the mannose-binding site on CD206 and/or interfere with or block the binding of SIRP-mannose to CD206. For example, the anti-inflammatory polypeptide can bind to at least

one amino acid residue of CD206 (SEQ ID NO: 379) selected from the group consisting of Glu-725, Tyr-729, Glu-733, Asn-747, and Asp-748, or the equivalent amino acid residue(s) in a CD206 protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human CD206 (SEQ ID NO: 379) selected from the group consisting of Phe-708, Thr-709, Trp-710, Pro-714, Glu-719, Asn-720, Trp-721, Ala-722, Glu-725, Tyr-729, Glu-733, Asn-747, Asp-748, Ser-1691, Cys-1693, Phe-1694, and Phe-1703, or the equivalent amino acid residue(s) in a CD206 protein of another species. In certain embodiments, the anti-inflammatory polypeptide can bind to at least one amino acid residue of CD206 (SEQ ID NO: 379) selected from the group consisting of Phe-708, Trp-710, Trp-721, Glu-725, Tyr-729, Glu-733, or the equivalent amino acid residue(s) in a CD206 protein of another species.

**[00165]** In certain embodiments, an anti-inflammatory polypeptide can bind to human CD206 (SEQ ID NO: 379) with an affinity of at least -650 kcal/mol, and in certain embodiments at least -700, -750, -800, -850, -900, -925, -950, -975, -1000, -1025, -1050 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00166]** For modeling interactions between potential anti-inflammatory polypeptides and TGM2, any TGM2 protein sequence can be used. The TGM2 sequence used for modeling generally folds into a functional TGM2 protein or acyl-transferase catalytic fragment thereof. The TGM2 protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human TGM2 is selected if the intended subject is a human, a bovine TGM2 is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human TGM2 sequence (GenBank Acc. No. AAB95430.1), which is as follows:

```
MMDASKELQVLHIDFLNQDNAVSHHTWEFQTSSPVFRRGQVFHLRLVLNQPLQSYHQLKLEFSTG
PNPSIAKHTLVVLDPRTPSDHYNWQATLQNESGKEVTVAVTSSPNAILGKYQLNVKTGNHILKSE
ENILYLLFNPWCKEDMVFMPEDEDERKEYILNDTGCHYVGAARSIKCKPWNFGQFEKNVLDCCISL
LTESSLKPTDRRDPVLVCRAMCAMMSFEKGQGVLIIGNWTGDYEGGTAPYKWTGSAPILQQYYNTK
QAVCFGQCWVFAGILTTVLRLALGIPARSVTGFD SAHDTERNLTVDTYVNENGEKITSMTHDSVWN
FHVWTDAMKRPDLPGYDGWQAVDATPQERSQGVFCCGPSPLTAIRKGDIFIVYDTRFVFSEVN
GDRLIWLVMVNGQEELHVISMETTSIGKNISTKAVGQDRRRDITYEYKYPEGSSEERQVMDHAF
LLLSSEREHRRPVKENFLHMSVQSDDVLLGNSVNF TVILKRKTAALQNVNILGSFELQLYTGKKM
```

AKLCDLNKTSQIQGQVSEVTLTLD SKTYINSLAILDDEPVIRGFIIAEIVESKEIMASEVFTSFQ  
YPEFSIELPNTGRIGQLLVNCNCFKNTLAIP L TDVKFSLES LGISSLQTS DHGTVQPGETIQSQI  
KCTPIKGTGPKKFIVKLSSKQVKEINAQKIVLITK (SEQ ID NO: 380).

**[00167]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the active site on TGM2 and/or interfere with or block the acyl-transferase activity of TGM2. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of TGM2 (SEQ ID NO: 380) selected from the group consisting of Cys-277, His-335, and Asp-358, or the equivalent amino acid residue(s) in a TGM2 protein of another species.

**[00168]** In certain embodiments, an anti-inflammatory polypeptide can bind to human TGM2 (SEQ ID NO: 380) with an affinity of at least -650 kcal/mol, and in certain embodiments at least -700, -750, -800, -850, -900, -925, -950, -975, -1000, -1025, -1050 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00169]** For modeling interactions between potential anti-inflammatory polypeptides and serum albumin, any serum albumin protein sequence can be used. The serum albumin sequence used for modeling generally folds into a functional serum albumin protein or a functional fragment thereof. The serum albumin protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human serum albumin (HSA) is selected if the intended subject is a human, a bovine serum albumin (BSA) is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human serum albumin (HSA) sequence (NCBI Acc. No. NP\_000468.1), which is as follows:  
DAHKSEVAHRFKDLGEENFKALVLI AFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENC DK S  
LHTLFGDKLCTVATLRETYGEMADCCAKQE PERNECF LQHKDDNP NL PRLVRPEVDVMCTAFHDN  
EETFLKKYLYE IARRHPYFYAPELLFFAKRYKAAFT E C CQAADKAACLLPKLDEL RDEGKASSAK  
QRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLT KVHTECCHGDLLECADDRADL  
AKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDV  
FLGMFLYEYARRHPDYSVVL LRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQ  
NCELFEQLGEYKFQNAL LVRYTKKVPQVSTPTLVEVSRNLGKVGSKCKHPEAKRMPCAEDYLSV  
VLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVD E TYVPKEFNAETFTFHADICTLSEKE  
RQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCKADDKETCFAEEGKKLVAA SQAALGL

(SEQ ID NO: 381).

**[00170]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to HSA under physiological conditions (e.g., in the blood stream).

**[00171]** In certain embodiments, an anti-inflammatory polypeptide can bind to HSA (SEQ ID NO: 381) with an affinity of at least -650 kcal/mol, and in certain embodiments at least -700, -750, -800, -850, -900, -925, -950, -975, -1000, -1025, -1050 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00172]** In certain embodiments, an anti-inflammatory polypeptide binds to two or more targets (e.g., pro-inflammatory targets). In some embodiments, an anti-inflammatory polypeptide binds to three, four, five, or more pro-inflammatory targets. For example, an anti-inflammatory polypeptide can bind to any combination of targets disclosed herein. Such binding can be based on *in silico*, *in vitro*, or *in vivo* data. Thus, an anti-inflammatory polypeptide can bind to two or more NF-kB Class II subunits (e.g., RelB and at least one other NF-kB Class II subunit, such as RelA, cRel, NF-kB1, or NF-kB2). Alternatively (or in addition), an anti-inflammatory polypeptide can bind to an NF-kB Class II subunit (e.g., RelB) and at least one other signaling molecule (e.g., at least one signaling molecule selected from the group consisting of TGFβ, Notch1, Wnt8R, TRAIL, IL6R, IL10R, EGFR, CDK6, CD206, CD47, SIRP-α, HMT, and TGM2). For example, an anti-inflammatory polypeptide can bind to an NF-kB Class II subunit (e.g., RelB) and at least one signaling molecule selected from the group consisting of TGFβ, Notch1, Wnt8R, TRAIL, IL6R, IL10R, EGFR, and CDK6. Alternatively, an anti-inflammatory polypeptide can bind to an NF-kB Class II subunit (e.g., RelB) and at least one signaling molecule selected from the group consisting of CD206, CD47, SIRP-α, and TGM2. In other alternatives, an anti-inflammatory polypeptide can bind to an NF-kB Class II subunit (e.g., RelB) and HMT. In other alternatives, an anti-inflammatory polypeptide can bind to at least one signaling molecule selected from the group consisting of TGFβ, Notch1, Wnt8R, TRAIL, IL6R, IL10R, EGFR, and CDK6, and at least one signaling molecule selected from the group consisting of CD206, CD47, SIRP-α, and TGM2. In other alternatives, an anti-inflammatory polypeptide can bind to at least one signaling molecule selected from the group consisting of

TGF $\beta$ , Notch1, Wnt8R, TRAIL, IL6R, IL10R, EGFR, and CDK6, and also bind to HMT. In still other embodiments, an anti-inflammatory polypeptide can bind to an NF-kB Class II subunit (e.g., RelB), at least one signaling molecule selected from the group consisting of TGF $\beta$ , Notch1, Wnt8R, TRAIL, IL6R, IL10R, EGFR, and CDK6, at least one signaling molecule selected from the group consisting of CD206, CD47, SIRP- $\alpha$ , and TGM2, and also HMT. In certain embodiments, an anti-inflammatory polypeptide binds to two or more pro-inflammatory targets and also serum albumin (e.g., human serum albumin).

**[00173]** For modeling interactions between potential anti-inflammatory polypeptides and LEGUMAIN, any LEGUMAIN protein sequence can be used. The LEGUMAIN sequence used for modeling generally folds into a functional LEGUMAIN protein or a functional fragment thereof. The LEGUMAIN protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human LEGUMAIN is selected if the intended subject is a human, a bovine LEGUMAIN is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human LEGUMAIN sequence (GenBank Acc. No. AAH03061.1).

MVWKVAVFLSVALGIGAIPIDDPEDGGKHVVIVAGSNGWYNYRHQADACHAYQIIHRNGIPDEQ  
IVVMMYDDIAYSEDNPTPGIVINRPNGTDVYQGVPKDYTGEDVTPQNFLAVLRGDAEAVKGIGSG  
KVLKSGPQDHVFIYFTDHGSTGILVFPNEDLHVKDLNETIHMYKHKMYRKMFYIEACESGSM  
NHLPDNINVYATTAANPRESSYACYDEKRSTYLGDWYSVNW MEDSDVEDLTKETLHKQYHLVKS  
HTNTSHVMQYGNKTIISTMKVMQFQGMKRKASSPVPLPPVTHLDLTPSPDVPLTIMKRKLMNTNDL  
EESRQLTEEIQRHLDARHLIEKSVRKIVSLLAASEAEVEQLLSERAPLTGHSCYPEALLHFRTHC  
FNWHSPTYEYALRHLYVLVNLCEKPYPLHRIKLSMDHVCLGHY (SEQ ID NO: 413).

**[00174]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the active site on LEGUMAIN and/or interfere with or block the ability of LEGUMAIN to bind to its target. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human LEGUMAIN (SEQ ID NO: 413) selected from the group consisting of Asn-44, Arg-46, His-159, Glu-189, Cys-191, Ser-217, Ser-218 and Asp-233, or the equivalent amino acid residue(s) in a LEGUMAIN protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human LEGUMAIN (SEQ ID NO: 413) selected from the group consisting of Asn-44, Glu-189 and Asp-233, or the equivalent amino acid residue(s) in a LEGUMAIN protein of another species.

**[00175]** In certain embodiments, an anti-inflammatory polypeptide can bind to human LEGUMAIN (SEQ ID NO: 413) with an affinity of at least -600 kcal/mol, and in certain embodiments at least -650, -700, -750, -800, -850, -900, -925, -950 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00176]** For modeling interactions between potential anti-inflammatory polypeptides and CD209, any CD209 protein sequence can be used. The CD209 sequence used for modeling generally folds into a functional CD209 protein or a functional fragment thereof. The CD209 protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human CD209 is selected if the intended subject is a human, a bovine CD209 is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human CD209 sequence (GenBank Acc. No. NP\_001138366.1).

MSDSKEPRLQQLGLLVSKVPSSISQEQSRQDAIYQNLTLKAAVGESEKSKLQEIYQELTQLKAAVGESEKSKLQEIYQELTRLKAAVGESEKSKLQEIYQELTWLKAAVGESEKSKMQEIYQELTRLKAAVGESEKSKQQEIYQELTRLKAAVGESEKSKQQEIYQELTRLKAAVGESEKSKQQEIYQELTQLKAAVERLCHPCPWEWTFQGNCFMSNSQRNWHDSITACKEVGAQLVVIKSAEEQNFLQLQSSRSNREFTWMGLSDLNQEGTWQWVDGSPLLPSFKQYWNRGEPNNVGEEDCAEFSGNGWNDDKC NLAKFWICKKSAASCSRDEEQFLSPAPATPNPPPA (SEQ ID NO:414)

**[00177]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the active site on CD209 and/or interfere with or block the ability of CD209 to bind to its receptor. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human CD209 (SEQ ID NO: 414) selected from the group consisting of Phe-269, Glu-280, Glu-303, Asn-305, Asn-306, Glu-310, Asp-311, Ser-316, Gly-317, Asn-321 and Lys-324 or the equivalent amino acid residue(s) in a CD209 protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human CD209 (SEQ ID NO: 414) selected from the group consisting of Phe-269, Glu-280, Glu-303, Glu-310, Asp-311, Asn-321 and Lys-324, or the equivalent amino acid residue(s) in a CD209 protein of another species.



**[00178]** In certain embodiments, an anti-inflammatory polypeptide can bind to human CD209 (SEQ ID NO: 414) with an affinity of at least -600 kcal/mol, and in certain embodiments at least -650, -700, -750, -800, -850, -900, -925, -950, -1,000, -1,050 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00179]** For modeling interactions between potential anti-inflammatory polypeptides and FAS, any FAS protein sequence can be used. The FAS sequence used for modeling generally folds into a functional FAS protein or a functional fragment thereof. The FAS protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human FAS is selected if the intended subject is a human, a bovine FAS is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human FAS sequence (NCBI Reference Sequence: NP\_000034.1).

MLGIWTLPLVLTSVARLSSKSVNAQVTDINSKGLELRKTVTTVETQNLEGLHHDGQFCHKPCPP  
GERKARDCTVNGDEPDCVPCQEGKEYTDKAHFSSKCRRCRLCDEGHGLEVEINCTRTQNTKCRCK  
PNFFCNSTVCEHCDPCTKCEHGI I KECTLT SNTKCKEEGSRNLGWLCLLLPIPLIVWVKRKEV  
QKTCRKHRRKENQGSHESTLNPETVAINLSDVDLSKYITTIAGVMTLSQVKGFVRKNGVNEAKID  
EIKNDNVQDTAEQKVQLLRNWHQLHGKKEAYDTLIKDLKKANLCTLAEKIQTIILKDITSDSENS  
NFRNEIQSLV (SEQ ID NO: 415).

**[00180]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the active site on FAS and/or interfere with or block the ability of FAS to bind to its ligand. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human FAS (SEQ ID NO: 415) selected from the group consisting of Lys-251, Lys-296, Lys-299, Leu-303, Leu-306, Ala-307, Glu-308, Lys-309, Gln-311, Ile-314, Leu-315, Asp-317, Ile-318 and Thr-319, or the equivalent amino acid residue(s) in a FAS protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human FAS (SEQ ID NO: 415) selected from the group consisting of Lys-296, Lys-299, Leu-306, Ala-307, Glu-308, Ile-314, Leu-315, Asp-317 and Ile-318, or the equivalent amino acid residue(s) in a FAS protein of another species.

**[00181]** In certain embodiments, an anti-inflammatory polypeptide can bind to human FAS (SEQ ID NO: 415) with an affinity of at least -600 kcal/mol, and in certain embodiments at

least -650, -700, -750, -800, -850, -900, -925, -950 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*.

Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00182]** Programmed cell death protein 1, also known as PD-1 and CD279 (cluster of differentiation 279), is a protein that in humans is encoded by the *PDCD1* gene. PD-1 is a cell surface receptor that belongs to the immunoglobulin superfamily and is expressed on T cells and pro-B cells. PD-1 binds two ligands, PD-L1 and PD-L2. PD-1, functioning as an immune checkpoint plays an important role in down regulating the immune system by preventing the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance. The inhibitory effect of PD-1 is accomplished through a dual mechanism of promoting apoptosis (programmed cell death) in antigen specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (suppressor T cells).

**[00183]** For modeling interactions between potential anti-inflammatory polypeptides and PD-1, any PD-1 protein sequence can be used. The PD-1 sequence used for modeling generally folds into a functional PD-1 protein or a functional fragment thereof. The PD-1 protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human PD-1 is selected if the intended subject is a human, a bovine PD-1 is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human PD-1 sequence (Locus: XP\_006712636.1).

MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPTFSPALLVVTEGDNATFTCSFSNTSESVL  
 NWRMSPSNQIDKLAAFPEDRSQPGQDCFRVLTQLPNGRDFHMSVVRARRNDSGTLYLCAISLAP  
 KAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVVGVGGLLGSLVLLVWVLAVICSRA  
 ARG (SEQ ID NO: 416).

**[00184]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the active site on PD-1 and/or interfere with or block the ability of PD-1 to bind to its receptor. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human PD-1 (SEQ ID NO: 416) selected from the group consisting of Val-64, Asn-66, Tyr-68, Met-70, Thr-76, Lys-78, Thr-120, Leu-122, Ala-125, Ser-127, or the equivalent amino acid residue(s) in a PD-1 protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human PD-1 (SEQ ID NO: 416)

selected from the group consisting of Tyr-68, Met-70, Lys-78 and Leu-122, or the equivalent amino acid residue(s) in a PD-1 protein of another species.

**[00185]** In certain embodiments, an anti-inflammatory polypeptide can bind to human PD-1 (SEQ ID NO: 416) with an affinity of at least -600 kcal/mol, and in certain embodiments at least -650, -700, -750, -800, -850, -900, -925, -950, -1,000 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00186]** Dual specificity mitogen-activated protein kinase kinase 7, also known as MAP kinase kinase 7 or MKK7, is an enzyme that in humans is encoded by the *MAP2K7* gene. This protein is a member of the mitogen-activated protein kinase kinase family. The MKK7 protein exists as six different isoforms with three possible N-termini ( $\alpha$ ,  $\beta$ , and  $\gamma$  isoforms) and two possible C-termini (1 and 2 isoforms). MKK7 is involved in signal transduction mediating the cell responses to proinflammatory cytokines, and environmental stresses. This kinase specifically activates MAPK8/JNK1 and MAPK9/JNK2, and this kinase itself is phosphorylated and activated by MAP kinase kinase kinases including MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK5, and MAP4K2/GCK.

**[00187]** For modeling interactions between potential anti-inflammatory polypeptides and MKK7, any MKK7 protein sequence can be used. The MKK7 sequence used for modeling generally folds into a functional MKK7 protein or a functional fragment thereof. The MKK7 protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human MKK7 is selected if the intended subject is a human, a bovine MKK7 is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the human MKK7 sequence (NCBI Reference Sequence: NP\_001284484.1).

MAASSLEQKLSRLEAKLKQENREARRRIDLNLDISPQRPRPIIVITLSPAPAPSQRAALQLPLAN  
DGGSRSPSSSESPQHPTPPARPRHMLGLPSTLFTPRSMESIEIDQKLQEIMKQTGYLTIGGQRYQ  
AEINDLENLGEIMGSGTCGQVWKMFRKKTGHVIAVKQMRRSGNKEENKRILMDLDVVLKSHDCPYI  
VQCFGTFITNTDVFIAEELMGTCAEKLKRMQGPIPERILGKMTVAIVKALYYLKEKHGVIHRDV  
KPSNIILLDERGQIKLCEFGISGRLVDSKAKTRSAGCAAYMAPERIDPPDPTKPDYDIRADVWSLG  
ISLVELATGQFPYKNCKTDFEVLTKVLQEEPPLLPGHMGFSGDFQSFVKDCLTKDHRKRPKYNKL  
LEHSFIKRYETLEVDVASWFKDVMAKTESPRTSGVLSQPHLPFFR (SEQ ID NO: 417).

[00188] An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the active site on MKK7 and/or interfere with or block the ability of MKK7 to bind to its receptor. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human MKK7 (SEQ ID NO: 417) selected from the group consisting of Met-142, Val-150, Lys-152, Lys-165, Met-212, Met-215, Thr-217, Lys-221, Leu-266, Cys-276 and Asp-277, or the equivalent amino acid residue(s) in a MKK7 protein of another species. Alternatively, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human MKK7 (SEQ ID NO: 417) selected from the group consisting of Met-142, Val-150, Lys-165, Met-212, Met-215, Leu-266 and Asp-277, or the equivalent amino acid residue(s) in a MKK7 protein of another species.

[00189] In certain embodiments, an anti-inflammatory polypeptide can bind to human MKK7 (SEQ ID NO: 417) with an affinity of at least -600 kcal/mol, and in certain embodiments at least -650, -700, -750, -800, -850, -900, -925, -950, -1,000 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

[00190] For modeling interactions between potential anti-inflammatory polypeptides and ribonucleotide reductase (RNR), any RNR protein sequence can be used. The RNR sequence used for modeling generally folds into a functional RNR protein or a functional fragment thereof. The RNR protein sequence used for modeling can be selected based on the type of subject that the anti-inflammatory polypeptide is intended to treat (e.g., a human RNR is selected if the intended subject is a human, a bovine RNR is selected if the intended subject is a cow, etc.). The sequence used for modeling can be the yeast RNR sequence (GenBank: AJV34160.1).

MYVYKRDGRKEPVQFDKITARISRLCYGLDPKHIDAVKVTQRIISGVYEGVTTIELDNLAAETCA  
YMTTVHPDYATLAARIAISNLHKQTTKQFSKVVEDLYRYVNAATGKPAPMISDDVYNIVMENKDK  
LNSAIVYDRDFQYSYFGFKTLERSYLLRINGQVAERPQHLIMRVALGIHGRDIEAALETYNLMSL  
KYYTHASPTLFNAGTPKPMSSCFLVAMKEDSIEGIYDTLKECALISKTAGGIGLHIHNIRSTGS  
YIAGTNGTSNGLIPMIRVFNNNTARYVDQGGNKRPGAFALYLEPWHADIFDFIDIRKNHGKEEIRA  
RDLFPALWIPDLFMKRVEENGWTWTLFSPTSAPGLSDCYGDEFEALYTRYEKEGRGKTIKAQKLWY  
SILEAQTTETGTPFVYKDACNRKSNQKNLGVIKSSNLCCEIVEYSAPDETAVCNLASVALPAFIE  
TSEDGKTSTYNFKKLHEIAKVVTRNLNRVIDRNYYPVEEARKSNMRHRPIALGVQGLADTFMLLR  
LPFDSEEARLLNIQIFETIYHASMEASCELAQKDGPHYETFGQSPASQGILQFDMWDQKPYGMWDW

DTLRKDIMKHGIRNSLTMAPMETASTSQILGYNECFEPVTSNMYSRRLVLSGEFQVVNPYLLRDLV  
DLGIWDEGMKQYLITQNGSIQGLPNVPQELKDLYKTVWEISQKTIINMAADRSVYIDQSHSLNLF  
LRAPTMGKLTSMHFYGWKKGLKTGMYYLRTQAASAAIQFTIDQKIADQATENVADISNLKRPSYM  
PSSASYAASDFVPAAVTANATIPSLDSSSEASREASPAPTGSHSLTKGMAELNVQESKVEVPEVP  
APTKNEEKAAPIVDDEETEFDIYNSKVIACAIDNPEACEMCSG (SEQ ID NO: 418).

**[00191]** An anti-inflammatory polypeptide can be identified, for example, based on its ability to bind to the active site on RNR and/or interfere with or block the ability of RNR to bind to its receptor. For example, the anti-inflammatory polypeptide can bind to at least one amino acid residue of human RNR (SEQ ID NO: 418) selected from the group consisting of Asn-426, Leu-427, Cys-428, Glu-430, Met-606, Pro-608 and Ala-610, or the equivalent amino acid residue(s) in a RNR protein of another species.

**[00192]** In certain embodiments, an anti-inflammatory polypeptide can bind to human RNR (SEQ ID NO: 418) with an affinity of at least -600 kcal/mol, and in certain embodiments at least -650, -700, -750, -800, -850, -900, -925, -950, -1,000 kcal/mol, or greater. The requisite binding affinity can correspond to a binding affinity that can be detected *in vitro* or *in vivo*. Alternatively, the requisite binding affinity can correspond to a binding affinity that can be detected *in silico*, e.g., using the ClusPro™ algorithm.

**[00193]** Excluded Polypeptides

**[00194]** Compositions of the invention optionally exclude polypeptides that satisfy the Structural Algorithm described herein which may have been known in the art prior to the filing of the present application. Various publications have discussed synthetic and naturally occurring anti-inflammatory polypeptides and/or polypeptides having a striapathic sequence including, for example, US Patent Application Nos. 2012/0270770 and 2003/0109452, and US Pat. No. 6,559,281. Accordingly, one or more polypeptides and/or uses of such polypeptides described in such publications can be excluded from the scope of the presently disclosed composition and/or methods. For example, peptide RP-398 (SEQ ID NO: 155) is optionally excluded from compositions disclosed herein and/or methods of using such compositions. Moreover, any of the polypeptides disclosed in Tables 3-9, below, can be optionally excluded from compositions disclosed herein and/or methods of using such compounds.

**[00195]** Linked Anti-Inflammatory Polypeptide Combinations

**[00196]** The invention further includes any two anti-inflammatory polypeptides which have been linked together. The linkage can be formed by a peptide linker, such as a Gly-Gly-Gly (GGG), Gly-Gly-Gly-Arg (GGGR), Gly-Pro-Gly (GPG), or Gly-Pro-Gly-Arg (GPGR) sequence, that links the C-terminal end of a first anti-inflammatory polypeptide to the N-terminal end of a second anti-inflammatory polypeptide. Alternatively, the linkage can be a peptoid linker (e.g., a poly N-substituted version of any of the foregoing peptide linkers), a polymer containing g-amino acids (e.g., corresponding to any of the foregoing peptide linkers), or a non-peptide, chemical linker. The linked anti-inflammatory polypeptides can be any of the polypeptides disclosed herein (e.g., in Tables 3-9), and can include the same polypeptide being linked to form a homodimer or different polypeptides being linked to form a heterodimer. Techniques for linking peptides via peptide and non-peptide linkers are well known in the art, and the inventive polypeptide combinations are intended to encompass all such linkages.

**[00197]** Anti-inflammatory polypeptides can be linked to another molecule via a biodegradable linkage, such as a disulfide bond. The disulfide bond can be mediated by the sulfhydryl group of a cysteine residue found in the anti-inflammatory polypeptide and a sulfhydryl group in the other molecule. The cysteine residue can be, e.g., located at either the C-terminal or N-terminal end of anti-inflammatory polypeptide. Specific examples include RP-433 (FAKKFAKKFKC, SEQ ID NO: 384) and RP-434 (KFRKAFKRFFC; SEQ ID NO: 385), though any of the peptides disclosed herein could be similarly modified. Using a disulfide linkage of this sort, polypeptides of the invention can be conveniently linked to various types of useful molecules. For example, the linkage can be with another anti-inflammatory polypeptide (which optionally includes a C-terminal or N-terminal cysteine residue), a fluorescent label (e.g., Dylight 350), a chemotherapeutic agent (e.g., a taxol derivative formed by adding a sulfhydryl group to an appropriate site on the taxol ring structure, followed by oxidation with a cysteine-containing peptide of the invention), or the like.

**[00198]** Linked anti-inflammatory polypeptides (e.g., homo- or heterodimers) can bind to a target molecule (e.g., a target protein, such as a pro-inflammatory signaling protein) with a binding energy that is greater than that of either monomer polypeptide alone. Thus, for example, the energy of binding of linked anti-inflammatory polypeptides to an NF- $\kappa$ B Class II protein (e.g., RelB) can be at least -700 kcal/mol, and in certain embodiments at least -750, -800, -900, -1000, -1100, -1200, -1250, -1300, -1350, -1400, -1425, -1450, -1475, -1500, -1525, -1550, -

1575, -1600 kcal/mol, or greater. The energy of binding can be determined, e.g., *in silico*, *in vitro*, or *in vivo*, using methods well-known in the art (e.g., using the ClusPro™ algorithm).

**[00199]**      Modified Polypeptides

**[00200]**      Embodiments of the invention include the modification of any of the anti-inflammatory polypeptides of the invention, by chemical or genetic means. Examples of such modification include construction of peptides of partial or complete sequence with non-natural amino acids and/or natural amino acids in L or D forms. For example, any of the peptides disclosed herein and any variants thereof could be produced in an all-D form. Furthermore, polypeptides of the invention can be modified to contain carbohydrate or lipid moieties, such as sugars or fatty acids, covalently linked to the side chains or the N- or C-termini of the amino acids. In addition, the polypeptides of the invention can be modified to enhance solubility and/or half-life upon being administered. For example, polyethylene glycol (PEG) and related polymers have been used to enhance solubility and the half-life of protein therapeutics in the blood. Accordingly, the polypeptides of the invention can be modified by PEG polymers and the like. Polypeptides of the invention can also be modified to contain sulfur, phosphorous, halogens, metals, etc. And amino acid mimics can be used to produce polypeptides of the invention (e.g., having a structure based on the Structural Algorithm or a structure similar to any of the anti-inflammatory polypeptides disclosed herein). In certain embodiments, polypeptides of the invention that include amino acid mimics have enhanced properties, such as resistance to degradation. For example, polypeptides of the invention can include one or more (e.g., all) peptoid monomers.

**[00201]**      Compositions

**[00202]**      Compositions of the invention include an anti-inflammatory polypeptide that satisfies the structural algorithm described herein. For example, the anti-inflammatory polypeptide can have a striapathic region having a sequence that conforms with any one of Formulas I-LIV. In particular, the anti-inflammatory polypeptide can be any of the polypeptides listed in Table 3-9, or a fragment or variant thereof. Typically, the anti-inflammatory polypeptide included in the compositions of the invention will be a synthetic polypeptide (e.g., made by chemical synthesis and/or produced recombinantly).

**[00203]**      The compositions of the invention can include a single anti-inflammatory polypeptide, or combinations thereof. The compositions can be substantially free of proteins and

other polypeptides that do not satisfy the structural algorithm disclosed herein. As used herein, the term “substantially free of proteins and other polypeptides” means that less than 5% of the protein content of the composition is made up of proteins and other polypeptides that are not an anti-inflammatory polypeptide of the invention. A composition that is substantially free of non-anti-inflammatory polypeptides of the invention can have less than 4%, 3%, 2% , 1%, 0.5%, 0.1%, 0.05%, 0.01%, or less of proteins or other polypeptides that do not satisfy the structural algorithm disclosed herein. Thus, the compositions can be substantially free of blood proteins, such as serum albumin, globulins, fibrinogen, and clotting factors. Alternatively, the compositions can be substantially free of globulins, fibrinogen, and clotting factors, but can include purified or recombinantly produced serum albumin.

**[00204]** The compositions of the invention in certain embodiments contain an anti-inflammatory polypeptide that is not naturally found in a human or other mammal or animal. However, compositions of the invention can include an anti-inflammatory polypeptide that is naturally found in a human or other mammal or animal, provided that the composition is substantially free of biological molecules (such as non-anti-inflammatory polypeptides, nucleic acids, lipids, carbohydrates, and metabolites) that are associated with the anti-inflammatory polypeptide *in vivo* or co-purify with the anti-inflammatory polypeptide. As used herein, the term “substantially free of biological molecules” means that less than 5% of the dry weight of the composition is made up of biological molecules that are not anti-inflammatory polypeptides. A composition that is substantially free of such biological molecules can have less than 4%, 3%, 2% , 1%, 0.5%, 0.1%, 0.05%, 0.01%, or less of biological molecules that are not anti-inflammatory polypeptides. Thus, for example, the composition can be substantially free of biological molecules that are abundant in the blood, such the proteins discussed above, fatty acids, cholesterol, non-protein clotting factors, metabolites, and the like. In addition, the composition can be substantially free of cells, including red blood cells, white blood cells, and platelets, and cell fragments.

**[00205]** The compositions of the invention can include at least 1 mg (e.g., at least 5, 10, 20, 30, 40, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000 mg, or more) of anti-inflammatory polypeptide. Thus, for example, the compositions can include an amount of anti-inflammatory polypeptide equal to about 1 mg to about 1000 mg (e.g., about 5 mg to about 900 mg, about 5 mg to about 800 mg, about 5 mg to about 700 mg, about 5 mg to about 600 mg,



about 10 mg to about 500 mg, about 10 mg to about 400 mg, about 10 mg to about 300 mg, about 10 mg to about 250 mg, about 10 mg to about 200 mg, about 10 mg to about 150 mg, about 10 mg to about 100 mg, about 50 mg to about 500 mg, about 50 mg to about 400 mg, about 50 mg to about 300 mg, about 50 mg to about 250 mg, about 50 mg to about 200 mg, about 50 mg to about 150 mg, about 50 mg to about 100 mg, about 75 mg to about 500 mg, about 75 mg to about 400 mg, about 75 mg to about 300 mg, about 75 mg to about 250 mg, about 75 mg to about 200 mg, about 75 mg to about 150 mg, about 75 mg to about 100 mg, about 100 mg to about 500 mg, about 100 mg to about 400 mg, about 100 mg to about 300 mg, about 100 mg to about 250 mg, about 100 mg to about 200 mg, or any other range containing two of the foregoing endpoints).

**[00206]** The compositions of the invention can include a solution that contains at least 1 mg/ml (e.g., at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 mg/ml or more) of an anti-inflammatory polypeptide. Thus, for example, the compositions can include a solution having an anti-inflammatory polypeptide concentration of about 1 mg/ml to about 1000 mg/ml (e.g., about 5 mg/ml to about 900 mg/ml, about 5 mg/ml to about 800 mg/ml, about 5 mg/ml to about 700 mg/ml, about 5 mg/ml to about 600 mg/ml, about 5 mg/ml to about 500 mg/ml, about 10 mg/ml to about 500 mg/ml, about 10 mg/ml to about 400 mg/ml, about 10 mg/ml to about 300 mg/ml, about 10 mg/ml to about 250 mg/ml, about 10 mg/ml to about 200 mg/ml, about 10 mg/ml to about 150 mg/ml, about 10 mg/ml to about 100 mg/ml, about 50 mg/ml to about 500 mg/ml, about 50 mg/ml to about 400 mg/ml, about 50 mg/ml to about 300 mg/ml, about 50 mg/ml to about 250 mg/ml, about 50 mg/ml to about 200 mg/ml, about 50 mg/ml to about 150 mg/ml, about 50 mg/ml to about 100 mg/ml, about 75 mg/ml to about 500 mg/ml, about 75 mg/ml to about 400 mg/ml, about 75 mg/ml to about 300 mg/ml, about 75 mg/ml to about 250 mg/ml, about 75 mg/ml to about 200 mg/ml, about 75 mg/ml to about 150 mg/ml, about 75 mg/ml to about 100 mg/ml, about 100 mg/ml to about 500 mg/ml, about 100 mg/ml to about 400 mg/ml, about 100 mg/ml to about 300 mg/ml, about 100 mg/ml to about 250 mg/ml, about 100 mg/ml to about 200 mg/ml, about 10 mg/ml to about 150 mg/ml, or any other range containing two of the foregoing endpoints).

**[00207]** The compositions of the invention include pharmaceutical compositions. Such pharmaceutical compositions can comprise one or more anti-inflammatory polypeptides and a pharmaceutically acceptable carrier. Pharmaceutical compositions can further include a protein

other than an anti-inflammatory polypeptide of the invention and/or a chemotherapeutic agent. The other protein can be a therapeutic agent, such as a therapeutic antibody. The therapeutic protein or antibody can have anti-inflammatory properties or other properties that the anti-inflammatory polypeptides of the invention augment or are augmented by. Alternatively, the other protein can be a carrier protein, such as serum albumin (e.g., HSA). The serum albumin (e.g., HAS, BSA, etc.) can be purified or recombinantly produced. By mixing the anti-inflammatory polypeptide(s) in the pharmaceutical composition with serum albumin, the anti-inflammatory polypeptides can be effectively “loaded” onto the serum albumin, allowing a greater amount of anti-inflammatory polypeptide to be successfully delivered to a site of inflammation. The chemotherapeutic agent can be, for example, an anti-cancer chemotherapeutic agent. Such chemotherapeutic agents include, but are not limited to, Gemcitabine, Docetaxel, Bleomycin, Erlotinib, Gefitinib, Lapatinib, Imatinib, Dasatinib, Nilotinib, Bosutinib, Crizotinib, Ceritinib, Trametinib, Bevacizumab, Sunitinib, Sorafenib, Trastuzumab, Ado-trastuzumab emtansine, Rituximab, Ipilimumab, Rapamycin, Temsirolimus, Everolimus, Methotrexate, Doxorubicin, Abraxane, Folfirinox, Cisplatin, Carboplatin, 5-fluorouracil, Teysumo, Paclitaxel, Prednisone, Levothyroxine, and Pemetrexed.

**[00208]**      Methods

**[00209]**      The anti-inflammatory polypeptides of the invention provide powerful tools for reducing inflammation and/or treating conditions associated with excessive inflammation (whether acute or chronic). As used herein, the terms “treat,” “treating,” and similar words shall mean stabilizing, reducing the symptoms of, preventing the occurrence of, or curing a medical condition.

**[00210]**      Accordingly, the invention provides methods of reducing the expression level and/or activity of at least one (e.g., 2, 3, 4, 5, or more) pro-inflammatory cytokine(s) at a site of inflammation in a subject. The methods include administering an anti-inflammatory polypeptide of the invention (or, for example, a pharmaceutical composition comprising an anti-inflammatory polypeptide) to the subject. The pro-inflammatory cytokine can be selected from the group consisting of NF- $\kappa$ B, TNF $\alpha$ , IL-1, IL-6, IL-8, IL-12, IL-17, IL-23, MCP-1, MMP-1, and MMP-9. The reduction can be a reduction of at least 10% (e.g., 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or more) in the expression or activity of the cytokine.

**[00211]** The invention also provides methods of inhibiting an increase in the expression level and/or activity of at least one (e.g., 2, 3, 4, 5, or more) pro-inflammatory cytokine(s) at a potential site of inflammation in a subject. The methods include administering an anti-inflammatory polypeptide of the invention (or, for example, a pharmaceutical composition comprising an anti-inflammatory polypeptide) to the subject. The pro-inflammatory cytokine can be selected from the group consisting of NF- $\kappa$ B, TNF $\alpha$ , IL-1, IL-6, IL-8, IL-12, IL-17, IL-23, MCP-1, MMP-1, and MMP-9. The methods can inhibit increased cytokine expression and/or activity by limiting such increases to no more than 20% (e.g., 15%, 12.5%, 10%, 7.5%, 5%, 4%, 3%, 2%, 1%, or less).

**[00212]** The invention also provides a method of treating or preventing a condition associated with chronic inflammation. The condition associated with chronic inflammation can be irritable bowel disease, ulcerative colitis, colitis, Crohn's disease, idiopathic pulmonary fibrosis, asthma, keratitis, arthritis, osteoarthritis, rheumatoid arthritis, auto-immune diseases, a feline or human immunodeficiency virus (FIV or HIV) infection, cancer, age-related inflammation and/or stem cell dysfunction (e.g., age-related increases in Nlrp3 expression, age-related elevation of SOCS3 in muscle stem cells, etc.), graft-versus-host disease (GVHD), keloids, scleroderma, obesity, diabetes, diabetic wounds, other chronic wounds, atherosclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, macular degeneration, gout, gastric ulcers, gastritis, mucositis, toxoplasmosis, and chronic viral or microbial infections (e.g., such as chronic bacterial or protozoan infections). The methods includes administering an anti-inflammatory polypeptide of the invention (or, for example, a pharmaceutical composition comprising an anti-inflammatory polypeptide) to a subject suffering from or likely to develop the condition.

**[00213]** The invention also provides methods of treating or preventing fibrosis. The fibrosis can be, for example, pulmonary fibrosis, dermal fibrosis, hepatic fibrosis, renal fibrosis, or fibrosis caused by ionizing radiation. The methods include administering an anti-inflammatory polypeptide of the invention (or, for example, a pharmaceutical composition comprising an anti-inflammatory polypeptide) to a subject suffering from or likely to develop fibrosis.

**[00214]** The invention also provides methods of treating cancer. The cancer can be colon cancer, breast cancer, leukemia, lymphoma, ovarian cancer, prostate cancer, liver cancer, lung

cancer, testicular cancer, cervical cancer, bladder cancer, endometrial cancer, kidney cancer, melanoma, cancers of the thyroid or brain, or ophthalmic cancer. The methods include administering an anti-inflammatory polypeptide of the invention (or, for example, a pharmaceutical composition comprising an anti-inflammatory polypeptide) to a subject suffering from cancer.

**[00215]** For any of the foregoing methods, the subject can be an animal, such as a domesticated animal (e.g., a horse, cow, pig, goat, sheep, rabbit, chicken, turkey, duck, etc.), a pet (e.g., a dog, cat, rabbit, hamster, gerbil, bird, fish, etc.), a lab animal (e.g., a mouse, rat, monkey, chimpanzee, owl, fish, etc.), a zoo animal (e.g., a gorilla, orangutan, chimpanzee, monkey, elephant, camel, zebra, boar, lion, tiger, giraffe, bear, bird, etc.), a wild animal (e.g., a deer, wolf, mountain lion, bird, etc.), or a human.

**[00216]** In conjunction with any of the foregoing methods, the anti-inflammatory polypeptide(s) can be administered at a dose and frequency that depends on the type of animal, the size of the animal, and the condition being treated. Typically, the anti-inflammatory polypeptide is administered daily (or every other day, or weekly), in an amount between about 1 mg and about 1000 mg (e.g., about 5 mg to about 900 mg, about 5 mg to about 800 mg, about 5 mg to about 700 mg, about 5 mg to about 600 mg, about 10 mg to about 500 mg, about 10 mg to about 400 mg, about 10 mg to about 300 mg, about 10 mg to about 250 mg, about 10 mg to about 200 mg, about 10 mg to about 150 mg, about 10 mg to about 100 mg, about 50 mg to about 500 mg, about 50 mg to about 400 mg, about 50 mg to about 300 mg, about 50 mg to about 250 mg, about 50 mg to about 200 mg, about 50 mg to about 150 mg, about 50 mg to about 100 mg, about 75 mg to about 500 mg, about 75 mg to about 400 mg, about 75 mg to about 300 mg, about 75 mg to about 250 mg, about 75 mg to about 200 mg, about 75 mg to about 150 mg, about 75 mg to about 100 mg, about 100 mg to about 500 mg, about 100 mg to about 400 mg, about 100 mg to about 300 mg, about 100 mg to about 250 mg, about 100 mg to about 200 mg, or any other range containing two of the foregoing endpoints). The daily dose can be administered once during the day, or broken up into smaller doses that are taken at multiple time points during the day. For a human (and other similarly-sized mammals), a dose of 5mg/kg every other day can be administered. The anti-inflammatory polypeptide can be administered for a fixed period of time (e.g., for 2-3 weeks), at intervals (e.g., administer polypeptide for 2-3 weeks, wait 2-3 weeks, then repeat the cycle), or until such time as the pro-inflammatory

cytokine levels have been reduced or stabilized, the chronic inflammatory condition or fibrosis has ameliorated, or the cancer has gone into remission.

**[00217]** The administration of the anti-inflammatory polypeptides (or pharmaceutical compositions comprising such polypeptides) in conjunction with any of the foregoing methods can be performed intravenously, intraperitoneally, parenteral, orthotopically, subcutaneously, topically, nasally, orally, sublingually, intraocularly, by means of an implantable depot, using nanoparticle-based delivery systems, microneedle patch, microspheres, beads, osmotic or mechanical pumps, and/or other mechanical means.

**[00218]** In conjunction with any of the foregoing methods, the anti-inflammatory polypeptides (or pharmaceutical compositions comprising such polypeptides) can be administered in combination with another drug designed to reduce or prevent inflammation, treat or prevent chronic inflammation or fibrosis, or treat cancer. In each case, the anti-inflammatory polypeptide can be administered prior to, at the same time as, or after the administration of the other drug. For the treatment of cancer, the anti-inflammatory polypeptide(s) can be administered in combination with a chemotherapeutic agent selected from the group consisting of steroids, anthracyclines, thyroid hormone replacement drugs, thymidylate-targeted drugs, Chimeric Antigen Receptor/T cell therapies, and other cell therapies. Specific chemotherapeutic agents include, for example, Gemcitabine, Docetaxel, Bleomycin, Erlotinib, Gefitinib, Lapatinib, Imatinib, Dasatinib, Nilotinib, Bosutinib, Crizotinib, Ceritinib, Trametinib, Bevacizumab, Sunitinib, Sorafenib, Trastuzumab, Ado-trastuzumab emtansine, Rituximab, Ipilimumab, Rapamycin, Temsirolimus, Everolimus, Methotrexate, Doxorubicin, Abraxane, Folfirinox, Cisplatin, Carboplatin, 5-fluorouracil, Teysumo, Paclitaxel, Prednisone, Levothyroxine, and Pemetrexed.

**[00219]** Alternatively, for the methods of treating cancer, the anti-inflammatory polypeptide(s) (or pharmaceutical compositions comprising such polypeptides) can be administered in combination with radiation therapy. Again, the anti-inflammatory polypeptide(s) can be administered prior to, or after the administration of the radiation therapy.

**[00220]** Any of the foregoing methods of the invention further include a step of assessing the efficacy of the therapeutic treatment. Because the anti-inflammatory polypeptides of the invention have a demonstrable ability to reduce tissue inflammation and suppress the excessive production of inflammatory mediators such as IL-1, IL-6, IL-12, and TNF $\alpha$ , both in tissues and

in serum (data not shown), the efficacy of the therapeutic treatment can be assessed by measuring the levels of such cytokines (e.g., in the serum) to determine whether the levels have responded appropriately to the treatment. Depending on the cytokine levels, the dosage of anti-inflammatory polypeptide(s) can be adjusted up or down, as needed.

## EXAMPLES

### [00221] Example 1: Peptide Designs

[00222] Polypeptides were designed *in silico* to include a striapathic region of alternating  $X_m$  and  $Y_n$  modules, with each  $X_m$  module having one to five hydrophilic amino acid residues and each  $Y_n$  module having one to five hydrophobic residues.

[00223] Initial designs focused on polypeptides consisting of a striapathic region having a total length of around 10 amino acid residues, with each  $X_m$  module having one or two hydrophilic amino acid residues and each  $Y_n$  module having one or two hydrophobic residues, and with the ratio of hydrophobic to hydrophilic amino acid residues being around 1:1. Such polypeptides were predicted to have an amphipathic, helical secondary structure, with a hydrophobic surface on one side of the helix and a hydrophilic surface on the opposite side of the helix.

[00224] Additional peptide designs were subsequently generated that maintained a total length of around 10 amino acid residues, but expanded the number of possible amino acid residues in a hydrophilic or hydrophobic module from two to three and varied the hydrophobic to hydrophilic ratio. For example, larger hydrophobic modules having three hydrophobic amino acid residues were coupled with shorter hydrophilic modules having one hydrophilic amino acid residue, giving rise to polypeptides predicted to have a stronger hydrophobic character. Such peptides were predicted to maintain an amphipathic, helical secondary structure, but have a larger hydrophobic surface on one side of the helix and a correspondingly smaller hydrophilic surface on the other side. Similarly, larger hydrophilic modules having three hydrophilic amino acid residues were coupled with shorter hydrophobic modules having one hydrophobic amino acid residue, giving rise to peptides having a stronger hydrophilic character. Such peptides were also predicted to maintain an amphipathic, helical secondary structure, but have a larger hydrophilic surface on one side of the helix and a correspondingly smaller hydrophobic surface on the other side.

[00225] Other peptide designs included: polypeptides having modules of four or five hydrophilic amino acid residues and/or four or five hydrophobic; polypeptides having a total length of around 10 amino acid residues but lacking hydrophobic amino acid residues; polypeptides having hydrophilic and hydrophobic modules each consisting of a single amino acid residue; and proline-rich polypeptides. Finally, larger polypeptides comprising two of the smaller peptide designs were also generated.

[00226] Exemplary polypeptides designed as described above are presented in Tables 3-9, below. To provide greater clarity into the types of polypeptides that have been developed, the peptides have been organized into Classes. Typically, the striapathic region of a specific Class of polypeptides shares a common sequence of hydrophobic and hydrophilic modules that is at least six or seven amino acid residues long. However, because the data indicates that polypeptides that have the same sequence but reversed N-terminal to C-terminal orientation have surprisingly similar anti-inflammatory activities, efforts have been made to keep such polypeptides in the same Class. Accordingly, some polypeptides have been grouped into the same Class even though the common sequence of hydrophobic and hydrophilic modules is less than six amino acid residues long. In addition, some of the polypeptides could have been grouped differently because they contain the common sequence of hydrophobic and hydrophilic modules of more than one Class. Thus, while providing a helpful framework for organizing the polypeptides around structural and functional similarities, the classification system does not capture all aspects of the relationships between different polypeptides.

[00227] Table 3 presents various Class I polypeptides, which have a striapathic region that includes a sequence corresponding to Formula I (i.e.,  $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}$ ). Two different types of Class I polypeptides are presented in Table 3: peptides that have a striapathic region consisting of a sequence corresponding to Formula II (i.e.,  $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}-X_{2a}-Y_{3a}-X_{3a}$ ); and peptide that have a striapathic region consisting of a sequence corresponding to Formula III (i.e.,  $X_{2a}-Y_{3a}-X_{3a}-Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}$ ). In addition, a peptide having a striapathic region having a sequence corresponding to Formula I, but not Formulas II or III, is presented.

**Table 3: Class I Polypeptides**

RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
------	----------	---------------------------------	---------	------------

RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
394	NFNFFFRFFF	-1,286.6	III	33
108	WWWRWWWEWQ	-1,278.0	II	34
109	EFNFFFRFFF	-1,247.7	III	35
110	DFEFFFFRFFF	-1,232.0	III	36
111	QFEFFFFRFFF	-1,226.8	III	37
112	EFEFFFFRFFF	-1,216.0	III	38
113	FFFRFFFEEFQ	-1,208.9	II	39
114	FFFRFFFEEFE	-1,176.3	II	40
115	FFFRFFFEEFD	-1,172.3	II	41
116	FFFRFFFNFE	-1,162.6	II	42
117	FFFRFFFDFE	-1,147.7	II	43
118	FFFRFFFNFN	-1,139.9	II	44
119	FFFHFFFEEFQ	-1,135.4	II	45
120	FFFHFFFNFE	-1,126.4	II	46
121	FFFHFFFNFE	-1,126.4	II	47
122	EFNFFFHFFF	-1,125.1	III	48
123	FFFRFFFNFE	-1,124.5	II	49
125	FFFHFFFEEFE	-1,115.4	II	50
126	QFEFFFHFFF	-1,114.4	III	51
127	FFFHFFFEEFD	-1,114.3	II	52
128	FFFHFFFDFE	-1,111.4	II	53
129	YYYRYYYEYQ	-1,110.2	II	54
130	NFEFFFHFFF	-1,109.1	III	55
131	FFKFFFKFE	-1,107.0	II	56
133	EFDFFFFRFFF	-1,103.4	III	57
135	FFFHFFFDFD	-1,102.4	II	58
136	FFFHFFFNFN	-1,100.4	II	59
137	FFFRFFFDFD	-1,100.3	II	60
138	FFKFFFKFN	-1,098.2	II	61
139	FFKFFFEEFE	-1,095.1	II	62
140	FFFEFFFKFE	-1,091.8	II	63
141	FFQFFFQFQ	-1,088.8	II	64
143	FFKFFFQFQ	-1,084.4	II	65
144	FFKFFFNFN	-1,083.5	II	66
145	FFNFFFNFN	-1,083.3	II	67
146	FFKFFFEEFQ	-1,082.6	II	68
148	FFKFFFKFQ	-1,080.0	II	69



RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
149	FFFKFFFQFK	-1,079.6	II	70
150	FFFKFFFKFD	-1,077.4	II	71
152	FFFKFFFDFD	-1,074.5	II	72
153	FFFNFFFKFN	-1,074.2	II	73
154	FFFDFFFDFD	-1,073.5	II	74
155	FFFKFFFDFK	-1,073.3	II	75
156	FFFKFFFDFK	-1,072.6	II	76
157	FFFEFFFFEFE	-1,070.8	II	77
158	FFFDFFFKFD	-1,070.7	II	78
159	FFFKFFFKFK	-1,070.7	II	79
160	FFFEFFFFKFK	-1,069.7	II	80
161	FFQFFFKFK	-1,069.6	II	81
162	FFFKFFFNFK	-1,069.2	II	82
163	FFFNFFFKFK	-1,066.7	II	83
164	FFQFFFKFKQ	-1,062.5	II	84
165	FFFDFFFKFK	-1,061.9	II	85
179	LLRLLELQ	-966.7	II	86
395	FVKFVKFV	-917.2	I	87
211	CCCRCCCECQ	-818.2	II	88
230	MMMRMMEMQ	-774.6	II	89
232	VVVRVVVEVQ	-771.6	II	90
258	IIIRIIIEIQ	-699.2	II	91
267	GGGRGGGEGQ	-640.4	II	92
268	PPRPPEPQ	-627.1	II	93
271	TTTRTTTETQ	-614.4	II	94
273	AAARAAAEAQ	-609.4	II	95
280	AAKAAAKAA	-556.0	II	96
281	AAAEAAAEAE	-541.6	II	97
287	SSSRSSSESQ	-499.3	II	98

[00228] Table 4 presents some quasi-Class I polypeptides. These peptides include a sequence similar to the striathic sequence of Formula II (i.e.,  $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}-X_{2a}-Y_{3a}-X_{3a}$ ), but the hydrophobic amino acid residues have all been replaced with a particular hydrophilic amino acid residue.

**Table 4: Quasi-Class I Polypeptides**

RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
173	HHHRHHHEHQ	-1,002.2	II*	99
195	RRRRRRRERQ	-855.2	II*	100
275	QQQRQQQEQQ	-575.6	II*	101
276	EEEREIEEEEQ	-569.5	II*	102
284	NNNRNNNENQ	-522.7	II*	103
288	DDDRDDDEDQ	-463.6	II*	104
290	KKKRKKKEKQ	-423.7	II*	105

\*These peptides do not comply with the sequence requirements of Formula II, but instead represent an “all hydrophilic” variation on the sequence requirements of Formula II.

**[00229]** Table 5 presents various Class II, Sub-class 1 polypeptides. The presented peptides have a striapathic region consisting of a sequence corresponding to Formula X (i.e.,  $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}-X_{3a}$ ), or a striapathic region consisting of a sequence corresponding to Formula XI (i.e.,  $X_{1a}-Y_{1a}-X_{2a}-X_{2b}-Y_{2a}-Y_{2b}-X_{3a}-X_{3b}-Y_{3a}-Y_{3b}$ ).

**Table 5: Class II, Sub-class 1 Polypeptides**

RP#	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
124	FFQKFFKRWR	-1,121.3	X	106
132	FFRKFFKRFR	-1,104.8	X	107
134	RFRKFFKRFF	-1,103.3	XI	108
142	RFRKFFKQFF	-1,085.5	XI	109
147	FFQKFFKRFR	-1,080.3	X	110
151	RWRKFFKQFF	-1,077.0	XI	111
166	FFEHWKEFN	-1,044.8	X	112
167	FFQHFWKQFN	-1,024.9	X	113
168	QFNHFFKEFF	-1,022.8	XI	114
169	FFDKFFHDFQ	-1,014.2	X	115
170	QFDHFFKDFF	-1,011.9	XI	116
171	FFEKFFHNFQ	-1,009.9	X	117
172	NFEKWFHEFF	-1,007.9	XI	118
175	LFRRAFKQLD	-989.5	X	119
177	NFQKWFHQFF	-976.3	XI	120
182	KFRKAFKRFF	-944.8	XI	121

RP#	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
183	FFRKFAKRFK	-933.2	X	122
185	FFKKFFKKFK	-920.6	X	123
186	KFKKFFKKFF	-919.6	XI	124
424	KARKAFKRFF	-910.2	XI	125
190	WVKDAMQHLD	-888.7	X	126
194	FFKKFAKKFK	-859.1	X	127
198	FAEKFFKNFK	-850.4	X	128
199	KFNKFFKEAF	-847.1	XI	129
200	FAKQFFNKFK	-846.0	X	130
201	KFNKAFKQAF	-837.8	XI	131
202	KFNKAFKQAF	-837.8	XI	132
204	FAQKFFKDFK	-835.9	X	133
206	FAEEFAEEFE	-823.1	X	134
207	KFKKFFKKAF	-820.7	XI	135
209	KFKNFFQKAF	-819.1	XI	136
210	KFKNFFQKAF	-819.1	XI	137
212	FAKQFANKFK	-817.9	X	138
213	KFKNAFQKAF	-815.2	XI	139
214	KFKNAFQKAF	-815.2	XI	140
215	FAKKFFKKFK	-814.0	X	141
216	KFKKAFKKFF	-811.2	XI	142
218	FAEKFAEKFE	-807.6	X	143
219	DLHQMADKVV	-807.6	XI	144
425	KARKAAKRFF	-800.3	XI	145
225	FAKNFAKKFK	-794.0	X	146
227	FAEKFAKNFK	-786.6	X	147
233	KFKKAFKKAF	-771.2	XI	148
234	FAKNFAKNFK	-769.8	X	149
235	FAKEFAKEFE	-768.9	X	150
236	KFDKAFKQAF	-766.2	XI	151
237	KFDKAFKQAF	-766.2	XI	152
238	FAEKFAKKFK	-765.1	X	153
239	FAEKFAEKFK	-764.2	X	154
398	FAKKFAKKFK	-760.3	X	155
241	FAKNFAKNFN	-758.7	X	156
242	FAQKFAKNFK	-758.6	X	157
243	FANNFANNFN	-755.2	X	158

RP#	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
244	FANNFANNFN	-755.2	X	159
245	FANKFANKFN	-754.0	X	160
246	FANKFAKKFK	-752.2	X	161
247	FAQKFAKDFK	-750.7	X	162
250	FAKEFAKEFK	-745.7	X	163
251	FANKFANKFK	-739.7	X	164
252	KFDKFFKQAF	-739.1	XI	165
253	KFDKFFKQAF	-739.1	XI	166
254	KFNKAFKEAF	-738.4	XI	167
255	KFNKAFKEAF	-738.4	XI	168
256	FAKEFAKKFK	-702.8	X	169
426	KARKAAKRAF	-634.5	XI	170
427	KARKAAKRAA	-578.1	XI	171
285	AAEEAAEEAE	-511.6	X	172
387	AAKKAACKAK	-301.6	X	173

**[00230]** Table 6 presents polypeptides that fall into a variety of different Classes, including: Class II peptides (having a striapathic region that includes a sequence corresponding to any of Formulas VI to XVI); Class II, Sub-class 2 (having a striapathic region that includes a sequence corresponding to Formulas VIII and XII); Class II, Sub-class 3 (having a striapathic region that includes a sequence corresponding to Formula IX); Class II, Sub-class 4 (having a striapathic region that includes a sequence corresponding to Formulas XIV and XV); Class II, Sub-class 5 (having a striapathic region that includes a sequence corresponding to Formulas XIII and XVI); Class III peptides (having a striapathic region that includes a sequence corresponding to any of Formulas XVII to XX); Class III, Sub-class 1 peptides (having a striapathic region that includes a sequence corresponding to Formulas XIX or XX); Class IV peptides (having a striapathic region that includes a sequence corresponding to Formulas IV and V); Class V peptides (having a striapathic region that includes a sequence corresponding to Formula XXI); Class VI peptides (having a striapathic region that includes a sequence corresponding to Formulas XXII and XXIII); Class VII peptides (having a striapathic region that includes a sequence corresponding to any of Formulas XXIV to XXVI); Class VIII peptides (having a striapathic region that includes a sequence corresponding to any of Formulas XXVII to XXXII);

Class VIII, Sub-class 3 and 4 peptides (having a striapathic region that includes a sequence corresponding to Formulas XXXI and XXXII, respectively); Class IX peptides (having a striapathic region that includes a sequence corresponding to any of Formulas XXXIII to XXXVIII); Class IX, Sub-class 3 and 4 peptides (having striapathic regions that include a sequence corresponding to Formulas XXXVII and XXXVIII, respectively); and Class XIII (having a striapathic region that includes a sequence corresponding to Formula L). Because polypeptides of Class VIII, Sub-class 3 and Class IX, Sub-class 3 share the same sequence of hydrophobic and hydrophilic modules, but reversed N-terminal to C-terminal orientation, they could have been grouped into the same Class and Sub-class. Similarly, because polypeptides of Class VIII, Sub-class 4 and Class IX, Sub-class 4 share the same sequence of hydrophobic and hydrophilic modules, but reversed N-terminal to C-terminal orientation, they could have been grouped into the same Class and Sub-class.

**Table 6: Class II to Class IX and Class XIII Polypeptides**

RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
396	FVKFVKFVKF	-1,039.7	L	174
405	KRKAFRKFFF	-1,026.6	XIV	175
174	LHKMYNQVW	-1,000.2	VII	176
176	WVQNYMKHL	-979.3	VII	177
178	RLVEMMRQIW	-972.2	XX	178
180	FLKRLLQEI	-955.9	VII	179
181	LRLLRLL	-950.2	XVII	180
184	WVRDSMKHL	-925.6	VII	181
408	KFFRKKFRFA	-917.4	XXII	182
187	WVQRVVEKFL	-906.4	IX	183
416	AFFRRFKFKK	-904.1	XXV	184
188	LFKEVVRQVW	-902.9	IX	185
189	MDKIYDQVWK	-893.3	VIII	186
388	FVKKFVKKFV	-891.9	X	187
417	KKFKFRFFFA	-888.8	XXVI	188
191	WVRDVVRSD	-874.1	XIX	189
192	ELSNIERVW	-872.4	XX	190
193	WIQRMMEVLR	-866.9	XIX	191
404	FFFKRFAKRK	-856.7	XV	192
196	LHKMSDRVW	-852.4	VII	193

RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
197	WVREYINSLE	-851.2	XIX	195
402	FFKKRFAFRK	-851.0	XXXI	196
203	KWVQDYIKDM	-837.0	XII	197
409	AFRFKKRFFK	-832.7	XXIII	198
205	LLRHLLRL	-830.0	XVII	199
208	WIKKLLESSQ	-819.7	XIX	200
217	DMSRVVDRVW	-810.4	XX	201
220	EEEEEEEEFE	-804.8	V	202
221	WVKNSINHL	-803.7	VII	203
222	LTKKGRRFC	-799.7	XXI	204
223	IEQLLRKLF	-796.8	VII	205
224	LHNISNKVW	-794.5	VII	206
226	CFRRGKCTL	-786.7	XXI	207
229	IVRRADRAAV	-781.5	XXI	208
231	TVERFKNLS	-771.8	XXI	209
240	QSSELLKKIW	-761.9	XX	210
248	SLNKFREVT	-750.5	XXI	211
249	LIKQIVKKLF	-750.5	IX	212
397	FAKKFAKKF	-739.3	VII	194
415	KKKFFF	-706.8	XXVII	213
257	LYKKI IKKLL	-699.8	IX	214
259	FKKKFKKKFK	-686.5	V	215
260	VAARDARRVI	-684.6	XXI	216
261	FLKKVIQKIL	-679.4	IX	217
262	LIKEI IKQVM	-668.4	IX	218
263	LLKKI IKKYL	-666.7	IX	219
264	AFEEEEAEFE	-652.2	XXXVIII	220
265	KKWVQDSMK	-650.1	XVIII	221
266	NFANKVQEVA	-644.1	XXI	222
269	AVEQVKNAFN	-621.1	XXI	223
272	MVQKI IEKIL	-613.1	IX	224
274	KMSDQVWKK	-595.9	XVIII	225
277	MVKKI IEKM	-569.2	VII	226
278	ALKKQVIKKI	-559.1	XVI	227
279	IKKIVQKKLA	-556.7	XIII	228
282	AFFKKKAKFK	-537.6	XXXVIII	229
283	MKEI IKVM	-533.1	VII	230

RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
286	AEEEEAEAE	-504.4	V	231
289	AKKKAKKKAK	-431.6	V	232
414	KKKAAA	0.0	XXVII	233

[00231] Table 7 presents polypeptide of Classes VIII through XI. All of the peptides presented in Table 7 have a striapathic region that includes a hydrophilic module having four or five hydrophilic amino acid residues and/or a hydrophobic module having four or five hydrophobic amino acid residues. Class VIII, Sub-class 1 peptides have a striapathic region that includes a sequence corresponding to Formulas XXVIII or XXIX; Class VIII, Sub-class 2 peptides have a striapathic region that includes a sequence corresponding to Formula XXX; Class IX, Sub-class 1 peptides have a striapathic region that includes a sequence corresponding to Formulas XXXIV or XXXV; Class IX, Sub-class 2 peptides have a striapathic region that includes a sequence corresponding to Formula XXXVI; Class X peptides have a striapathic region that includes a sequence corresponding to any of Formulas XXXIX to XLIII; and Class XI peptides have a striapathic region that includes a sequence corresponding to any of Formulas XLIV to XLVIII. Because polypeptides of Class VIII, Sub-class 1 and Class IX, Sub-class 1 share the same sequence of hydrophobic and hydrophilic modules, but reversed N-terminal to C-terminal orientation, they could have been grouped into the same Class and Sub-class. Similarly, because polypeptides of Class VIII, Sub-class 2 and Class IX, Sub-class 2 share the same sequence of hydrophobic and hydrophilic modules, but reversed N-terminal to C-terminal orientation, they could have been grouped into the same Class and Sub-class.

**Table 7: Class VIII to XI Polypeptides**

RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
406	KRKKRFAPFF	-993.5	XXX	234
422	RKRKFAPFFK	-948.2	XLVIII	235
407	FFFAFRKKRK	-914.7	XXXVI	236
400	FRKKRFAPFFK	-900.5	XXIX	237
419	FFFRKKKKFA	-881.9	XLII	238
401	KFFAFRKKRF	-880.1	XXXV	239
423	KFFAFFKRKR	-877.1	XLV	240

RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
411	KKKKKFFFFFF	-863.7	XXX	241
418	AFKKKRFFFF	-854.1	XLI	242
428	KRKKRAAFFF	-842.0	XXX	243
420	KKFFAFFRKR	-840.2	XLVI	244
421	RKRFFAFFKK	-835.5	XLVII	245
429	KRKKRAAAFF	-758.1	XXX	246
413	KKKKFFFF	-715.8	XXVIII	247
430	KRKKRAAAAF	-676.7	XXX	248
270	KKKAFFFAKK	-614.4	XLVII	249
431	KRKKRAAAAA	-544.9	XXX	250
410	KKKKKAAAAA	-385.3	XXX	251
412	KKKKAAAA	-382.8	XXVIII	252

[00232] Table 8 presents polypeptides of Class XII and Class XIV. Class XII peptides have a striapathic region that includes a sequence corresponding to Formula XLIX (i.e.,  $Y_{1a}-X_{1a}-Y_{2a}-X_{2a}-Y_{3a}-X_{3a}$ ). Class XII peptides are predicted to adopt a beta-strand secondary structure. Class XIV peptides are proline-rich peptides that have a striapathic region that includes a sequence corresponding to one of Formulas LI-LIV.

**Table 8: Beta-Strand and Proline-Rich Polypeptides**

RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
393	FKFKFKFKF	-1,193.2	XLIX	253
391	FRFKFKFR	-1,190.8	XLIX	254
392	RFQFKFRF	-1,170.3	XLIX	255
390	FRFKFKF	-1,083.3	XLIX	256
389	FRFKFA	-1,009.8	XLIX	257
449	RRFPRPPFF	-1,116.8	LI	258
450	FFPPRPFR	-1,100.0	LII	259
448	LYPPRPFR	-1,059.3	LII	260
447	RRIPRPPYL	-1,050.5	LI	261
452	PFRPPRPFR	-1,012.2	LIII	262
451	PRPRPPRFF	-1,002.1	LIV	263
444	FFPKPKPKK	-954.8	LII	264
441	KKIPKPPYL	-922.1	LI	265
446	PKPKPPKPKP	-882.3	LIII	266
445	PKPKPPKFP	-866.3	LIV	267



RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
442	LYPPKPIKK	-846.6	LII	268
443	KKFPKPPFF	-802.8	LI	269

[00233] Table 9 presents fusion peptides, which include combinations of Class I, Class II, and/or Class III peptides linked together by a peptide bond and, optionally, a short peptide linker (e.g., a tri-glycine (GGG) linker).

**Table 9: Peptide Combinations**

RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
292	EFEFFFRFFFGGGEFEFFFRFFF	-1,606.1	III + III	270
293	QFEFFFRFFFGGGQFEFFFRFFF	-1,602.0	III + III	271
294	DFEFFFRFFFGGGDFEFFFRFFF	-1,591.8	III + III	272
295	EFNFFFRFFFGGGEFNFFFRFFF	-1,591.8	III + III	273
296	FFFRFFFEFQFFFRFFFEFQ	-1,511.6	II + II	274
297	FFFRFFFEFQGGGFFFRFFFEFQ	-1,511.5	II + II	275
298	RWRKFFKRFFQFEFFFRFFF	-1,505.2	XI + III	276
299	RWRKFFKRFFGGGFFFRFFFNFN	-1,501.3	XI + II	277
300	RFRKFFKRFFQFEFFFRFFF	-1,486.0	XI + III	278
301	RFRKFFKRFFGGGFFFRFFFNFN	-1,485.0	XI + II	279
302	RWRKFFKRFFGGGFFFRFFFEFQ	-1,479.6	XI + II	280
303	RFRKFFKRFFGGGFFFRFFFEFQ	-1,476.8	XI + II	281
304	EFEFFFRFFFEFEFFFRFFF	-1,476.0	III + III	282
305	RWRKFFKRFFNFNFFFRFFF	-1,474.2	XI + III	283
306	QFEFFFRFFFQFEFFFRFFF	-1,467.0	III + III	284
307	RWRKFFKRFFGGGNFNFFFRFFF	-1,464.2	XI + III	285
308	EFNFFFRFFFEFNFFFRFFF	-1,460.5	III + III	286
309	RFRKFFKRFFNFNFFFRFFF	-1,458.4	XI + III	287
310	FFRKFFKRFRGGGNFNFFFRFFF	-1,447.1	X + III	288
311	RFRKFFKRFFGGGNFNFFFRFFF	-1,432.1	XI + III	289
312	DFEFFFRFFFDFEFFFRFFF	-1,430.0	III + III	290
313	RWRKFFKRFFFFFRFFFEFQ	-1,427.4	XI + II	291
314	RFRKFFKRFFFFFRFFFEFQ	-1,425.6	XI + II	292
315	FFRKFFKRFRGGGFFFRFFFNFN	-1,420.6	X + II	293
316	FFRKFFKRWRGGGFFFRFFFNFN	-1,417.5	X + II	294

RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
317	RFRKFFKRFFFFRFFNFNFN	-1,406.6	XI + II	295
318	FFRKFFKRFRFFFFRFFFEFQR	-1,402.0	X + II	296
291	FFEHFWKEFNNGGNFQKWFHQFF	-1,401.6	X + XI	297
319	FFRKFFKRWRQFEFFFRFFF	-1,400.7	X + III	298
320	RWRKFFKRFFFFRFFNFNFN	-1,397.9	XI + II	299
321	NFQKWFHQFFGGGFEEHFWKEFN	-1,396.0	XI + X	300
322	FFRKFFKRWRGGGNFNFFFRFFF	-1,394.4	X + III	301
323	FFRKFFKRWRFFFFRFFFEFQR	-1,394.3	X + II	302
324	FFRKFFKRWRNFNFFFRFFF	-1,393.7	X + III	303
325	FFRKFFKRFRGGGFFRFFFEFQR	-1,386.8	X + II	304
326	FFRKFFKRFRQFEFFFRFFF	-1,382.8	X + III	305
327	FFRKFFKRFRNFNFFFRFFF	-1,378.2	X + III	306
328	RFRKFFKRFFGGGQFEFFFRFFF	-1,368.5	XI + III	307
329	FFRKFFKRWRGGGFFRFFFEFQR	-1,354.5	X + II	308
330	FFRKFFKRFRGGGQFEFFFRFFF	-1,352.8	X + III	309
331	FFRKFFKRWRGGGQFEFFFRFFF	-1,352.2	X + III	310
332	RWRKFFKRFFGGGQFEFFFRFFF	-1,349.8	XI + III	311
333	QFNHFFKEFGGGQFNHFFKEFF	-1,340.0	VII + XI	312
334	FFRKFFKRFRFFFRFFNFNFN	-1,337.5	X + II	313
335	FFRKFFKRWRFFFRFFNFNFN	-1,337.0	X + II	314
336	FFEHFWKEFNNGGGFEEHFWKEFN	-1,325.5	X + X	315
337	FFEHFWKEFGGGNFQKWFHQFF	-1,324.8	VII + XI	316
338	NFQKWFHQFGGGFEEHFWKEFN	-1,317.9	VII + X	317
339	FFEHFWKEFNNGGLHKMYNQVW	-1,315.4	X + VII	318
340	NFQKWFHQFFGGGNFQKWFHQFF	-1,309.9	XI + XI	319
341	FAKKFAKKFKGGGNFQKWFHQFF	-1,308.3	X + XI	320
342	FFEKFFHNFGGGFFEKFFHNFG	-1,304.6	X + X	321
343	FFQHFWKQFNNGGGFFQHFWKQFN	-1,300.2	X + X	322
344	NFQKWFHQFFNFQKWFHQFF	-1,293.5	XI + XI	323
345	FAKKFAQKFKGGGNFQKWFHQFF	-1,291.9	X + XI	324
346	FAKKFAKKFKGGGQFEFFFRFFF	-1,290.9	X + III	325
347	QFNHFFKEFQFNHFFKEFF	-1,279.8	VII + XI	326
348	FAKKFAKKFKGGGDFEFFFRFFF	-1,278.4	X + III	327
349	FFEHFWKEFNNGGWVQNYMKHL	-1,268.8	X + VII	328
350	FAKKFAKKFKQFEFFFRFFF	-1,268.5	X + III	329
351	FFQHFWKQFNFFQHFWKQFN	-1,263.2	X + X	330
352	FFEHFWKEFNFFEHFWKEFN	-1,251.5	X + X	331

RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
353	NFEKWFHEFFNFEKWFHEFF	-1,247.0	XI + XI	332
354	FAKKFAKKFKGGGQFNHFFKEFF	-1,244.6	X + XI	333
355	NFEKWFHEFFGGGNFEKWFHEFF	-1,241.4	XI + XI	334
356	FAKKFAKKFKGGGFFRFFFEFQ	-1,237.9	X + II	335
357	FAKKFAKKFKDFEFFFFRFFF	-1,235.3	X + III	336
358	QFNHFFKEFFGGGQFNHFFKEFF	-1,230.0	XI + XI	337
359	FAKKFAKKFKGGGEFEFFFFRFFF	-1,221.7	X + III	338
360	FAKKFAKKFKGGGEFNFFFRFFF	-1,221.0	X + III	339
361	FAKKFAKKFKGGGNFEKWFHEFF	-1,212.3	X + XI	340
362	FAKKFAKKFKGGGFFEKFFHNQ	-1,210.8	X + X	341
363	QFNHFFKEFFQFNHFFKEFF	-1,208.6	XI + XI	342
364	FFEKFFHNQFFEKFFHNQ	-1,207.5	X + X	343
365	FAKKFAKKFKEFEFFFFRFFF	-1,204.2	X + III	344
366	FAKKFAKKFKEFNFFFRFFF	-1,187.6	X + III	345
367	FAKKFAKKFKFFEHWKEFN	-1,168.1	X + X	346
368	FAKKFAKKFKFFRFFFEFQ	-1,166.4	X + II	347
369	FAKKFAKKFKLHKMYNQVW	-1,159.5	X + VII	348
370	FAKKFAKKFKGGGFFEHWKEFN	-1,140.4	X + X	349
371	FAKKFAKKFKGGGWVQNYMKHL	-1,130.4	X + VII	350
372	FAKKFAKKFKNFQKWFHQFF	-1,126.1	X + XI	351
373	FAKKFAKKFKFFQHFWKQFN	-1,119.8	X + X	352
374	FAKKFAKKFKGGGFFQHFWKQFN	-1,119.6	X + X	353
375	FAKKFAKKFKWVQNYMKHL	-1,119.2	X + VII	354
376	FAKKFAKKFKQFNHFFKEFF	-1,108.3	X + XI	355
377	FAKKFAKKFKGGGLHKMYNQVW	-1,100.3	X + VII	356
378	FAKKFAKKFKNFEKWFHEFF	-1,081.4	X + XI	357
379	FAKKFAKKFKFFEKFFHNQ	-1,046.8	X + X	358
380	FAKKFAKKFKGGGAFFKKKAKFK	-950.9	X + XXXVIII	359
381	AFFKKKAKFKGGGAFFKKKAKFK	-935.5	XXXVIII + XXXVIII	360
382	KFKKAFKKAFKFKKAFKAF	-925.2	XI + XI	361
383	KFKKAFKKAFGGGKFKKAFKAF	-923.8	XI + XI	362
384	FAKKFAKKFKGGGFAKKFAKKFK	-909.2	X + X	363
385	FAKKFAKKFKAFFKKKAKFK	-839.9	X + XXXVIII	364
228	PSRKSMEKSVAKLLNKIAKSEP	-782.4	IX + XVIII	365
386	AFFKKKAKFKAFKKKAKFK	-716.0	XXXVIII +	366

RP #	Sequence	RelB Binding E (kCal/mol)	Formula	SEQ ID NO:
			XXXVIII	

[00234] In each of Tables 3-9, the RP# is a randomly assigned designation used to identify specific peptide sequences. The “Binding E” (see column 3 in each of the Tables) corresponds to a predicted measure of the energy released when individual peptides bind to the protein dimerization domain of RelB, an NFkB Class II protein (see Example 2, below).

[00235] Example 2: Predicted Binding of Peptides to Rel B

[00236] To identify peptides having anti-inflammatory activity, the NF-kB complex was selected as a target, since it is known to be a key component in the signaling pathways that regulate inflammation. Dimerization of NF-kB (either homologous or heterologous), which is mediated by the dimerization domains found in NF-kB Class II proteins (e.g., RelA, RelB, cRel, NF-kB1, and NF-kB2), is essential for activation of the NF-kB complex and its generation of pro-inflammatory signals. Accordingly, peptide designs were selected for their ability to specifically bind to the dimerization domain of RelB (NCBI Acc. No. NP\_033072.2), with the goal that such binding would inhibit NF-kB dimerization and activation.

[00237] Peptide binding to the dimerization domain of Rel B was evaluated *in silico*, using the web-based ClusPro™ algorithm developed at Boston University. The ClusPro™ algorithm filters docked conformations between a protein target and a putative ligand and determines surface complementarity, ranking the conformations based on their clustering properties. The free energy filters select complexes with the lowest desolvation and electrostatic energies. Clustering is then used to smooth the local minima and to select the ones with the broadest energy wells, a property associated with the free energy at the binding site. Using this method, it is possible to evaluate the affinity a ligand possesses for a particular target, whereupon the ligands can be ranked and then tested for biological activity *in vitro* or *in vivo*.

[00238] The binding energies calculated by the ClusPro™ algorithm are shown for each of the peptides in Tables 3-9, in the third columns of the tables. In each of Tables 3-9, the peptides are ranked according to the calculated RelB binding energy, from highest to lowest binding energy. The RelB binding energies were used to explore the structure-function relationship of the peptides, particularly with regard to (i) increasing or decreasing hydrophobicity, (ii)

positive/negative charge density, and (iii) altering the arc of the hydrophobic and hydrophilic faces of the peptides. The peptides shown in Table 10 (below) will be used to illustrate the results of the study.

**Table 10: Predicted Binding of Select Peptides to RelB**

RP#	Sequence	RelB Binding E (kCal/mol)*	Formula	SEQ ID NO:
RP-182	KFRKAFKRFF	-944.8	XI	121
RP-166	FFEHWKEFN	-1,044.8	X	112
RP-113	FFFRFFFEFQ	-1,208.9	II	39
RP-289	AKKKAKKKAK	-431.6	V	232
RP-387	AAKKAACKAK	-338.3	X	173
NF-CONTR2	IESKRRKKKP	-476.6	N/A	382
NF-CONTR3	APGPGDGGTA	-621.1	N/A	383

\* The lower the energy value, the greater affinity the ligand possesses for the binding site on the target protein.

**[00239]** A structural model of the RelB subunit of NF- $\kappa$ B is shown in Figure 1. Amino acids with the dimerization site are shaded to indicate their hydrophobic or hydrophilic character. In particular, the amino acid residues colored magenta are hydrophilic, while the amino acid residues colored cyan are hydrophobic. Given the distinct locations of the hydrophilic and hydrophobic amino acid residues within the binding pocket of the dimerization domain, it is evident that striapathic peptides having an amphipathic secondary structure have the potential to bind site-specifically to the dimerization domain binding pocket.

**[00240]** The secondary structure of RP-182 (SEQ ID NO: 121) and its binding to RelB (SEQ ID NO: 367) is modeled in Figure 2. As can be seen in the panels on the right, RP-182's predicted secondary structure has distinct hydrophobic and hydrophilic sides that comprise approximately equal facial arcs (see also Fig. 9) and are of high volume. Overall, the structure of RP-182 possesses high hydrophobicity and high cationicity (with a total of five cationic amino acid residues). These characteristics of RP-182 are summarized in Table 11, below. Based on the structural modeling, RP-182 binds with high affinity to the RelB dimerization domain binding pocket, with an estimated binding energy of -944.8 kcal/mol.

**[00241]** The secondary structure of RP-166 (SEQ ID NO: 112) and its binding to RelB (SEQ ID NO: 367) is modeled in Figure 3. As can be seen in the panels on the right, RP-166's

predicted secondary structure also has distinct hydrophobic and hydrophilic sides that comprise approximately equal facial arcs (see also Fig. 9). These characteristics are not surprising, as the striapathic region of RP-166 has a modular structure that is identical (albeit reversed) to that of RP-182's (compare Formulas X and XI). As with RP-182, the hydrophobic and hydrophilic surfaces of RP-166 are of high volume, but RP-166 has a greater ratio of hydrophobic volume to hydrophilic volume as compared to RP-182. In addition, the cationicity of RP-166 is significantly reduced relative to that of RP-182, since RP-166 has an equal number of cationic amino acid residues and anionic amino acid residues. These characteristics of RP-166 are summarized in Table 11, below. Based on the structural modeling, RP-166 binds to the RelB dimerization domain binding pocket with even higher affinity than RP-182, having an estimated binding energy of -1,044.8 kcal/mol.

**[00242]** The secondary structure of RP-113 (SEQ ID NO: 39) and its binding to RelB (SEQ ID NO: 367) is modeled in Figure 4. As can be seen in the panels on the right, RP-113's predicted secondary structure also has distinct hydrophobic and hydrophilic sides, but the hydrophobic side comprises a much larger facial arc than the hydrophilic side. As shown in Figure 9, the facial arc of the polar side of RP-113 is only 60°, while the facial arc of the non-polar side is 300°. Consistent with this shift toward a larger hydrophobic surface, RP-113 has a larger hydrophobic volume than either RP-182 or RP-166, as well as a significantly larger ratio of hydrophobic to hydrophilic volume. See Table 11, below. Like RP-166, the cationicity of RP-113 is significantly reduced relative to that of RP-182, since RP-113 has an equal number of cationic amino acid residues and anionic amino acid residues. Based on the structural modeling, RP-113 binds to the RelB dimerization domain binding pocket with one of the highest affinities predicted for the peptides of the invention, having an estimated binding energy of -1,208.9 kcal/mol.

**[00243]** The secondary structure of RP-387 (SEQ ID NO: 173) and its binding to RelB (SEQ ID NO: 367) is modeled in Figure 5. As can be seen in the panels on the right, RP-387's predicted secondary structure has distinct hydrophobic and hydrophilic sides. However, in contrast to RP-113, the hydrophilic side of RP-387 comprises a much larger facial arc than the hydrophobic side. As shown in Figure 10, the facial arc of the polar side of RP-387 is 245°, while the facial arc of the non-polar side is 115°. Consistent with this shift toward a larger hydrophilic surface, RP-387 has a smaller hydrophobic volume than any of RP-182, RP-166, and

RP-113, as well as a significantly smaller ratio of hydrophobic to hydrophilic volume. See Table 11, below. With regard to cationicity, RP-387 is similar to RP-182, having a total of five cationic amino acid residues. Based on the structural modeling, RP-387 binds to the RelB dimerization domain binding pocket, but it does so relatively poorly, having an estimated binding energy of only -338.3 kcal/mol.

**[00244]** The secondary structure of RP-289 (SEQ ID NO: 232) and its binding to RelB (SEQ ID NO: 367) is modeled in Figure 6. As can be seen in the panels on the right, RP-289's predicted secondary structure has distinct hydrophobic and hydrophilic sides. However, RP-289's hydrophobic side is one of the smallest of the peptides screened. As shown in Figure 9, the facial arc of the polar side of RP-289 is 290°, while the facial arc of the non-polar side is only 70°. Of the peptides listed in Table 11, RP-289 has the smallest hydrophobic volume and the smallest ratio of hydrophobic to hydrophilic volume. RP-289 also has the highest cationicity of the peptides listed in Table 11, having a total of seven cationic amino acid residues. Based on the structural modeling, RP-289 binds to the RelB dimerization domain, though comparatively much more weakly than RP-182, RP-166, and RP-113, having an estimated binding energy of only -431.6 kcal/mol.

**[00245]** Tables 10 and 11 also identify two control peptides, NF-CONTR2 and NF-CONTR3, which are fragments of the RelB subunit of NF- $\kappa$ B. The sequences of NF-CONTR2 and NF-CONTR3 do not conform to any of structural Formulas I-LIII. The secondary structure of NF-CONTR2 (SEQ ID NO: 382) and its binding to RelB (SEQ ID NO: 367) is modeled in Figure 7. The secondary structure of NF-CONTR3 (SEQ ID NO: 383) and its binding to RelB (SEQ ID NO: 367) is modeled in Figure 8. Neither peptide is predicted to adopt a clearly amphipathic secondary structure throughout the length of the peptide. Moreover, although the ClusPro™ algorithm identifies a binding interaction between each of NF-CONTR2 and NF-CONTR3 and RelB, the binding energies are not very strong and neither peptide displays a preference for binding to the RelB dimerization domain binding pocket.

**Table 11: Physical Characteristics of Select Peptides**

RP#	Sequence	SEQ ID NO:	RelB Binding Energy	(+)	(-)	HPL Vol	HPB Vol	HPB Vol/HPL Vol	tH HPL	tH HPB	tH HPB/tH HPL
182	KFRKAFKRFF	121	-944.8	6	1	696.9	659.8	0.95	-50.8	16.4	-0.32
166	FFEHFWEFN	112	-1,044.8	3	3	637.7	775.0	1.22	-33.0	16.7	-0.51

RP#	Sequence	SEQ ID NO:	RelB Binding Energy	(+)	(-)	HPL Vol	HPB Vol	HPB Vol/HPL Vol	tH HPL	tH HPB	tH HPB/tH HPL
113	FFFRFFFEFQ	39	-1,208.9	2	2	414.5	1030.4	2.49	-23.5	25.9	-1.10
289	AKKKAKKKAK	232	-431.6	8	1	896.8	213.3	0.24	-61.6	4.8	-0.08
387	AAKKAACKAK	173	-338.3	6	1	640.5	355.5	0.55	-44.0	8.0	-0.18
NF-C2	IESKRRKKKP	382	-476.6	7	2	954.9	297.4	0.31	-66.8	3.5	-0.05
NF-C3	APGPGDGGTA	383	-621.1	1	1	115.1	665.7	5.78	-9.2	8.0	-0.87

\*Binding energies are in kcal/mol. Volumes are in cubic angstroms. HPL means hydrophilic; HPB means hydrophobic. “tH” is the total hydrophobicity (in kcal/mol), as defined by Engleman et al. (1986), “Identifying nonpolar transbilayer helices in amino acid sequences of membrane proteins,” *Annu. Rev. Biophys. Bioeng.* 15: 321–53.

**[00246]** Figures 1 through 10 and Table 11 reveal some important aspects of the structure-function relationship for the peptides of the invention. First, all of the peptides that are predicted to bind the RelB dimerization domain binding pocket have an amphipathic secondary structure. Second, greater hydrophobic volume, a greater ratio of hydrophobic to hydrophilic volume, and a greater hydrophobic arc are all associated with increased affinity for the binding pocket of the RelB dimerization domain. Third, increased cationicity is associated with decreased binding affinity for the binding pocket of the RelB dimerization domain.

**[00247]** Table 4, which lists some “all hydrophilic” variants of the Class I peptides, appears to potentially refute the conclusion that increased cationicity is associated with decreased binding affinity for the binding pocket of the RelB dimerization domain. In each of the peptides in Table 4, the hydrophobic residues of a Class I, Formula II peptide have been replaced with a single type of hydrophilic residue. Significantly, RP-173 (HHHRHHHEHQ; SEQ ID NO: 99) and RP-195 (RRRRRRRRERQ; SEQ ID NO: 100) both have a high affinity for the binding pocket of the RelB dimerization domain (-1,002.2 and -855.2 kcal/mol, respectively), despite have eight amino acid residues that generally have a cationic charge in solution. Because both histidine and arginine have large side chains, a potential explanation for their high RelB binding affinities is that the uncharged hydrocarbon groups in the side chains provide some hydrophobicity that would otherwise have been lost by switching from a hydrophobic residue to a hydrophilic residue. In addition, when bound to RelB, some of the histidine and arginine residues may adopt an uncharged state. Table 4 therefore sheds further light on the structure-function relationship of



the peptides of the invention by indicating that histidine and arginine can function in a quasi-hydrophobic capacity, at least with regard to the binding affinities of peptides for the RelB dimerization domain binding pocket. Accordingly, in some peptides of the invention, it can be energetically advantageous to place a histidine or arginine adjacent to a hydrophobic module that is made up of one or two hydrophobic amino acid residues.

**[00248]**      Example 3: RelB Amino Acid Residues Involved in Peptide Binding

**[00249]**      A model of the amino acid residues that line the binding pocket of the RelB dimerization domain is shown in Figure 11. The model shows that Glu-298, Asp-330, and His-332 are key hydrophilic amino acid residues that line the binding pocket, while Tyr-300, Leu-301, Leu-302, and Leu-371 are important hydrophobic residues. The same model, with the addition of a stick diagram of the RP-182 peptide (SEQ ID NO: 121) is shown in Figure 12. The dotted lines in Figure 12 show ionic bonds between (1) Lys-7 of RP-183 and Asp-330 of RelB, and (2) Lys-4 of RP-183 and Glu-298 of RelB. Further stabilizing the interaction is an intra-ionic bond formed between Arg-8 of RP-183 and the carboxy terminal Lys-10 of RP-183. In addition to the ionic binds, there are numerous Van der Waals interactions. For the sake of clarity, only that of Phe-9 of RP-182 with Leu-371 of Rel-B is shown. However, the other hydrophobic amino acid residues on the hydrophobic face of RP-183 interact with the hydrophobic “floor” of the cleft of dimerization site of Rel-B.

**[00250]**      An analysis of the ionic and Van der Waals interactions involved with the binding of different peptides of the invention has revealed that the peptides bind to a subset of the RelB amino acid residues selected from the group consisting of Leu-281, Ile-283, Cys-284, Glu-298, Tyr-300, Leu-301, Leu-302, Cys-303, Ile-311, Ser-312, Ala-329, Asp-330, Val-331, His-332, Gln-334, and Leu-371. See Table 13, below. Tyr-300, Leu-302, and His-332 are designated in the literature as being critical for dimerization. The amino acids most critical to binding by peptides of the invention include Glu-298, Tyr-300, Leu-302, Asp-330, Gln-334, and Leu-371.

**[00251]**      Example 4: Binding of Peptides to Protein Targets Other Than RelB

**[00252]**      A subset of the peptides shown in Tables 3-9 were further evaluated *in silico* to determine whether they bind to signaling proteins involved in the inflammatory response other than RelB. In doing so, it was discovered the dimerization cleft of the RelB subunit of NF-κB has structural parallels in a number of other signaling molecules. Consistent with these structural parallels, the peptides of the invention are predicted (by the ClusPro™ algorithm) to bind with

high affinity to important signaling molecules in the inflammatory cascade, including: TGF $\beta$  (NCBI Acc. No. NP\_000651.3; SEQ ID NO: 368); Notch1 (GenBank Acc. No. AAG33848.1; SEQ ID NO: 369); Wnt8R (NCBI Acc. No. XP\_005214377.1; SEQ ID NO: 370); TRAIL (GenBank Acc. No. EAW78466.1; SEQ ID NO: 371); IL6R (NCBI Acc. No. NP\_786943.1; SEQ ID NO: 372); IL10R (NCBI Acc. No. NP\_001549.2; SEQ ID NO: 373); EGFR (GenBank Acc. No. AAR85273.1; SEQ ID NO: 374); and CDK6 (NCBI Acc. No. NP\_001250.1; SEQ ID NO: 375). Representative peptides of the invention and the predicted binding energies between the peptides and each of these signaling molecules is shown in Tables 12A and 12B, below.

**Table 12A: Predicted Binding of Select Peptides to Different Inflammatory Targets**

RP#	Sequence	SEQ ID NO:	RelB	TGF $\beta$	NOTCH1	WNT8R	TRAIL
185	FFKKFFKKFK	123	-920.6	-880.1	-817.7	-747.2	-904.5
186	KFKKFFKKFF	124	-919.6	-846.0	-887.7	-739.1	-884.3
183	FFRKFAKRFK	122	-933.2	-878.9	-890.8	-763.1	-938.8
182	KFRKAFKRFF	121	-944.8	-851.8	-1,096.3	-733.7	-938.8
118	FFFRFFFNFN	44	-1,139.9	-1,074.7	-1,032.4	-990.9	-995.4
394	NFNFFFRFFF	33	-1,286.6	-1,002.6	-1,059.6	-971.2	-943.8
389	FRFKFA	257	-1,009.8	-878.4	-846.4	-804.5	-916.8
390	FRFKFKF	256	-1,083.3	-933.2	-1,005.3	-871.0	-1,014.4
391	FRFKFKFR	254	-1,190.8	-987.5	-1,005.4	-897.9	-1,049.2
392	RFQFKFRF	255	-1,170.3	-943.2	-923.1	-853.8	-1,039.6
387	AAKKAACKAK	173	-301.6	-397.7	-385.5	-394.9	-397.7

\*All binding affinities are in kcal/mol.

**Table 12A: Predicted Binding of Select Peptides to Different Inflammatory Targets**

RP#	Sequence	SEQ ID NO:	RelB	EGFR	IL6R	IL10R	CDK6
185	FFKKFFKKFK	123	-920.6	-785.4	-747.5	-756.3	-753.9
186	KFKKFFKKFF	124	-919.6	-866.3	-755.0	-742.0	-718.1
183	FFRKFAKRFK	122	-933.2	-795.6	-696.7	-738.6	-783.0
182	KFRKAFKRFF	121	-944.8	-853.8	-784.5	-785.9	-781.5
118	FFFRFFFNFN	44	-1,139.9	-1,039.4	-1,074.8	-881.4	-1,020.8
394	NFNFFFRFFF	33	-1,286.6	-1,061.4	-1,069.9	-850.8	-1,075.3
389	FRFKFA	257	-1,009.8	-896.0	-812.3	-779.2	-900.5

RP#	Sequence	SEQ ID NO:	RelB	EGFR	IL6R	IL10R	CDK6
390	FRFKFKF	256	-1,083.3	-1,036.3	-952.2	-876.2	-861.1
391	FRFKFKFR	254	-1,190.8	-1,024.9	-957.6	-882.3	-899.9
392	RFQFKFRF	255	-1,170.3	-1,010.4	-1,052.3	-901.7	-870.0
387	AAKKAACKAK	173	-301.6	-395.9	-342.0	-338.1	-351.4

**[00253]** The data reveals that the strength of binding to RelB is highly correlated with the strength of binding to the various inflammatory targets. In other words, peptides that are predicted to bind with high affinity to RelB are likewise predicted to bind with high affinity to TGF $\beta$ , Notch1, Wnt8R, TRAIL, EGFR, IL6R, and IL10R.

**[00254]** A closer evaluation of the predicted binding interactions between the peptides of the invention and each of TGF $\beta$ , Notch1, Wnt8R, TRAIL, EGFR, IL6R, and IL10R reveals that the peptides not only bind with high affinity, but also bind to functionally critical sites on the targets. For example, peptides of the invention are predicted to bind to the receptor-binding site on TGF $\beta$ , the calcium-binding site on Notch1, the Wnt8-binding site on Wnt8R, the receptor-binding site on TRAIL, the IL6-binding site on IL6R, the IL10-binding site on IL10R, and the general ligand-binding site on EGFR. A non-exhaustive list of amino acid residues in each of these targets that are bound by the peptides of the invention is shown in Table 13.

**Table 13: Amino Acid Residues in Target Proteins Contacted by Peptides of the Invention**

Target	SEQ ID NO:	AA Residue Contacts	Most Critical AAs
RelB	367	Leu-281, Ile-283, Cys-284, Glu-298, Tyr-300, Leu-301, Leu-302, Cys-303, Ile-311, Ser-312, Ala-329, Asp-330, Val-331, His-332, Gln-334, Leu-371	Glu-298, Tyr-300, Leu-302, Asp-330, Gln-334, Leu-371
TGF $\beta$	368	Leu-20, Ile-22, Phe-24, Asp-27, Leu-28, Trp-30, Trp-32, Tyr-39, Phe-43, Pro-80, Leu-83, Leu-101, Ser-112	Asp-27, Leu-28, Trp-30, Trp-32
Notch1	369	Phe-1520, Gln-1523, Arg-1524, Glu-1526, Ala-1553, Glu-1556, Trp-1557, Cys-1562, His-1602, Arg-1684, Gln-1685, Cys-1686, Ser-1691, Cys-1693, Phe-1694, Phe-1703	Phe-1520, Trp-1557, Cys-1562, Phe-1703
Wnt8R	370	Tyr-52, Gln-56, Phe-57, Asn-58, Met-91, Tyr-100, Lys-101, Pro-103, Pro-105, Pro-106, Arg-137, Asp-145	Tyr-52, Phe-57, Tyr-100, Asp-145
TRAIL	371	Ala-123, His-161, Ser-162, Phe-163, Tyr-183, Tyr-185, Tyr-243, His-270, Glu-271, Phe-274,	Phe-163, Tyr-243, Glu-271, Phe-278

Target	SEQ ID NO:	AA Residue Contacts	Most Critical AAs
		Phe-278, Leu-279, Val-280	
IL6R	372	Leu-108, Glu-140, Pro-162, Phe-229, Tyr-230, Phe-279	Glu-140, Phe-229, Tyr-230, Phe-279
IL10R	373	Leu-41, Arg-42, Tyr-43, Ile-45, Glu-46, Ser-47, Trp-48, Arg-76, Arg-78	Tyr-43, Ile-45, Glu-46, Trp-48
EGFR	374	Leu-10, Thr-40, Trp-41, Asp-48, Phe-51, Leu-63, His-66, Asp-68, Leu-88, Tyr-101	Trp-41, Asp-48, Phe-51, Asp-68, Tyr-101,
CDK6	375	Val-142, Arg-144, Asp-145, Ser-171, Val-180, Val-181, Leu-183, Arg-186, Val-190, Gln-193, Tyr-196, Val-200	Asp-145, Val-180, Tyr-196
HMT	376	Tyr-16, Glu-48, Tyr-50, Leu-51, Phe-52, Asn-69	Tyr-16, Glu-48, Tyr-50, Leu-51, Phe-52, Asn-69
CD47	377	Tyr-37, Thr-49, Phe-50, Asp-51, Ala-53, Glu-97, Val-98, Glu-100, Leu-101, Thr-102, Glu-104, Glu-106, Gly-107	Tyr-37, Glu-97, Glu-100, Leu-101, Glu-104, Glu-106
SIRP- $\alpha$	378	Tyr-50, Gln-52, Pro-58, Ser-66, Thr-67, Ser-77	Tyr-50, Gln-52, Ser-66, Thr-67
CD206	379	Phe-708, Thr-709, Trp-710, Pro-714, Glu-719, Asn-720, Trp-721, Ala-722, Glu-725, Tyr-729, Glu-733, Asn-747, Asp-748, Ser-1691, Cys-1693, Phe-1694, Phe-1703	Phe-708, Trp-710, Trp-721, Glu-725, Tyr-729, Glu-733
TGM2	380	Cys-277, His-335, Asp-358	Cys-277, His-335, Asp-358

**[00255]** Given the large number of immunologically important signaling proteins that are targeted by the peptides of the invention, the data suggests that the peptides act in a pleiotropic manner, making many different interactions that sum together to create a broad anti-inflammatory response. This may make possible a reduction in disease conditions without the toxicity observed in the use of more highly-targeted chemotherapeutic agents.

**[00256]** Example 5: Binding of Peptides to Histone Modifying Enzymes and Ribonuclease Reductase

**[00257]** A number of the peptides of the invention were observed to share structural characteristics of the N-terminal regions of histones. Accordingly, representative peptides were evaluated *in silico* for their ability to bind to histone modification enzymes. In this manner, it was discovered that the peptides of the invention have high binding affinity for histone methyl transferase (HMT)(NCBI Acc. No. NP\_048968.1; SEQ ID NO: 376), binding close to the active site of the enzyme. Predicted binding energies of select peptides of the invention for HMT,

calculated using the ClusPro™ algorithm, are shown in Table 14. Again, the predicted binding energies correlate well with the predicted energies for binding RelB.

**Table 14: Binding Affinities of Select Peptides to HMT, MKK7, and RNR**

RP#	Sequence	SEQ ID NO:	RelB	HMT
185	FFKKFFKKFK	123	-920.6	-846.4
186	KFKKFFKKFF	124	-919.6	-795.7
183	FFRKFAKRFK	122	-933.2	-839.4
182	KFRKAFKRFF	121	-944.8	-826.6
118	FFFRFFFNFN	44	-1,139.9	-1,000.2
394	NFNFFFRRFF	33	-1,286.6	-998.4
389	FRFKFA	257	-1,009.8	-836.8
390	FRFKFKF	256	-1,083.3	-906.6
391	FRFKFKFR	254	-1,190.8	-949.2
392	RFQFKFRF	255	-1,170.3	-962.2
387	AAKKAACKAK	173	-301.6	-334.5

\*All binding affinities are in kcal/mol.

**[00258]** A model of Histone Methyl Transferase (HMT) bound by RP-182 is shown in Figure 13. The orange amino acids are the active site of the histone methyl transferase enzyme. Inhibition of methyl transferase activity by RP-182 is expected since RP-182 binds to at least one residue of the active site, in a manner that appears to obstruct access to the active site. A non-exhaustive list of amino acid residues in HMT that are bound by the peptides of the invention is shown in Table 13, above.

**[00259]** Peptides of the invention are also observed to display strong predicted affinities to MAP kinase kinase 7 (MKK7; SEQ ID NO: 417), a member of the mitogen-activated protein kinase kinase family involved in signal transduction mediating cell responses to proinflammatory cytokines, and therefore likely involved in peptides' anti-inflammatory activity. The predicted affinity of e.g. RP-182 for MKK7 is -738.2 kcals/mol.

**[00260]** In addition, peptides of the invention were observed to display substantial predicted affinities to ribonuclease reductase (RNR; SEQ ID NO: 418) also known as ribonucleoside diphosphate reductase. This is an enzyme that catalyzes the formation of deoxyribonucleotides from ribonucleotides. Deoxyribonucleotides in turn are used in the synthesis of DNA. The reaction catalyzed by RNR is strictly conserved in all living organisms. Furthermore, RNR plays a critical role in regulating the total rate of DNA synthesis, so that DNA

to cell mass is maintained at a constant ratio during cell division and DNA repair. A somewhat unusual feature of the RNR enzyme is that it catalyzes a reaction that proceeds via a free radical mechanism of action. The substrates for RNR are ADP, GDP, CDP and UDP. dTDP (deoxythymidine diphosphate) is synthesized by another enzyme (thymidylate kinase) from dTMP (deoxythymidine monophosphate). The predicted affinity of e.g. RP-182 for RNR is - 814.0 kcal/mol.

**[00261]**      Example 6: Binding of Peptides to Targets Associated with Macrophage Activation

**[00262]**              Peptides of the invention are also predicted to interact with several proteins relevant to macrophage activity and apoptosis, properties associated with inflammation and with tumor genesis and metastasis. Targets identified to date include CD47, SIRP- $\alpha$ , CD206, TGM2, LEGUMAIN, DC-SIGN, CSF1, CSF1R, and IL34.

**[00263]**              CD47 (or “Cluster of Differentiation 47”), also known as integrin associated protein (IAP), is a transmembrane protein that belongs to the immunoglobulin superfamily. CD47 protein partners with membrane-bound cellular adhesion receptors known as integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRP- $\alpha$ ). CD47 is involved in a range of cellular processes, including apoptosis, proliferation, adhesion, and migration. Furthermore, it plays a key role in immune and angiogenic responses. CD47 is expressed in many types of human cells and has been found to be overexpressed in many different types of tumors. The overexpression of CD47 has received considerable attention as a possible protective agent for human cancers. By binding to SIRP- $\alpha$  on the surface of macrophages, CD47 is believed to send a “don’t eat me” signal that disables the macrophages from attacking the cancer cell.

**[00264]**              CD206 and TGM2 have likewise been identified as potentially important regulators of macrophage activity. CD206 is a C-type lectin, primarily present on the surface of macrophages and dendritic cells. It is the first member of a family of endocytic receptors that includes Endo180 (CD280), M-type PLA2R, and DEC-205 (CD205). The receptor recognizes terminal mannose, *N*-acetylglucosamine, and fucose residues that make up glycans, which are attached to proteins found on the surface of some microorganisms. Accordingly, the CD206 receptor appears to play a role in both the innate and adaptive immune systems. In addition, tumor-associated macrophages may use CD206 to ingest collagen, yielding degradation products

capable of nourishing both themselves and tumor cells, and weakening collagen binding of tumor cells so as to encourage metastasis.

**[00265]** TGM2 belongs to a family of enzymes that catalyze the calcium-dependent translational modification of proteins. The family members are found both intracellularly and extracellularly. TGM2 is unique in the family because of its multi-functionality and specialized structure, which includes four distinct domains: an N-terminal  $\beta$ -sandwich that contains fibronectin and integrin binding sites; a catalytic core that contains the catalytic triad for acyl-transfer reactions (Cys-277, His-335, and Asp-358); and two C-terminal  $\beta$ -barrel domains, with the second having a phospholipase-binding sequence. TGM2 has been implicated as a regulator of extracellular matrix functions, including cell adhesion and migration, cellular growth and differentiation, apoptosis, tumor growth, and wound healing. Although TGM2 is ubiquitously expressed, it is most highly expressed in M2 macrophages. Furthermore, increased TGM2 levels are associated with scleroderma, lung and kidney fibrosis, worsening symptoms for diabetes, arthritis, and EAE, and poor outcomes in a number of different cancers, all of which can be linked to M2 macrophages.

**[00266]** Predicted binding energies of select peptides of the invention for CD47 (NCBI Acc. No. XP\_005247966.1; SEQ ID NO: 377), SIRP- $\alpha$  (GenBank Acc. No. AAH26692.1; SEQ ID NO: 378), CD206 (NCBI Acc. No. NP\_002429.1; SEQ ID NO: 379), and TGM2 (GenBank Acc. No. AAB95430.1; SEQ ID NO: 380) calculated using the ClusPro™ algorithm, are shown in Table 15. As with the other targets discussed above, the predicted binding energies correlate well with the predicted energies for binding RelB.

**[00267]** LEGUMAIN is a protein that in humans is encoded by the *LGMN* gene. This gene encodes a cysteine protease, legumain that has a strict specificity for hydrolysis of asparaginyl bonds. This enzyme may be involved in the processing of bacterial peptides and endogenous proteins for MHC class II presentation in the lysosomal/endosomal systems. Enzyme activation is triggered by acidic pH and appears to be autocatalytic. Protein expression occurs after monocytes differentiate into dendritic cells. A fully mature, active enzyme is produced following lipopolysaccharide expression in mature dendritic cells. Overexpression of this gene may be associated with the majority of solid tumor types. LEGUMAIN is also overexpressed in M2 macrophages, and inhibition of its activity by the disclosed peptides is expected to downregulate M2-activated macrophages.

**[00268]** DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin) also known as CD209 (Cluster of Differentiation 209) is a protein that in humans is encoded by the *CD209* gene. DC-SIGN is a C-type lectin receptor present on the surface of both macrophages and dendritic cells. DC-SIGN on macrophages recognizes and binds to mannose type carbohydrates, a class of pathogen associated molecular patterns PAMPs commonly found on viruses, bacteria and fungi. This binding interaction activates phagocytosis. On myeloid and pre-plasmacytoid dendritic cells DC-SIGN mediates dendritic cell rolling interactions with blood endothelium and activation of CD4<sup>+</sup> T cells, as well as recognition of pathogen haptens. DC-SIGN is significantly overexpressed in M2 macrophages, and inhibition of its activity by the disclosed peptides is expected to downregulate M2-activated macrophages.

**Table 15: Binding Affinities of Select Peptides to CD47, SIRP- $\alpha$ , CD206, and TGM2**

RP#	Sequence	SEQ ID NO:	RelB	SIRP- $\alpha$	CD47	CD206	TGM2
185	FFKKFFKKFK	123	-920.6	-799.2	-639.3	-807.1	-827.2
186	KFKKFFKKFF	124	-919.6	-711.8	-637.4	-881.3	-885.3
183	FFRKFAKRFK	122	-933.2	-834.2	-658.1	-786.7	-860.7
182	KFRKAFKRFF	121	-944.8	-733.1	-723.1	-844.5	-869.1
118	FFFFRFFNFN	44	-1,139.9	-805.2	-751.5	-1,048.7	n/a
394	NFNFFFRFFF	33	-1,286.6	-854.2	-751.5	-986.6	n/a
389	FRFKFA	257	-1,009.8	-934.6	-688.3	-861.9	n/a
390	FRFKFKF	256	-1,083.3	-887.2	-783.5	-978.1	n/a
391	FRFKFKFR	254	-1,190.8	-932.1	-790.1	-941.3	n/a
392	RFQFKRF	255	-1,170.3	-982.5	-792.1	-981.6	n/a
387	AAKKAACKAK	173	-301.6	-392.3	-308.7	-416.6	n/a

\*All binding affinities are in kcal/mol.

**[00269]** Figure 14 (left panel) shows a model of the ecto-domain of a CD47 dimer (top view) (SEQ ID NO: 377), with magenta- and cyan-colored surfaces representing the polar and non-polar amino acids, respectively, that are involved in the binding of CD47 to the SIRP- $\alpha$  receptor. Figure 14 (right panel) is a model of the ecto-domain of the CD47 dimer when bound by RP-183 (SEQ ID NO: 121). Based on this predicted interaction between RP-183 and CD47, peptides of the invention are expected to block the interaction between CD47 and SIRP- $\alpha$ .



**[00270]** Figure 15 shows a model of a SIRP- $\alpha$  dimer (SEQ ID NO: 378), with magenta- and cyan-colored surfaces representing the polar and non-polar amino acids involved in its binding to CD47 (see left-most dimer). In a slightly-skewed view of the same SIRP- $\alpha$  dimer bound by RP-183 (SEQ ID NO: 122) (see right-most dimer), it can be seen that RP-183 binds tightly to the amino acids involved in binding to the CD47 receptor. It therefore appears that RP-183 (and other peptides of the invention) block the interaction between CD47 and SIRP- $\alpha$  by two distinct mechanisms, binding to the corresponding binding sites in both CD47 and SIRP- $\alpha$ . Thus, predicted activities associated with the peptides of the invention include thwarting of an important defense mechanism for cancer cells.

**[00271]** Peptides of the invention are also predicted to block key sites on the CD206 receptor subunit. Figure 16 shows a model of CD206 (SEQ ID NO: 379) bound by RP-182 (SEQ ID NO: 121). The cyan-colored tyrosine residue on the bend region of CD206 (left-most molecule) forms a planar, hydrophobic stacking interactions with the mannose ligands on the surface of target cells. The magenta colored amino acids are acidic residues that help chelate the required calcium ion necessary for stable interactions with the mannose receptor. The RP-182 peptide (seen in mesh on the right-most molecule) blocks activity by interacting with both of these key sites on the receptor subunit. Peptides of the invention are therefore expected to reduce the viability of M2 macrophages, which has been experimentally confirmed (as set forth below).

**[00272]** Furthermore, peptides of the invention are predicted to block the active site of TGM2. Figure 17 (left panel) shows a model of TGM2 (SEQ ID NO: 380) with the active site residues highlighted in blue. Figure 17 (right panel) shows the same model of TGM2 bound by RP-182 (SEQ ID NO: 121), which is colored magenta. As can be seen, RP-182 is predicted to bind to TGM2 in a manner that completely covers the active site, thereby obstructing substrate access and inhibiting TGM2 function. Significantly, decreased levels of TGM2 is associated with reduced NF- $\kappa$ B activation, so the interaction of the polypeptides of the invention with TGM2 would appear to reinforce and/or augment their suppression of NF- $\kappa$ B activity.

**[00273]** Non-exhaustive lists of specific amino acid residues in CD47, SIRP- $\alpha$ , CD206, and TGM2 that are bound by the peptides of the invention are shown in Table 13, above.

**[00274]** Example 7: Binding of Peptides to Checkpoint Inhibitors and Related Targets

[00275] It has also been observed that peptides of the present invention display substantial affinity to checkpoint inhibitor proteins and their ligands. Such proteins, including cytotoxic T-lymphocyte antigen 4 (CTLA-4), PD-1, and other inhibitory coreceptors, expressed on the surface of effector immune cells, when activated appear to exhaust the activity of the immune cells, serving as immune checkpoints in order to prevent uncontrolled immune reactions. Tumor cells often express ligands to the checkpoint inhibitors, e.g. PD-L1 and PD-L2, attenuating the capacity of the immune system to attack the tumor.

[00276] In particular, programmed cell death protein 1, also known as PD-1 and CD279 (cluster of differentiation 279), is a protein that in humans is encoded by the *PDCD1* gene. PD-1 is a cell surface receptor that belongs to the immunoglobulin superfamily and is expressed on T cells and pro-B cells. PD-1 binds two ligands, PD-L1 and PD-L2. PD-1, functioning as an immune checkpoint plays an important role in downregulating the immune system by preventing the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance. The inhibitory effect of PD-1 is accomplished through a dual mechanism of promoting apoptosis (programmed cell death) in antigen specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (suppressor T cells).

[00277] Programmed death-ligand 1 (PD-L1) also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1) is a protein that in humans is encoded by the *CD274* gene. Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis. Normally the immune system reacts to foreign antigens where there is some accumulation in the lymph nodes or spleen that triggers a proliferation of antigen-specific CD8+ T cell. The formation of PD-1 receptor / PD-L1 or B7.1 receptor /PD-L1 ligand complex transmits an inhibitory signal which reduces the proliferation of these CD8+ T cells at the lymph nodes and supplementary to that PD-1 is also able to control the accumulation of foreign antigen specific T cells in the lymph nodes through apoptosis which is further mediated by a lower regulation of the gene Bcl-2.

[00278] As illustrations of the binding of peptides of the present invention with checkpoint inhibitors and their ligands, the predicted affinity of RP-182 to PD-1 is -742.9, and that of RP-621 is -1,008.8. The affinity of RP-182 to PD-L1 is -677.4, and that of RP-621 to PD-L1 is -

1,010.6. As with inflammatory targets, there is a striking correlation among predicted affinities to several other checkpoint inhibitors and their ligands, as well as other proteins known to play a role in modulating the immune apparatus. These include: TIM-1 (believed to play a role in T-helper cell development: predicted affinity to RP-182, -850.1); CTLA-4 (checkpoint inhibitor: predicted affinity to RP-182, -663.2); ADORA2a (modulates activity of neutrophils and mast cells: predicted affinity to RP-182, -938.7); OX40 (secondary co-stimulatory immune checkpoint: predicted affinity to RP-182, -759.9); IDO (immune checkpoint: predicted affinity to RP-182, -934.0); LAG-3 (immune checkpoint receptor: predicted affinity to RP-182, -873.1); CD73 (enzyme limiting T cell activity through adenosine receptor signaling: predicted affinity of CD73-I to RP-182, -808.7; predicted affinity of CD73-II to RP-182, -949.1); Arginase-1 (blocks activity of cytotoxic T lymphocytes: predicted affinity to RP-182, -984.2); Colony Stimulating Factor 1 (blockade shown to upregulate checkpoint molecules, as well as reprogramming macrophage responses; predicted affinity of CSF1 to RP-182, -854.7; predicted affinity of CSF1D to RP-182, -847.1; predicted affinity of CSF1R to RP-182, -774.1); and IL34 (also activates CSF1R; predicted affinity to RP-182, -828.5).

**[00279]**      Example 8: Binding of Peptides to MKK7

**[00280]**      Dual specificity mitogen-activated protein kinase kinase 7, also known as MAP kinase kinase 7 or MKK7, is an enzyme that in humans is encoded by the *MAP2K7* gene. This protein is a member of the mitogen-activated protein kinase kinase family. The MKK7 protein exists as six different isoforms with three possible N-termini ( $\alpha$ ,  $\beta$ , and  $\gamma$  isoforms) and two possible C-termini (1 and 2 isoforms). MKK7 is involved in signal transduction mediating the cell responses to proinflammatory cytokines, and environmental stresses. This kinase specifically activates MAPK8/JNK1 and MAPK9/JNK2, and this kinase itself is phosphorylated and activated by MAP kinase kinase kinases including MAP3K1/MEKK1, MAP3K2/MEKK2, MAP3K3/MEKK5, and MAP4K2/GCK.

**[00281]**      Example 9: Binding of Peptides to Serum Albumin

**[00282]**      It is well-known that the most abundant protein in the circulation is serum albumin. It is also known that solid tumors will take up serum albumin into their cells (through the process of pinocytosis) and use it as an energy source. Therefore, peptides of the invention were evaluated *in silico* for their ability to bind to human serum albumin (HSA)(NCBI Acc. No. NP\_000468.1; SEQ ID NO: 381). It was discovered that peptides of the invention have the

capacity to bind to HSA with high affinity. Predicted binding energies of select peptides of the invention for binding to HSA are shown in Table 16, below.

**Table 16: Binding Affinities of Select Peptides to Human Serum Albumin (HSA)**

RP#	Sequence	SEQ ID NO:	RelB	HSA
185	FFKKFFKKFK	123	-920.6	-880.2
186	KFKKFFKKFF	124	-919.6	-850.5
183	FFRKFAKRFK	122	-933.2	-860.1
182	KFRKAFKRFF	121	-944.8	-789.0
118	FFFRFFFNFN	44	-1,139.9	-1,064.7
394	NFNFFFRRFF	33	-1,286.6	-1,016.5
389	FRFKFA	257	-1,009.8	-904.8
390	FRFKFKF	256	-1,083.3	-1,046.0
391	FRFKFKFR	254	-1,190.8	-1,021.9
392	RFQFKFRF	255	-1,170.3	-1,037.4
387	AAKKAACKAK	173	-301.6	-410.7

\*All binding affinities are in kcal/mol.

**[00283]** Figure 18 is a model of HSA (shown in green) bound by RP-183 (blue). The computational modeling has identified a number of possible peptide binding sites on HSA. Therefore, it is believed that a single HSA molecule is able to bind to multiple peptides of the invention. The binding interaction between peptides of the invention and HSA suggest that HSA could be used as an in vivo carrier of the peptides. In this manner, HSA could protect the peptides from degradation in the blood and carry the peptides to sites of action, such as sites of inflammation and/or cancer cells, thereby increasing the efficacy of the peptides.

**[00284]** Example 10: In vitro Modulation of NF- $\kappa$ B Activity

**[00285]** NF- $\kappa$ B activity was monitored using the a 3T3-L1 preadipocyte cell line stably transformed with a *Nfkb*-RE/GFP construct, as described in Shen et al. (2013), “Adipocyte reporter assays: Application for identification of anti-inflammatory and antioxidant properties of mangosteen xanthones,” Mol. Nutr. Food Res. 00:1-9, the entire contents of which are incorporated herein by reference. NF- $\kappa$ B expressing adipocyte reporter cells were plated in DMEM in wells of a 24-well plate, at a seeding density of  $5 \times 10^4$ . On the second and third days post-plating, test peptides were individually added to the wells to a final concentration of .01  $\mu$ M. The test peptides included RP-398 (SEQ ID NO: 155), and RP-185 (SEQ ID NO: 123). On day 4 post-plating, lipopolysaccharide was added to the medium to a final concentration of 20

ng/ml. Finally, on day 5 post-plating, the cells were harvested and a fluorescence assay performed to detect GFP expression levels.

[00286] In this experiment, NF- $\kappa$ B expression was reduced approximately 58% relative to control cells that were not exposed to RP-398 or RP-185 peptide.

[00287] Example 11: *In vivo* Modulation of Macrophage Activity

[00288] A frequently observed phenotype associated with tumor genesis and metastasis is the polarization of macrophage cells into the “M2” transition state, in which they are in an inflammatory state. Such macrophages are among those designated as “tumor-associated macrophages” (TAMs). To determine whether the peptides of the invention could influence macrophage polarization, the following experiment was performed.

[00289] Primary bone marrow cells were collected from male C57BL/6J (The Jackson Laboratory, Bar Harbor, ME). Mouse bone marrow macrophages were differentiated *in vitro* from the primary bone marrow cells by culturing in Dulbecco’s minimal essential medium (DMEM) with 10% FBS and 30 ng/ml murine M-CSF (colony stimulating factor) for 6 days. At day 7, macrophages were plated into 12-well plates and cultured in DMEM (10% FBS) with (i) IL-4 peptide (20 ng/mL), (ii) INF- $\gamma$  (10 ng/mL), or (iii) neither IL-4 nor INF- $\gamma$  for 24 hours. After 24 hours, the media was replaced with pure DMEM and the cells were cultured for an additional 48 hours. The resulting macrophages were (i) M2-polarized, (ii) M1-polarized, or (iii) undifferentiated, respectively.

[00290] A macrophage sample containing approximately 70,000 undifferentiated macrophages per ml was incubated for 72 hours with 100 nM RP-182 (SEQ ID NO: 121). Following the incubation, a count of viable cells revealed that there were 68,000 cells per ml. Similarly, incubating M1-polarized macrophages for 72 hours with 100 nM RP-182 resulted in a viable cell count of 68,000 cells per ml. Thus, the RP-182 had little effect on the viability of M1 macrophages. In contrast, incubating M2-polarized macrophages for 72 hours with 100 nM RP-182 resulted in a viable cell count of only 20,000 cells per ml. The results indicate that RP-182 reduces the viability of M2 macrophages.

[00291] Example 12: Downregulation of Checkpoint Inhibitors and Ligands

[00292] Based on their predicted affinity to checkpoint inhibitors (e.g. PD-1) and their ligands (e.g. PD-L1 and PD-L2), the polypeptides of the invention were also evaluated to determine whether the concentration of these proteins in treated tissue would be downregulated

*in vivo*. In one experiment, tumors in transgenic p53/KRAS mice were allowed to grow to approximately 100m<sup>3</sup> in volume, and the animals were then treated daily subcu for one week with either vehicle only, or 10 mg/kg RP-182, following which the animals were sacrificed and the tumors resected, formalin-fixed, and stained with antibodies to PD-1 (Figure 19), PD-L1 and PD-L2 (Figure 20). It is clear from the figures that both the checkpoint inhibitor PD-1 and each of its ligands PD-L1 and PD-L2 are significantly downregulated *in vivo* in tissue treated with peptides of the present disclosure.

**[00293]**      Example 13: Suppression of Tumor Growth

**[00294]**      The polypeptides of the invention were also tested for their effect on tumor growth in a mouse model of non-metastatic breast cancer. MCF-7 human non-metastatic breast cancer cells were cultured at 37°C, 5% CO<sub>2</sub> in normal growth media. Cells were harvested at 80% to 90% confluence. Immune compromised athymic nude mice (J:NU) were divided into 2 groups (9 animals per group). All mice were injected with ~ 4.5 x 10<sup>6</sup> MCF-7 cells which had been stained with VIVO Tracker 680 and suspended in 200 µl of PBS/Matrigel mixture. Cells were injected subcutaneously on the dorsal surface of treated animals using a 22 gauge needle fitted with a 500 µl syringe.

**[00295]**      Animals were designated vehicle and peptide treated. The peptide treated animals were treated with the RP-397 polypeptide (SEQ ID NO: 194). Freshly prepared RP-397 peptide was dissolved in sterile saline at a concentration of 100 µM and was used to treat the animals in the peptide group. Vehicle treated animals were injected with saline buffer alone. All treatments were injected into the tumor mass two times weekly for 5 weeks using a 27 ½ gauge needle fitted with a 1 ml syringe. Animal weights and tumor volumes were measured 3 times weekly and the fluorescence labeling was followed by VIVO Tracker 680 and IVIS Imaging. The results are shown in Table 17, below.

**Table 17: Suppression of Tumor Growth Using RP-397**

	<b>Avg. Tumor Weight</b>	<b>Rate of Tumor Growth</b>	<b>Body Weight Before</b>	<b>Body Weight After</b>
Vehicle	1.5 g	63	25.2	30.2
RP-397	0.75 g*	20*	25.1	30.1

The rate of tumor growth was measured in mm<sup>3</sup>/day. The “\*” denotes a statistically significant difference from the vehicle control.

[00296] The data shows that polypeptides of the invention can suppress tumor growth *in vivo*.

[00297] Example 14: Administering Peptides in Combination with Chemotherapy

[00298] Given the significant role of inflammation in tumor genesis and metastasis, as well as the known association of M2 macrophage activity with tumor development, it was anticipated that the administration of peptides of the invention could positively influence the outcomes of cancer treatment.

[00299] To test this theory, cohorts of immunocompromised (“nude”) mice were injected with  $\sim 5 \times 10^6$  human triple-negative breast cancer cells (MDA-MB-231) under the upper left teat. Following this administration, one cohort received only vehicle; two of the cohorts received the chemotherapeutic agent Gemcitabine, at a q4d dose of 40 mg/kg of body weight. One of these cohorts also received RP-182 (SEQ ID NO: 121) at a daily dose of 5 mg/kg body weight; and a fourth cohort received only RP-182 at a daily dose of 5 mg/kg body weight. Beginning on day 32 of the study, in the Gemcitabine + RP-182 cohort, concentrations of RP-182 were increased to 20 mg/kg body weight. Tumor volume was assessed at various time points following initial cell administration (Figure 21). After 50 days, the mice were sacrificed.

[00300] The data demonstrates that, as compared to treatment with Gemcitabine alone, combined treatment with Gemcitabine and polypeptides of the invention resulted in reductions in mean tumor volume. When RP-182 concentration was increased to 20 mg/kg body weight, the increase in tumor volume was essentially halted..

[00301] In a second experiment, xenografts of C42B prostate cancer cells were introduced into four cohorts of mice, and the tumors allowed to grow to approximately  $100\text{mm}^3$  before treatment. One cohort was treated only with vehicle; a second with Docetaxel at 2.5 mg/kg body weight administered weekly; a third with RP-182 administered daily subcu at 10 mg/kg body weight; and a fourth with both Docetaxel at 2.5 mg/kg weekly and RP-182 at 10 mg/kg daily. Tumor volume was assessed at various time points following initial cell administration (Figure 22); after 27 days, the mice were sacrificed. Similarly, the administration of RP-182 plus Docetaxel resulted in decreases in mean tumor volume compared to Docetaxel alone.

[00302] It is anticipated that the peptides of the invention will produce synergistic effects when administered with chemotherapeutic agents other than Gemcitabine and Docetaxel, as well as checkpoint inhibitor therapies and other immunotherapies. In particular, the peptides of the

invention may be particularly useful when used in conjunction with recently-developed CAR-T (chimeric antigen receptor / T cell) therapies. Such therapies, while destroying tumor cells, create a very high systemic burden of dead cell material, overstimulating the immune system and creating a “cytokine storm” which can be fatal to the patient.

## EMBODIMENTS

**[00303]** The following embodiments are provided to illustrate aspects of the present invention.

**[00304]** 1. An anti-inflammatory composition comprising a peptide, wherein the peptide is 3 to 24 amino acid residues in length and comprises a striapathic region consisting of alternating  $X_m$  and  $Y_n$  modules, wherein  $m$  and  $n$  are positive integers that identify different modules, wherein each  $X_m$  module consists of a sequence according to the formula  $X_{ma}-X_{mb}-X_{mc}-X_{md}-X_{me}$ , wherein  $X_{ma}$  is selected from the group consisting of a naturally occurring hydrophilic amino acid, a non-naturally occurring hydrophilic amino acid, and a hydrophilic amino acid mimetic, and wherein  $X_{mb}$ ,  $X_{mc}$ ,  $X_{md}$  and  $X_{me}$  are each individually absent or selected from the group consisting of a naturally occurring hydrophilic amino acid, a non-naturally occurring hydrophilic amino acid, and a hydrophilic amino acid mimetic, wherein each  $Y_n$  module consists of a sequence according to the formula  $Y_{na}-Y_{nb}-Y_{nc}-Y_{nd}-Y_{ne}$ , wherein  $Y_{na}$  is selected from the group consisting of a naturally occurring hydrophobic amino acid, a non-naturally occurring hydrophobic amino acid, and a hydrophobic amino acid mimetic, and wherein  $Y_{nb}$ ,  $Y_{nc}$ ,  $Y_{nd}$ , and  $Y_{ne}$  are each individually absent or selected from the group consisting of a naturally occurring hydrophobic, a non-naturally occurring hydrophobic amino acid, and a hydrophobic amino acid mimetic, and wherein the peptide binds to the dimerization site on a NFkB Class II protein.

**[00305]** 2. The anti-inflammatory composition of embodiment 1, wherein each  $X_m$  module consists of a sequence according to the formula  $X_{ma}-X_{mb}-X_{mc}-X_{md}$ , and each  $Y_n$  module consists of a sequence according to the formula  $Y_{na}-Y_{nb}-Y_{nc}-Y_{nd}$ .

**[00306]** 3. The anti-inflammatory composition of embodiment 1, wherein each  $X_m$  module consists of a sequence according to the formula  $X_{ma}-X_{mb}-X_{mc}$ , and each  $Y_n$  module consists of a sequence according to the formula  $Y_{na}-Y_{nb}-Y_{nc}$ .

**[00307]** 4. The anti-inflammatory composition of any one of embodiments 1 to 3, wherein the peptide also binds to human serum albumin.



- [00308] 5. The anti-inflammatory composition of any one of embodiments 1 to 4, wherein the striapathic region of the peptide contains at least two  $X_m$  modules ( $X_1$ ,  $X_2$ , and  $X_3$ ) and at least two  $Y_n$  modules ( $Y_1$ ,  $Y_2$ , and  $Y_3$ ).
- [00309] 6. The anti-inflammatory composition of any one of embodiments 1 to 5, wherein the striapathic region of the peptide contains at least seven amino acid residues.
- [00310] 7. The anti-inflammatory composition of any one of embodiments 1 to 6, wherein the striapathic region of the peptide has a length of 7 to 12 amino acid residues.
- [00311] 8. The anti-inflammatory composition of any one of embodiments 1 to 7, wherein the striapathic region of the peptide constitutes at least 25% of the length of the peptide.
- [00312] 9. The anti-inflammatory composition of any one of embodiments 1 to 8, wherein the striapathic region of the peptide has an amphipathic conformation under physiological conditions.
- [00313] 10. The anti-inflammatory composition of embodiment 9, wherein the striapathic region of the peptide has an amphipathic  $3_{10}$ -helical conformation, an amphipathic  $\alpha$ -helical conformation, or an amphipathic  $\pi$ -helical conformation when bound to the NFkB Class II protein.
- [00314] 11. The anti-inflammatory composition of embodiment 10, wherein the amphipathic  $3_{10}$ -helical,  $\alpha$ -helical, or  $\pi$ -helical conformation includes a hydrophobic portion having a facial arc of at least  $100^\circ$ .
- [00315] 12. The anti-inflammatory composition of any one of embodiments 1 to 11, wherein the striapathic region contains hydrophobic amino acid residues having a total volume of at least 650 cubic angstroms.
- [00316] 13. The anti-inflammatory composition of any one of embodiments 1 to 12, wherein the striapathic region is characterized by a ratio of the sum of the volume of hydrophobic amino acid residues to the sum of the volume of hydrophilic amino acid residues, wherein the ratio is at least 0.75 or higher.
- [00317] 14. The anti-inflammatory composition of embodiment 9, wherein the striapathic region of the peptide comprises at least one proline residue and adopts an amphipathic conformation that includes a proline-rich helix.
- [00318] 15. The anti-inflammatory composition of embodiment 9, wherein the striapathic region of the peptide adopts an amphipathic beta-strand conformation.

**[00319]** 16. The anti-inflammatory composition of any one of embodiments 1 to 13, wherein the striapathic region includes a sequence selected from the group of sequences defined by Formula I:  $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}$  (Formula I).

**[00320]** 17. The anti-inflammatory composition of embodiment 16, wherein the module  $Y_{1a}-Y_{1b}-Y_{1c}$  has a sequence selected from the group consisting of Phe-Phe-Phe (FFF), Trp-Trp-Trp (WWW), Tyr-Tyr-Tyr (YYY), Leu-Leu-Leu (LLL), Cys-Cys-Cys (CCC), Met-Met-Met (MMM), Val-Val-Val (VVV), and Ile-Ile-Ile (III).

**[00321]** 18. The anti-inflammatory composition of embodiment 16, wherein the module  $Y_{1a}-Y_{1b}-Y_{1c}$  has a sequence selected from the group consisting of Phe-Phe-Phe (FFF), Trp-Trp-Trp (WWW), and Tyr-Tyr-Tyr (YYY).

**[00322]** 19. The anti-inflammatory composition of any one of embodiments 16 to 18, wherein the module  $Y_{2a}-Y_{2b}-Y_{2c}$  has a sequence selected from the group consisting of Phe-Phe-Phe (FFF), Trp-Trp-Trp (WWW), Tyr-Tyr-Tyr (YYY), Leu-Leu-Leu (LLL), Cys-Cys-Cys (CCC), Met-Met-Met (MMM), Val-Val-Val (VVV), and Ile-Ile-Ile (III).

**[00323]** 20. The anti-inflammatory composition of any one of embodiments 16 to 18, wherein the module  $Y_{2a}-Y_{2b}-Y_{2c}$  has a sequence selected from the group consisting of Phe-Phe-Phe (FFF), Trp-Trp-Trp (WWW), and Tyr-Tyr-Tyr (YYY).

**[00324]** 21. The anti-inflammatory composition of embodiment 16, wherein the striapathic region includes a sequence selected from the group consisting of FFF- $X_{1a}$ -FFF (SEQ ID NO: 1), WWW- $X_{1a}$ -WWW (SEQ ID NO: 2), and YYY- $X_{1a}$ -YYY (SEQ ID NO: 3).

**[00325]** 22. The anti-inflammatory composition of embodiment 16, wherein the sequence of the three modules is selected from the group consisting of LLL- $X_{1a}$ -LLL (SEQ ID NO: 4), CCC- $X_{1a}$ -CCC (SEQ ID NO: 5), MMM- $X_{1a}$ -MMM (SEQ ID NO: 6), VVV- $X_{1a}$ -VVV (SEQ ID NO: 7), and III- $X_{1a}$ -III (SEQ ID NO: 8).

**[00326]** 23. The anti-inflammatory composition of any one of embodiments 16 to 22, wherein  $X_{1a}$  is selected from the group consisting of Arg (R), His (H), and Lys (K).

**[00327]** 24. The anti-inflammatory composition of any one of embodiments 16 to 22, wherein  $X_{1a}$  is selected from the group consisting of Glu (E), Gln (Q), Asn (N), and Asp (D).

**[00328]** 25. The anti-inflammatory composition of any one of embodiments 16 to 24, wherein the striapathic region includes a sequence selected from the group of sequences defined

by Formula II or the group of sequences defined by Formula III:  $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}-X_{2a}-Y_{3a}-X_{3a}$  (Formula II);  $X_{2a}-Y_{3a}-X_{3a}-Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}$  (Formula III).

**[00329]** 26. The anti-inflammatory composition of embodiment 25, wherein  $X_{2a}$  and  $X_{3a}$  are each individually selected from the group consisting of Arg (R), His (H), Lys (K), Glu (E), Gln (Q), Asn (N), and Asp (D).

**[00330]** 27. The anti-inflammatory composition of embodiment 25, wherein  $X_{2a}$  and  $X_{3a}$  are each individually selected from the group consisting of Glu (E), Gln (Q), Asn (N), and Asp (D).

**[00331]** 28. The anti-inflammatory composition of any one of embodiments 25 to 27, wherein  $Y_{3a}$  is selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), and Ile (I).

**[00332]** 29. The anti-inflammatory composition of any one of embodiments 25 to 27, wherein  $Y_{3a}$  is selected from the group consisting of Phe (F), Trp (W), Tyr (Y), and Leu (L).

**[00333]** 30. The anti-inflammatory composition of embodiment 25, wherein the sequence of  $X_{2a}-Y_{3a}-X_{3a}$  is selected from the group consisting of EFQ, EFE, EFN, EFD, NFQ, NFE, NFN, NFD, QFQ, QFE, QFN, QFD, DFQ, DFE, DFN, DFD, EWQ, EWE, EWN, EWD, NWQ, NWE, NWN, NWD, QWQ, QWE, QWN, QWD, DWQ, DWE, DWN, DWD, EYQ, EYE, EFN, EYD, NYQ, NYE, NYN, NYD, QYQ, QYE, QYN, QYD, DYQ, DYE, DYN, DYD, ELQ, ELE, ELN, ELD, NLQ, NLE, NLN, NLD, QLQ, QLE, QLN, QLD, DLQ, DLE, DLN, DLD, RFR, RFQ, RFE, RFN, RFD, RWR, RWQ, RWE, RWN, and RWD.

**[00334]** 31. The anti-inflammatory composition of embodiment 25, wherein the striapathic region comprises, consists essentially of, or consists of a sequence selected from the group consisting of RP394, RP108-RP123, RP125-131, RP133, RP135-RP141, RP143-RP146, RP148-RP150, RP152-RP165, RP179, RP395, RP211, RP230, RP232, RP258, RP267, RP268, RP271, and RP273 ( SEQ ID NOs: 33-95, respectively).

**[00335]** 32. The anti-inflammatory composition of embodiment 25, wherein the striapathic region comprises, consists essentially of, or consists of a sequence selected from the group consisting of RP113 (SEQ ID NO: 39), RP118 (SEQ ID NO: 44), and RP394 (SEQ ID NO: 33).

**[00336]** 33. The anti-inflammatory composition of any one of embodiments 1 to 13, wherein the striapathic region includes a sequence selected from the group of sequences defined by Formula VII:  $Y_{1a}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}$  (Formula VII).

- [00337] 34. The anti-inflammatory composition of embodiment 33, wherein  $Y_{2a}$  is selected from the group consisting of Phe (F), Trp (W), and Tyr (Y).
- [00338] 35. The anti-inflammatory composition of embodiment 33, wherein  $Y_{2a}$  is selected from the group consisting of Leu (L), Cys (C), Met (M), Val (V), Ile (I), and Ala (A).
- [00339] 36. The anti-inflammatory composition of any one of embodiments 33 to 35, wherein  $Y_{2b}$  is selected from the group consisting of Phe (F), Trp (W), and Tyr (Y).
- [00340] 37. The anti-inflammatory composition of any one of embodiments 33 to 35, wherein  $Y_{2b}$  is selected from the group consisting of Leu (L), Cys (C), Met (M), Val (V), Ile (I), and Ala (A).
- [00341] 38. The anti-inflammatory composition of any one of embodiments 33 to 37, wherein  $X_{1b}$  is selected from the group consisting of Arg (R), Lys (K), and His (H).
- [00342] 39. The anti-inflammatory composition of any one of embodiments 33 to 37, wherein  $X_{1b}$  is selected from the group consisting of Asn (N), Gln (Q), Asp (D), and Glu (E).
- [00343] 40. The anti-inflammatory composition of any one of embodiments 33 to 39, wherein  $X_{2a}$  is selected from the group consisting of Arg (R), Lys (K), and His (H).
- [00344] 41. The anti-inflammatory composition of any one of embodiments 33 to 39, wherein  $X_{2a}$  is selected from the group consisting of Asn (N), Gln (Q), Asp (D), and Glu (E).
- [00345] 42. The anti-inflammatory composition of embodiment 33, wherein the sequence  $X_{1b}-Y_{2a}-Y_{2b}-X_{2a}$  is selected from the group consisting of Lys-Phe-Phe-Lys (KFFK), Lys-Trp-Trp-Lys (KWWK), Lys-Tyr-Tyr-Lys (KYYK), Lys-Phe-Trp-Lys (KFWK), Lys-Trp-Phe-Lys (KWFK), Lys-Phe-Tyr-Lys (KFYK), Lys-Tyr-Phe-Lys (KYFK), Lys-Trp-Tyr-Lys (KWYK), and Lys-Tyr-Trp-Lys (KYWK).
- [00346] 43. The anti-inflammatory composition of embodiment 33, wherein the sequence  $X_{1b}-Y_{2a}-Y_{2b}-X_{2a}$  is selected from the group consisting of Arg-Phe-Phe-Arg (RFFR), Arg-Trp-Trp-Arg (RWWR), Arg-Tyr-Tyr-Arg (RYYR), Arg-Phe-Trp-Arg (RFWR), Arg-Trp-Phe-Arg (RWFR), Arg-Phe-Tyr-Arg (RFYR), Arg-Tyr-Phe-Arg (RYFR), Arg-Trp-Tyr-Arg (RWYR), and Arg-Tyr-Trp-Arg (RYWR).
- [00347] 44. The anti-inflammatory composition of embodiment 33, wherein the sequence  $X_{1b}-Y_{2a}-Y_{2b}-X_{2a}$  is selected from the group consisting of His-Phe-Phe-His (HFFH), His-Trp-Trp-His (HWWH), His-Tyr-Tyr-His (HYYH), His-Phe-Trp-His (HFWH), His-Trp-Phe-His

(HWFH), His-Phe-Tyr-His (HFYH), His-Tyr-Phe-His (HYFH), His-Trp-Tyr-His (HWYH), and His-Tyr-Trp-His (HYWH).

**[00348]** 45. The anti-inflammatory composition of any one of embodiments 33 to 44, wherein  $X_{1a}$  is selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E).

**[00349]** 46. The anti-inflammatory composition of any one of embodiments 33 to 44, wherein  $X_{1a}$  is selected from the group consisting of Arg (R) and Gln (Q).

**[00350]** 47. The anti-inflammatory composition of any one of embodiments 33 to 46, wherein  $X_{2b}$  is selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E).

**[00351]** 48. The anti-inflammatory composition of any one of embodiments 33 to 46, wherein  $X_{2b}$  is selected from the group consisting of Arg (R) and Gln (Q).

**[00352]** 49. The anti-inflammatory composition of any one of embodiments 33 to 48, wherein  $Y_{1a}$  is selected from the group consisting of Phe (F), Trp (W), and Tyr (Y).

**[00353]** 50. The anti-inflammatory composition of any one of embodiments 33 to 48, wherein  $Y_{1a}$  is selected from the group consisting of Leu (L), Cys (C), Met (M), Val (V), Ile (I), and Ala (A).

**[00354]** 51. The anti-inflammatory composition of any one of embodiments 33 to 50, wherein  $Y_{3a}$  is selected from the group consisting of Phe (F), Trp (W), and Tyr (Y).

**[00355]** 52. The anti-inflammatory composition of any one of embodiments 33 to 50, wherein  $Y_{3a}$  is selected from the group consisting of Leu (L), Cys (C), Met (M), Val (V), Ile (I), and Ala (A).

**[00356]** 53. The anti-inflammatory composition of embodiment 33, wherein the striapathic region includes a sequence selected from the group consisting of F- $X_{1a}$ - $X_{1b}$ -FF- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 9), F- $X_{1a}$ - $X_{1b}$ -FF- $X_{2a}$ - $X_{2b}$ -W (SEQ ID NO: 10), W- $X_{1a}$ - $X_{1b}$ -FF- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 11), F- $X_{1a}$ - $X_{1b}$ -FW- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 12), F- $X_{1a}$ - $X_{1b}$ -WF- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 13), F- $X_{1a}$ - $X_{1b}$ -WW- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 14), W- $X_{1a}$ - $X_{1b}$ -WW- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 15), F- $X_{1a}$ - $X_{1b}$ -WW- $X_{2a}$ - $X_{2b}$ -W (SEQ ID NO: 16), W- $X_{1a}$ - $X_{1b}$ -WW- $X_{2a}$ - $X_{2b}$ -W (SEQ ID NO: 17), F- $X_{1a}$ - $X_{1b}$ -FF- $X_{2a}$ - $X_{2b}$ -Y (SEQ ID NO: 18), Y- $X_{1a}$ - $X_{1b}$ -FF- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 19), F- $X_{1a}$ - $X_{1b}$ -FY- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 20), F- $X_{1a}$ - $X_{1b}$ -YF- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 21), F- $X_{1a}$ - $X_{1b}$ -YY- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 22), Y- $X_{1a}$ - $X_{1b}$ -YY- $X_{2a}$ - $X_{2b}$ -F (SEQ ID NO: 23), F- $X_{1a}$ - $X_{1b}$ -YY- $X_{2a}$ - $X_{2b}$ -Y

(SEQ ID NO: 24), and Y-X<sub>1a</sub>-X<sub>1b</sub>-YY-X<sub>2a</sub>-X<sub>2b</sub>-Y (SEQ ID NO: 25), Y-X<sub>1a</sub>-X<sub>1b</sub>-YY-X<sub>2a</sub>-X<sub>2b</sub>-W (SEQ ID NO: 26), W-X<sub>1a</sub>-X<sub>1b</sub>-YY-X<sub>2a</sub>-X<sub>2b</sub>-Y (SEQ ID NO: 27), Y-X<sub>1a</sub>-X<sub>1b</sub>-YW-X<sub>2a</sub>-X<sub>2b</sub>-Y (SEQ ID NO: 28), Y-X<sub>1a</sub>-X<sub>1b</sub>-WY-X<sub>2a</sub>-X<sub>2b</sub>-Y (SEQ ID NO: 29), Y-X<sub>1a</sub>-X<sub>1b</sub>-WW-X<sub>2a</sub>-X<sub>2b</sub>-Y (SEQ ID NO: 30), W-X<sub>1a</sub>-X<sub>1b</sub>-WW-X<sub>2a</sub>-X<sub>2b</sub>-Y (SEQ ID NO: 31), and Y-X<sub>1a</sub>-X<sub>1b</sub>-WW-X<sub>2a</sub>-X<sub>2b</sub>-W (SEQ ID NO: 32).

**[00357]** 54. The anti-inflammatory composition of embodiment 53, wherein X<sub>1a</sub>, X<sub>1b</sub>, X<sub>2a</sub>, and X<sub>2b</sub> are each independently selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E).

**[00358]** 55. The anti-inflammatory composition of embodiment 53 or 54, wherein X<sub>1b</sub> and X<sub>2a</sub> are each independently selected from the group consisting of Arg (R), Lys (K), and His (H).

**[00359]** 56. The anti-inflammatory composition of any one of embodiments 33 to 55, wherein the striapathic region includes a first additional amino acid residue directly bound to Y<sub>1a</sub> of Formula VII, wherein the first additional amino acid residue is a hydrophobic amino acid residue.

**[00360]** 57. The anti-inflammatory composition of embodiment 56, wherein the first additional amino acid residue is selected from the group consisting of Phe (F), Trp (W), and Tyr (Y).

**[00361]** 58. The anti-inflammatory composition of any one of embodiments 33 to 55, wherein the striapathic region includes a first additional amino acid residue directly bound to Y<sub>3a</sub> of Formula VII, wherein the first additional amino acid residue is a hydrophobic amino acid residue.

**[00362]** 59. The anti-inflammatory composition of embodiment 58, wherein the first additional amino acid residue is selected from the group consisting of Phe (F), Trp (W), and Tyr (Y).

**[00363]** 60. The anti-inflammatory composition of any one of embodiments 33 to 55, wherein the striapathic region includes a first additional amino acid residue directly bound to Y<sub>1a</sub> of Formula VII, wherein the first additional amino acid residue is a hydrophilic amino acid residue.

**[00364]** 61. The anti-inflammatory composition of embodiment 60, wherein the first additional amino acid residue is selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E).

**[00365]** 62. The anti-inflammatory composition of any one of embodiments 33 to 55, wherein the striapathic region includes a first additional amino acid residue directly bound to  $Y_{3a}$  of Formula VII, wherein the first additional amino acid residue is a hydrophilic amino acid residue.

**[00366]** 63. The anti-inflammatory composition of embodiment 62, wherein the first additional amino acid residue is selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E).

**[00367]** 64. The anti-inflammatory composition of 56, 57, 60, or 61, wherein the striapathic region includes a second additional amino acid residue directly bound to  $Y_{3a}$  of Formula VII, wherein the second additional amino acid residue is a hydrophobic amino acid residue.

**[00368]** 65. The anti-inflammatory composition of embodiment 64, wherein the second additional amino acid residue is selected from the group consisting of Phe (F), Trp (W), and Tyr (Y).

**[00369]** 66. The anti-inflammatory composition of 58, 59, 62, or 63, wherein the striapathic region includes a second additional amino acid residue directly bound to  $Y_{1a}$  of Formula VII, wherein the second additional amino acid residue is a hydrophilic amino acid residue.

**[00370]** 67. The anti-inflammatory composition of embodiment 66, wherein the second additional amino acid residue is selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E).

**[00371]** 68. The anti-inflammatory composition of embodiment 33, wherein the striapathic region comprises, consists essentially of, or consists of a sequence selected from the group consisting of RP124, RP132, RP134, RP142, RP147, RP151, RP166-RP172, RP175, RP177, RP182, RP183, RP185, RP186, RP 424, RP190, RP194, RP198, RP199-RP202, RP204, RP206, RP207, RP209, RP210, RP212-RP216, RP218, RP219, RP425, RP225, RP227, RP233-RP239, RP398, RP241-RP247, RP250-RP256, and RP426 (SEQ ID NOs: 106-170, respectively).

**[00372]** 69. The anti-inflammatory composition of embodiment 33, wherein the striapathic region comprises, consists essentially of, or consists of a sequence selected from the group consisting of RP124 (SEQ ID NO: 106), RP166 (SEQ ID NO: 112), RP182 (SEQ ID NO: 121), and RP183 (SEQ ID NO: 122).

[00373] 70. The anti-inflammatory composition of any one of embodiments 1 to 15, wherein the striapathic region includes a sequence selected from the group of sequences defined by any one of Formulas I-XLVIII and L:  $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}$  (Formula I);  $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}-X_{2a}-Y_{3a}-X_{3a}$  (Formula II);  $X_{2a}-Y_{3a}-X_{3a}-Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}$  (Formula III);  $X_{1a}-X_{1b}-X_{1c}-Y_{2a}-X_{2a}-X_{2b}-X_{2c}$  (Formula IV);  $Y_{1a}-X_{1a}-X_{1b}-X_{1c}-Y_{2a}-X_{2a}-X_{2b}-X_{2c}-Y_{3a}-X_{3a}$  (Formula V);  $X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}$  (Formula VI);  $Y_{1a}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}$  (Formula VII);  $Y_{1a}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}-Y_{3b}-X_{3a}$  (Formula VIII);  $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}-Y_{3b}$  (Formula IX);  $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}-X_{3a}$  (Formula X);  $X_{1a}-Y_{1a}-X_{2a}-X_{2b}-Y_{2a}-Y_{2b}-X_{3a}-X_{3b}-Y_{3a}-Y_{3b}$  (Formula XI);  $X_{1a}-Y_{1a}-Y_{1b}-X_{2a}-X_{2b}-Y_{2a}-Y_{2b}-X_{3a}-X_{3b}-Y_{3a}$  (Formula XII);  $Y_{1a}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-X_{2c}-Y_{3a}-Y_{3b}$  (Formula XIII);  $X_{1a}-X_{1b}-X_{1c}-Y_{1a}-Y_{1b}-X_{2a}-X_{2b}-Y_{2a}-Y_{2b}-Y_{2c}$  (Formula XIV);  $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-X_{2c}$  (Formula XV);  $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-X_{1c}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}$  (Formula XVI);  $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}$  (Formula XVII);  $X_{1a}-Y_{1a}-Y_{1b}-X_{2a}-X_{2b}-Y_{2a}-Y_{2b}-X_{3a}$  (Formula XVIII);  $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-Y_{3a}-Y_{3b}-X_{3a}$  (Formula XIX);  $X_{1a}-Y_{1a}-Y_{1b}-X_{2a}-Y_{2a}-Y_{2b}-X_{3a}-X_{3b}-Y_{3a}-Y_{3b}$  (Formula XX);  $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-X_{2a}-X_{2b}-Y_{3a}-Y_{3b}$  (Formula XXI);  $X_{1a}-Y_{1a}-Y_{1b}-X_{2a}-X_{2b}-X_{2c}-Y_{2a}-X_{3a}-Y_{3a}-Y_{3b}$  (Formula XXII);  $Y_{1a}-Y_{1b}-X_{1a}-Y_{2a}-X_{2a}-X_{2b}-X_{2c}-Y_{3a}-Y_{3b}-X_{3a}$  (Formula XXIII);  $X_{1a}-X_{1b}-Y_{1a}-X_{2a}-Y_{2a}-X_{3a}-X_{3b}$  (Formula XXIV);  $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1b}-Y_{2a}-X_{2a}-Y_{3a}-X_{3a}-X_{3b}$  (Formula XXV);  $X_{1a}-X_{1b}-Y_{1a}-X_{2a}-Y_{2a}-X_{3a}-X_{3b}-Y_{3a}-Y_{3b}-Y_{3c}$  (Formula XXVI);  $X_{1a}-X_{1b}-X_{1c}-Y_{1a}-Y_{1b}-Y_{1c}$  (Formula XXVII);  $X_{1a}-X_{1b}-X_{1c}-X_{1d}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}$  (Formula XXVIII);  $Y_{1a}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-Y_{2a}-Y_{2b}-Y_{2c}-Y_{2d}-X_{2a}$  (Formula XXIX);  $X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}$  (Formula XXX);  $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-X_{1c}-Y_{2a}-Y_{2b}-Y_{2c}-X_{2a}-X_{2b}$  (Formula XXXI);  $X_{1a}-Y_{1a}-X_{2a}-Y_{2a}-X_{3a}-X_{3b}-X_{3c}-Y_{3a}-Y_{3b}-Y_{3c}$  (Formula XXXII);  $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1b}-X_{1c}$  (Formula XXXIII);  $Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-X_{1a}-X_{1b}-X_{1c}-X_{1d}$  (Formula XXXIV);  $X_{1a}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-X_{2a}-X_{2b}-X_{2c}-X_{2d}-Y_{2a}$  (Formula XXXV);  $Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}$  (Formula XXXVI);  $X_{1a}-X_{1b}-Y_{1a}-Y_{1b}-Y_{1c}-X_{2a}-X_{2b}-X_{2c}-Y_{2a}-Y_{2b}$  (Formula XXXVII);  $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1a}-X_{1c}-Y_{2a}-X_{2a}-Y_{3a}-X_{3a}$  (Formula XXXVIII);  $Y_{1a}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}$  (Formula XXXIX);  $Y_{1a}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}-Y_{2b}-Y_{2c}-Y_{2d}$  (Formula XL);  $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}-Y_{2b}-Y_{2c}$  (Formula XLI);  $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}-Y_{2b}$  (Formula XLII);  $Y_{1a}-Y_{1b}-Y_{1c}-Y_{1e}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}$  (Formula XLIII);  $X_{1a}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{2a}$  (Formula XLIV);  $X_{1a}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{2a}-X_{2b}-X_{2c}-X_{2d}$  (Formula XLV);  $X_{1a}-X_{1b}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{2a}-X_{2b}-X_{2c}$  (Formula XLVI);  $X_{1a}-X_{1b}-X_{1c}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{2a}$



X<sub>2b</sub> (Formula XLVII); X<sub>1a</sub>-X<sub>1b</sub>-X<sub>1c</sub>-X<sub>1d</sub>-Y<sub>1a</sub>-Y<sub>1b</sub>-Y<sub>1c</sub>-Y<sub>1d</sub>-Y<sub>1e</sub>-X<sub>2a</sub> (Formula XLVIII); and Y<sub>1a</sub>-Y<sub>1b</sub>-X<sub>1a</sub>-Y<sub>2a</sub>-Y<sub>2b</sub>-X<sub>2a</sub>-Y<sub>3a</sub>-Y<sub>3b</sub>-X<sub>3a</sub>-Y<sub>4a</sub> (Formula L).

**[00374]** 71. The anti-inflammatory composition of embodiment 70, wherein Y<sub>1a</sub>, Y<sub>1b</sub>, Y<sub>1c</sub>, Y<sub>2a</sub>, Y<sub>2b</sub>, Y<sub>2c</sub>, Y<sub>3a</sub>, Y<sub>3b</sub>, and Y<sub>3c</sub> are each individually selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), Ile (I), and Ala (A).

**[00375]** 72. The anti-inflammatory composition of embodiment 70, wherein Y<sub>1a</sub>, Y<sub>1b</sub>, Y<sub>1c</sub>, Y<sub>2a</sub>, Y<sub>2b</sub>, Y<sub>2c</sub>, Y<sub>3a</sub>, Y<sub>3b</sub>, and Y<sub>3c</sub> are each individually selected from the group consisting of Phe (F), Trp (W), and Tyr (Y).

**[00376]** 73. The anti-inflammatory composition of any one of embodiments 70 to 72, wherein X<sub>1a</sub>, X<sub>1b</sub>, X<sub>1c</sub>, X<sub>2a</sub>, X<sub>2b</sub>, X<sub>2c</sub>, X<sub>3a</sub>, and X<sub>3b</sub> are each individually selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E).

**[00377]** 74. The anti-inflammatory composition of any one of embodiments 70 to 73, wherein X<sub>1a</sub>, X<sub>1b</sub>, X<sub>1c</sub>, X<sub>2a</sub>, X<sub>2b</sub>, X<sub>2c</sub>, X<sub>3a</sub>, and X<sub>3b</sub> are each individually selected from the group consisting of Arg (R), Lys (K), His (H), and Gln (Q).

**[00378]** 75. The anti-inflammatory composition of any one of embodiments 70 to 74, wherein the striapathic region includes a first additional amino acid residue directly bound to the N-terminal end of any one of Formulas I-XLVIII and L, wherein the first additional amino acid residue is a hydrophobic amino acid residue.

**[00379]** 76. The anti-inflammatory composition of embodiment 70, wherein the first additional amino acid residue is selected from the group consisting of Phe (F), Trp (W), and Tyr (Y).

**[00380]** 77. The anti-inflammatory composition of any one of embodiments 70 to 74, wherein the striapathic region includes a first additional amino acid residue directly bound to the C-terminal end of any one of Formulas I-XLVIII and L, wherein the first additional amino acid residue is a hydrophobic amino acid residue.

**[00381]** 78. The anti-inflammatory composition of embodiment 77, wherein the first additional amino acid residue is selected from the group consisting of Phe (F), Trp (W), and Tyr (Y).

**[00382]** 79. The anti-inflammatory composition of any one of embodiments 70 to 74, wherein the striapathic region includes a first additional amino acid residue directly bound to the

N-terminal end of any one of Formulas I-XLVIII and L, wherein the first additional amino acid residue is a hydrophilic amino acid residue.

**[00383]** 80. The anti-inflammatory composition of embodiment 79, wherein the first additional amino acid residue is selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E).

**[00384]** 81. The anti-inflammatory composition of any one of embodiments 70 to 74, wherein the striapathic region includes a first additional amino acid residue directly bound to the C-terminal end of any one of Formulas I-XLVIII and L, wherein the first additional amino acid residue is a hydrophilic amino acid residue.

**[00385]** 82. The anti-inflammatory composition of embodiment 81, wherein the first additional amino acid residue is selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E).

**[00386]** 83. The anti-inflammatory composition of any one of embodiments 75, 76, 79, or 80, wherein the striapathic region includes a second additional amino acid residue directly bound to the C-terminal end of any one of Formulas I-XLVIII and L, wherein the second additional amino acid residue is a hydrophobic amino acid residue.

**[00387]** 84. The anti-inflammatory composition of embodiment 83, wherein the second additional amino acid residue is selected from the group consisting of Phe (F), Trp (W), and Tyr (Y).

**[00388]** 85. The anti-inflammatory composition of any one of embodiments 77, 78, 81, or 82, wherein the striapathic region includes a second additional amino acid residue directly bound to the N-terminal end of any one of Formulas I-XLVIII and L, wherein the second additional amino acid residue is a hydrophilic amino acid residue.

**[00389]** 86. The anti-inflammatory composition of embodiment 81, wherein the second additional amino acid residue is selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E).

**[00390]** 87. The anti-inflammatory composition of embodiment 70, wherein the striapathic region comprises, consists essentially of, or consists of a sequence selected from the group consisting of RP396, RP405, RP174, RP176, RP178, RP180-181, RP184, RP408, RP187, RP416, RP188, RP189, RP388, RP417, RP191-RP193, RP404, RP196, RP397, RP197, RP402, RP203, RP409, RP205, RP208, RP217, RP220-RP224, RP226, RP229, RP231, RP240, RP248,

RP249, RP415, RP257, RP259-RP266, RP269, RP272, RP406, RP422, RP407, RP400, RP419, RP401, RP423, RP411, RP418, RP428, RP420, RP421, RP429, RP413, RP430, RP270 (SEQ ID NOs: 174-224 and 234-249, respectively).

[00391] 88. The anti-inflammatory composition of any one of embodiments 1 to 9 or 15, wherein the striapathic region includes a sequence selected from the group of sequences defined by Formula XLIX:

[00392]  $Y_{1a}-X_{1a}-Y_{2a}-X_{2a}-Y_{3a}-X_{3a}$  (Formula XLIX).

[00393] 89. The anti-inflammatory composition of embodiment 88, wherein  $Y_{1a}$ ,  $Y_{2a}$ , and  $Y_{3a}$  are each independently selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Ile (I), Cys (C), and Met (M).

[00394] 90. The anti-inflammatory composition of embodiment 88, wherein  $Y_{1a}$ ,  $Y_{2a}$ , and  $Y_{3a}$  are each independently selected from the group consisting of Phe (F), Trp (W), and Tyr (Y).

[00395] 91. The anti-inflammatory composition of any one of embodiments 88 to 90, wherein  $X_{1a}$ ,  $X_{2a}$ , and  $X_{3a}$  are each independently selected from the group consisting of Arg (R), Lys (K), His (H), Gln (Q), Glu (E), Asn (N), and Asp (D).

[00396] 92. The anti-inflammatory composition of any one of embodiments 88 to 90, wherein  $X_{1a}$ ,  $X_{2a}$ , and  $X_{3a}$  are each independently selected from the group consisting of Arg (R), Lys (K), and His (H).

[00397] 93. The anti-inflammatory composition of any one of embodiments 88 to 92, wherein the striapathic region includes a first additional amino acid residue directly bound to  $Y_{1a}$  of Formula XLIX, wherein the first additional amino acid residue is a hydrophilic amino acid residue.

[00398] 94. The anti-inflammatory composition of embodiment 93, wherein the first additional amino acid residue is selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E).

[00399] 95. The anti-inflammatory composition of embodiment 93, wherein the first additional amino acid residue is selected from the group consisting of Arg (R), Lys (K), and His (H).

[00400] 96. The anti-inflammatory composition of any one of embodiments 88 to 92, wherein the striapathic region includes a first additional amino acid residue directly bound to  $X_{3a}$

of Formula XLIX, wherein the first additional amino acid residue is a hydrophobic amino acid residue.

**[00401]** 97. The anti-inflammatory composition of embodiment 96, wherein the first additional amino acid residue is selected from the group consisting of Phe (F), Trp (W), (Tyr), Leu (L), Ile (I), Cys (C), and Met (M).

**[00402]** 98. The anti-inflammatory composition of embodiment 96, wherein the first additional amino acid residue is selected from the group consisting of Phe (F), Trp (W), and (Tyr).

**[00403]** 99. The anti-inflammatory composition of any one of embodiments 93 to 95, wherein the striapathic region includes a second additional amino acid residue directly bound to X<sub>3a</sub> of Formula XLIX, wherein the second additional amino acid residue is a hydrophobic amino acid residue.

**[00404]** 100. The anti-inflammatory composition of embodiment 99, wherein the second additional amino acid residue is selected from the group consisting of Phe (F), Trp (W), (Tyr), Leu (L), Ile (I), Cys (C), and Met (M).

**[00405]** 101. The anti-inflammatory composition of embodiment 99, wherein the second additional amino acid residue is selected from the group consisting of Phe (F), Trp (W), and Tyr (Y).

**[00406]** 102. An anti-inflammatory composition comprising a peptide, wherein the peptide is 3 to 24 amino acids residues in length and comprises a striapathic region having at least 70% identity with the sequence NFNFFFRFFF (RP394, SEQ ID NO: 33), wherein the peptide binds to the dimerization site on a NFkB Class II protein.

**[00407]** 103. The anti-inflammatory composition of embodiment 102, wherein the peptide also binds to human serum albumin.

**[00408]** 104. The anti-inflammatory composition of embodiment 102 or 103, wherein the differences between the striapathic region of the peptide and the sequence NFNFFFRFFF (SEQ ID NO: 33) are limited to conservative or highly conservative amino acid substitutions.

**[00409]** 105. The anti-inflammatory composition of embodiment 102 or 103, wherein the striapathic region of the peptide differs from the sequence NFNFFFRFFF (SEQ ID NO: 33) by substitution of one or more of the phenylalanine (F) residues with an amino acid residue selected from the group consisting of Trp (W), Tyr (Y), His (H), and Leu (L).

**[00410]** 106. The anti-inflammatory composition of embodiment 102 or 103, wherein the striapathic region of the peptide differs from the sequence NFNFFFRFFF (SEQ ID NO: 33) by the deletion of one, two, or three amino acids.

**[00411]** 107. The anti-inflammatory composition of embodiment 106, wherein the deleted amino acids are located at the N-terminal end, the C-terminal end, or both ends of the sequence NFNFFFRFFF (SEQ ID NO: 33).

**[00412]** 108. An anti-inflammatory composition comprising a peptide, wherein the peptide is 3 to 24 amino acids residues in length and comprises a striapathic region having at least 70% identity with the sequence FFFRFFFNFN (RP118, SEQ ID NO: 44), wherein the peptide binds to the dimerization site on a NFkB Class II protein.

**[00413]** 109. The anti-inflammatory composition of embodiment 108, wherein the peptide also binds to human serum albumin.

**[00414]** 110. The anti-inflammatory composition of embodiment 108 or 109, wherein the differences between the striapathic region of the peptide and the sequence FFFRFFFNFN (SEQ ID NO: 44) are limited to conservative or highly conservative amino acid substitutions.

**[00415]** 111. The anti-inflammatory composition of embodiment 108 or 109, wherein the striapathic region of the peptide differs from the sequence FFFRFFFNFN (SEQ ID NO: 44) by substitution of one or more of the phenylalanine (F) residues with an amino acid residue selected from the group consisting of Trp (W), Tyr (Y), His (H), and Leu (L) .

**[00416]** 112. The anti-inflammatory composition of embodiment 108 or 109, wherein the striapathic region of the peptide differs from the sequence FFFRFFFNFN (SEQ ID NO: 44) by the deletion of one, two, or three amino acids.

**[00417]** 113. The anti-inflammatory composition of embodiment 112, wherein the deleted amino acids are located at the N-terminal end, the C-terminal end, or both ends of the sequence FFFRFFFNFN (SEQ ID NO: 44).

**[00418]** 114. An anti-inflammatory composition comprising a peptide, wherein the peptide is 3 to 24 amino acids residues in length and comprises a striapathic region having at least 70% identity with the sequence FFRKFAKRFK (RP183, SEQ ID NO: 122), wherein the peptide binds to the dimerization site on a NFkB Class II protein.

**[00419]** 115. The anti-inflammatory composition of embodiment 114, wherein the peptide also binds to human serum albumin.

**[00420]** 116. The anti-inflammatory composition of embodiment 114 or 115, wherein the differences between the striapathic region of the peptide and the sequence FFRKFAKRFK (SEQ ID NO: 122) are limited to conservative or highly conservative amino acid substitutions.

**[00421]** 117. The anti-inflammatory composition of embodiment 114 or 115, wherein the striapathic region of the peptide differs from the sequence FFRKFAKRFK (SEQ ID NO: 122) by substitution of one or more of the phenylalanine (F) residues with an amino acid residue selected from the group consisting of Trp (W), Tyr (Y), and Leu (L).

**[00422]** 118. The anti-inflammatory composition of embodiment 114 or 115, wherein the striapathic region of the peptide differs from the sequence FFRKFAKRFK (SEQ ID NO: 122) by the deletion of one, two, or three amino acids.

**[00423]** 119. The anti-inflammatory composition of embodiment 118, wherein the deleted amino acids are located at the N-terminal end, the C-terminal end, or both ends of the sequence FFRKFAKRFK (SEQ ID NO: 122).

**[00424]** 120. An anti-inflammatory composition comprising a peptide, wherein the peptide is 3 to 24 amino acids residues in length and comprises a striapathic region having at least 70% identity with the sequence KFRKAFKRFF (RP182, SEQ ID NO: 121), wherein the peptide binds to the dimerization site on a NFkB Class II protein.

**[00425]** 121. The anti-inflammatory composition of embodiment 120, wherein the peptide also binds to human serum albumin.

**[00426]** 122. The anti-inflammatory composition of embodiment 120 or 121, wherein the differences between the striapathic region of the peptide and the sequence KFRKAFKRFF (SEQ ID NO: 121) are limited to conservative or highly conservative amino acid substitutions.

**[00427]** 123. The anti-inflammatory composition of embodiment 120 or 121, wherein the striapathic region of the peptide differs from the sequence KFRKAFKRFF (SEQ ID NO: 121) by substitution of one or more of the phenylalanine (F) residues with an amino acid residue selected from the group consisting of Trp (W), Tyr (Y), and Leu (L) .

**[00428]** 124. The anti-inflammatory composition of embodiment 120 or 121, wherein the striapathic region of the peptide differs from the sequence KFRKAFKRFF (SEQ ID NO: 121) by the deletion of one, two, or three amino acids.

**[00429]** 125. The anti-inflammatory composition of embodiment 124, wherein the deleted amino acids are located at the N-terminal end, the C-terminal end, or both ends of the sequence KFRKAFKRFF (SEQ ID NO: 121).

**[00430]** 126. The anti-inflammatory composition of any one of embodiments 1 to 125, wherein the peptide binds to the dimerization site on Rel B (SEQ ID NO: 367) with a binding energy of at least -650 kcal/mol.

**[00431]** 127. The anti-inflammatory composition of any one of embodiments 1 to 126, wherein the peptide binds to the dimerization site on Rel B (SEQ ID NO: 367) and directly contacts at least one amino acid residue of Rel B selected from the group consisting of Glu 298, Tyr-300, Leu-301, Leu-302, Asp-330, His-332, and Leu-371.

**[00432]** 128. The anti-inflammatory composition of embodiment 127, wherein the peptide, when bound to the dimerization site on Rel B, forms an ionic bond with Asp-330, forms an ionic bond with His-332, and/or makes a hydrophobic contact with Leu-371.

**[00433]** 129. The anti-inflammatory composition of any one of embodiments 1 to 128, wherein the peptide binds to at least one signaling molecule selected from the group consisting of TGF $\beta$  (SEQ ID NO: 368), Notch1 (SEQ ID NO: 369), Wnt8R (SEQ ID NO: 370), TRAIL (SEQ ID NO: 371), IL6R (SEQ ID NO: 372), IL10R (SEQ ID NO: 373), EGFR (SEQ ID NO: 374), CDK6 (SEQ ID NO: 375), Histone Methyl Transferase (HMT) (SEQ ID NO: 376), CD47 (SEQ ID NO: 377), SIRP- $\alpha$  (SEQ ID NO: 378), CD206 (SEQ ID NO: 379), TGM2 (SEQ ID NO: 380); LEGUMAIN (SEQ ID NO: 413), CD209 (SEQ ID NO: 414), FAS (SEQ ID NO: 415), PD-1 (SEQ ID NO: 416), MKK7 (SEQ ID NO: 417), and RNR (SEQ ID NO: 418).

**[00434]** 130. The anti-inflammatory composition of embodiment 129, wherein the peptide binds to TGF $\beta$  (SEQ ID NO: 368) with a binding energy of at least -650 kcal/mol.

**[00435]** 131. The anti-inflammatory composition of embodiment 129 or 130, wherein the peptide binds to TGF $\beta$  (SEQ ID NO: 368) and directly contacts at least one amino acid residue of TGF $\beta$  selected from the group consisting of Leu-20, Ile-22, Phe-24, Asp-27, Leu-28, Trp-30, Trp-32, Tyr-39, Phe-43, Pro-80, Leu-83, Leu-101, and Ser-112.

**[00436]** 132. The anti-inflammatory composition of any one of embodiments 129 to 131, wherein the peptide binds to Notch1 (SEQ ID NO: 369) with a binding energy of at least -650 kcal/mol.

**[00437]** 133. The anti-inflammatory composition of any one of embodiments 120 to 123, wherein the peptide binds to Notch (SEQ ID NO: 369) and directly contacts at least one amino acid residue of Notch selected from the group consisting of Phe-1520, Gln-1523, Arg-1524, Glu-1526, Ala-1553, Glu-1556, Trp-1557, Cys-1562, His-1602, Arg-1684, Gln-1685, Cys-1686, Ser-1691, Cys-1693, Phe-1694, and Phe-1703.

**[00438]** 134. The anti-inflammatory composition of any one of embodiments 129 to 133, wherein the peptide binds to Wnt8R (SEQ ID NO: 370) with a binding energy of at least -600 kcal/mol.

**[00439]** 135. The anti-inflammatory composition of any one of embodiments 129 to 134, wherein the peptide binds to Wnt8R (SEQ ID NO: 370) and directly contacts at least one amino acid residue of Wnt8R selected from the group consisting of Tyr-52, Gln-56, Phe-57, Asn-58, Met-91, Tyr-100, Lys-101, Pro-103, Pro-105, Pro-106, Arg-137, and Asp-145.

**[00440]** 136. The anti-inflammatory composition of any one of embodiments 129 to 135, wherein the peptide binds to TRAIL (SEQ ID NO: 371) with a binding energy of at least -650 kcal/mol.

**[00441]** 137. The anti-inflammatory composition of any one of embodiments 120 to 127, wherein the peptide binds to TRAIL (SEQ ID NO: 371) and directly contacts at least one amino acid residue of TRAIL selected from the group consisting of Arg-130, Arg-158, Ser-159, Gly-160, His-161, Phe-163, Tyr-189, Arg-189, Gln-193, Glu-195, Glu-236, Tyr-237, Leu-239, Asp-267, Asp-269, His-270, and Glu-271.

**[00442]** 138. The anti-inflammatory composition of any one of embodiments 129 to 137, wherein the peptide binds to IL6R (SEQ ID NO: 372) with a binding energy of at least -600 kcal/mol.

**[00443]** 139. The anti-inflammatory composition of any one of embodiments 129 to 138, wherein the peptide binds to IL6R (SEQ ID NO: 372) and directly contacts at least one amino acid residue of IL6R selected from the group consisting of Glu-163, Gly-164, Phe-168, Gln-190, Phe-229, Tyr-230, Phe-279, and Gln-281.

**[00444]** 140. The anti-inflammatory composition of any one of embodiments 129 to 139, wherein the peptide binds to IL10R (SEQ ID NO: 373) with a binding energy of at least -600 kcal/mol.



**[00445]** 141. The anti-inflammatory composition of any one of embodiments 129 to 140, wherein the peptide binds to IL10R (SEQ ID NO: 373) and directly contacts at least one amino acid residue of IL10R selected from the group consisting of Tyr-43, Ile-45, Glu-46, Asp-61, Asn-73, Arg-76, Asn-94, Arg-96, Phe-143, Ala-189, Ser-190, and Ser-191.

**[00446]** 142. The anti-inflammatory composition of any one of embodiments 129 to 141, wherein the peptide binds to EGFR (SEQ ID NO: 374) with a binding energy of at least -650 kcal/mol.

**[00447]** 143. The anti-inflammatory composition of any one of embodiments 129 to 142, wherein the peptide binds to EGFR (SEQ ID NO: 374) and directly contacts at least one amino acid residue of EGFR selected from the group consisting of Leu-10, Thr-40, Trp-41, Leu-63, His-66, Asp-68, Leu-88, Tyr-101, Asp-48, and Phe-51.

**[00448]** 144. The anti-inflammatory composition of any one of embodiments 129 to 143, wherein the peptide binds to CDK6 (SEQ ID NO: 375) with a binding energy of at least -600 kcal/mol.

**[00449]** 145. The anti-inflammatory composition of any one of embodiments 129 to 144, wherein the peptide binds to CDK6 (SEQ ID NO: 375) and directly contacts at least one amino acid residue of CDK6 selected from the group consisting of Val-142, Arg-144, Asp-145, Ser-171, Val-180, Val-181, Leu-183, Arg-186, Val-190, Gln-193, Tyr-196, and Val-200.

**[00450]** 146. The anti-inflammatory composition of any one of embodiments 129 to 145, wherein the peptide binds to histone methyl transferase (HMT) (SEQ ID NO: 376) with a binding energy of at least -600 kcal/mol.

**[00451]** 147. The anti-inflammatory composition of any one of embodiments 129 to 146, wherein the peptide binds to HMT (SEQ ID NO: 376) and directly contacts at least one amino acid residue of HMT selected from the group consisting of Asn-69, His-70, Ser-71, Lys-72, Asp-73, Pro-74, and Asn-75.

**[00452]** 148. The anti-inflammatory composition of any one of embodiments 129 to 147, wherein the peptide binds to the SIRP- $\alpha$  binding site on CD47 (SEQ ID NO: 377) with a binding energy of at least -550 kcal/mol.

**[00453]** 149. The anti-inflammatory composition of any one of embodiments 129 to 148, wherein the peptide binds to CD47 (SEQ ID NO: 377) and directly contacts at least one amino

acid residue of CD47 selected from the group consisting of Glu-29, Ala-30, Glu-35, Val-36, Tyr-37, Lys-39, Thr-49, Asp-51, Glu-97, Thr-99, Leu-101, Thr-102, Arp-103, Glu-104, and Glu-106.

**[00454]** 150. The anti-inflammatory composition of any one of embodiments 129 to 149, wherein the peptide binds to the CD47 binding site on SIRP- $\alpha$  (SEQ ID NO: 378) with a binding energy of at least -600 kcal/mol.

**[00455]** 151. The anti-inflammatory composition of any one of embodiments 129 to 150, wherein the peptide binds to SIRP- $\alpha$  (SEQ ID NO: 378) and directly contacts at least one amino acid residue of SIRP- $\alpha$  selected from the group consisting of Leu-30, Gln-37, Gln-52, Lys-53, Ser-66, Thr-67, Arg-69, Met-72, Phe-74, Lys-96, and Asp-100.

**[00456]** 152. The anti-inflammatory composition of any one of embodiments 129 to 151, wherein the peptide binds to CD206 (SEQ ID NO: 379) with a binding energy of at least -650 kcal/mol.

**[00457]** 153. The anti-inflammatory composition of any one of embodiments 129 to 152, wherein the peptide binds to CD206 (SEQ ID NO: 379) and directly contacts at least one amino acid residue of CD206 selected from the group consisting of Glu-725, Tyr-729, Glu-733, Asn-747, and Asp-748.

**[00458]** 154. The anti-inflammatory composition of any one of embodiments 129 to 153, wherein the peptide binds to TGM2 (SEQ ID NO: 380) with a binding energy of at least -650 kcal/mol.

**[00459]** 155. The anti-inflammatory composition of any one of embodiments 129 to 154, wherein the peptide binds to TGM2 (SEQ ID NO: 380) and directly contacts at least one amino acid residue of TGM2 selected from the group consisting of Cys-277, His-335, and Asp-358.

**[00460]** 156. The anti-inflammatory composition of any one of embodiments 129 to 155, wherein the peptide binds to LEGUMAIN (SEQ ID NO: 413) with a binding energy of at least -600 kcal/mol.

**[00461]** 157. The anti-inflammatory composition of any one of embodiments 129 to 156, wherein the peptide binds to LEGUMAIN (SEQ ID NO: 413) and directly contacts at least one amino acid residue of LEGUMAIN selected from the group consisting of Asn-44, Arg-46, His-159, Glu-189, Cys-191, Ser-217, Ser-218 and Asp-233.

**[00462]** 158. The anti-inflammatory composition of any one of embodiments 129 to 157, wherein the peptide binds to CD209 (SEQ ID NO: 414) with a binding energy of at least -600 kcal/mol.

**[00463]** 159. The anti-inflammatory composition of any one of embodiments 129 to 158, wherein the peptide binds to CD209 (SEQ ID NO: 414) and directly contacts at least one amino acid residue of CD209 selected from the group consisting of Phe-269, Glu-280, Glu-303, Asn-305, Asn-306, Glu-310, Asp-311, Ser-316, Gly-317, Asn-321 and Lys-324.

**[00464]** 160. The anti-inflammatory composition of any one of embodiments 129 to 159, wherein the peptide binds to FAS (SEQ ID NO: 415) with a binding energy of at least -600 kcal/mol.

**[00465]** 161. The anti-inflammatory composition of any one of embodiments 129 to 160, wherein the peptide binds to FAS (SEQ ID NO: 415) and directly contacts at least one amino acid residue of FAS selected from the group consisting of Lys-251, Lys-296, Lys-299, Leu-303, Leu-306, Ala-307, Glu-308, Lys-309, Gln-311, Ile-314, Leu-315, Asp-317, Ile-318 and Thr-319.

**[00466]** 162. The anti-inflammatory composition of any one of embodiments 129 to 161, wherein the peptide binds to PD-1 (SEQ ID NO: 416) with a binding energy of at least -600 kcal/mol.

**[00467]** 163. The anti-inflammatory composition of any one of embodiments 129 to 162, wherein the peptide binds to PD-1 (SEQ ID NO: 416) and directly contacts at least one amino acid residue of PD-1 selected from the group consisting of Val-64, Asn-66, Tyr-68, Met-70, Thr-76, Lys-78, Thr-120, Leu-122, Ala-125, and Ser-127.

**[00468]** 164. The anti-inflammatory composition of any one of embodiments 129 to 163, wherein the peptide binds to MKK7 (SEQ ID NO: 417) with a binding energy of at least -600 kcal/mol.

**[00469]** 165. The anti-inflammatory composition of any one of embodiments 129 to 164, wherein the peptide binds to MKK7 (SEQ ID NO: 417) and directly contacts at least one amino acid residue of MKK7 selected from the group consisting of Met-142, Val-150, Lys-152, Lys-165, Met-212, Met-215, Thr-217, Lys-221, Leu-266, Cys-276 and Asp-277.

**[00470]** 166. The anti-inflammatory composition of any one of embodiments 129 to 165, wherein the peptide binds to RNR (SEQ ID NO: 418) with a binding energy of at least -600 kcal/mol.

**[00471]** 167. The anti-inflammatory composition of any one of embodiments 129 to 166, wherein the peptide binds to RNR (SEQ ID NO: 418) and directly contacts at least one amino acid residue of RNR selected from the group consisting of Asn-426, Leu-427, Cys-428, Glu-430, Met-606, Pro-608 and Ala-610.

**[00472]** 168. The anti-inflammatory composition of any one of embodiments 1 to 167, wherein the peptide binds to human serum albumin (HSA) (SEQ ID NO: 381) with a binding energy of at least -650 kcal/mol.

**[00473]** 169. The anti-inflammatory composition of any one of embodiments 1 to 168, wherein the peptide comprises a striapathic region that is composed exclusively of D-form amino acid residues.

**[00474]** 170. The anti-inflammatory composition of any one of embodiments 1 to 169, wherein the peptide is in solution at a concentration of about 0.1 mg/ml to about 100 mg/ml.

**[00475]** 171. The anti-inflammatory composition of any one of embodiments 1 to 170, wherein the composition contains about 1 mg to about 500 mg of the peptide.

**[00476]** 172. The anti-inflammatory composition of embodiment 158 or 171, wherein the composition is substantially free of protein other than the peptide.

**[00477]** 173. An anti-inflammatory composition comprising a first peptide as defined in any one of embodiments 1 to 171 in combination with a second peptide as defined in any one of embodiments 1 to 171, wherein the first and second peptides can have the same sequence or different sequences.

**[00478]** 174. The anti-inflammatory composition of embodiment 173, wherein the first and second peptides are linked together by a peptide bond, a peptide linker, or a non-peptide linker.

**[00479]** 175. The anti-inflammatory composition of embodiment 173, wherein the first and second peptides are linked together by a peptide linker, wherein the peptide linker has a sequence selected from the group consisting of Gly-Gly-Gly (GGG), Gly-Gly-Gly-Arg (GGGR), Gly-Pro-Gly (GPG), and Gly-Pro-Gly-Arg (GPGR).

**[00480]** 176. The anti-inflammatory composition of embodiment 174 or 175, wherein the linked first and second peptides bind to the dimerization site on Rel B (SEQ ID NO: 367) with a binding energy of at least -700 kcal/mol.

- [00481] 177. The anti-inflammatory composition of any one of embodiments 1 to 171 and embodiments 173 to 176, further comprising serum albumin.
- [00482] 178. The anti-inflammatory composition of embodiment 177, wherein the composition is substantially free of blood proteins other than serum albumin.
- [00483] 179. A pharmaceutical composition comprising the anti-inflammatory composition of any one of embodiments 1 to 178, and a pharmaceutically acceptable carrier.
- [00484] 180. The pharmaceutical composition of embodiment 179, wherein the composition comprises a chemotherapeutic agent.
- [00485] 181. A method of treating a condition associated with chronic inflammation, the method comprising administering a composition according to any one of embodiments 1 to 180 to a subject suffering from the condition.
- [00486] 182. The method of embodiment 181, wherein the condition is selected from the group consisting of irritable bowel disease, ulcerative colitis, colitis, Crohn's disease, idiopathic pulmonary fibrosis, asthma, keratitis, arthritis, osteoarthritis, rheumatoid arthritis, auto-immune diseases, a feline or human immunodeficiency virus (FIV or HIV) infection, and cancer.
- [00487] 183. The method of embodiment 181 or 182, wherein the subject is a mammal.
- [00488] 184. The method of any one of embodiments 181 to 183, wherein the subject is a human.
- [00489] 185. The method of any one of embodiments 181 to 184, wherein the anti-inflammatory composition is administered in a dosage that includes between about 1 mg and about 500 mg of peptide.
- [00490] 186. The method of any one of embodiments 181 to 185, wherein the anti-inflammatory composition is administered intravenously, intraperitoneally, parenteral, orthotopically, subcutaneously, topically, nasally, by means of an implantable depot, using nanoparticle-based delivery systems, microneedle patch, microspheres, beads, osmotic or mechanical pumps, and/or other mechanical means.
- [00491] 187. The method of any one of embodiments 181 to 186, wherein the anti-inflammatory composition is administered in conjunction with another drug known to be effective in treating the condition.
- [00492] 188. The method of embodiment 187, wherein the anti-inflammatory composition is administered prior to, at the same time as, or after the administration of the other drug.

- [00493] 189. A method of treating fibrosis in a subject, the method comprising administering a composition according to any one of embodiments 1 to 180 to the subject.
- [00494] 190. The method of embodiment 189, wherein the fibrosis is selected from the group consisting of pulmonary fibrosis, dermal fibrosis, hepatic fibrosis, renal fibrosis, and fibrosis caused by ionizing radiation.
- [00495] 191. The method of embodiment 189 or 190, wherein the subject is a mammal.
- [00496] 192. The method of any one of embodiments 189 to 191, wherein the subject is a human.
- [00497] 193. The method of any one of embodiments 189 to 192, wherein the anti-inflammatory composition is administered in a dosage that includes between about 1 mg and about 500 mg of peptide.
- [00498] 194. The method of any one of embodiments 189 to 193, wherein the anti-inflammatory composition is administered intravenously, intraperitoneally, parenteral, orthotopically, subcutaneously, topically, nasally, by means of an implantable depot, using nanoparticle-based delivery systems, microneedle patch, microspheres, beads, osmotic or mechanical pumps, and/or other mechanical means.
- [00499] 195. The method of any one of embodiments 189 to 194, wherein the anti-inflammatory composition is administered in conjunction with another drug known to be effective in treating fibrosis.
- [00500] 196. The method of embodiment 195, wherein the anti-inflammatory composition is administered prior to, at the same time as, or after the administration of the other drug.
- [00501] 197. A method of reducing pro-inflammatory cytokine levels in a subject suffering from a chronic inflammatory condition, the method comprising administering a composition according to any one of embodiments 1 to 180 to the subject.
- [00502] 198. The method of embodiment 197, wherein the chronic inflammatory condition is selected from the group consisting of irritable bowel disease, ulcerative colitis, colitis, Crohn's disease, idiopathic pulmonary fibrosis, asthma, keratitis, arthritis, osteoarthritis, rheumatoid arthritis, auto-immune diseases, a feline or human immunodeficiency virus (FIV or HIV) infection, and cancer.

[00503] 199. The method of embodiment 197 or 198, wherein the method reduces the level of at least one cytokine selected from group consisting of NF-kB, TNF $\alpha$ , IL1, IL6, IL12, MMP-1, MMP-9, MCP-1, IL8, IL17, and IL23.

[00504] 200. The method of embodiment 199, wherein the level of the at least one cytokine is reduced by at least 10%.

[00505] 201. The method of any one of embodiments 197 to 200, wherein the subject is a mammal.

[00506] 202. The method of any one of embodiments 197 to 201, wherein the subject is a human.

[00507] 203. The method of any one of embodiments 197 to 202, wherein the anti-inflammatory composition is administered in a dosage that includes between about 1 mg and about 500 mg of peptide.

[00508] 204. The method of any one of embodiments 197 to 203, wherein the anti-inflammatory composition is administered intravenously, intraperitoneally, parenteral, orthotopically, subcutaneously, topically, nasally, by means of an implantable depot, using nanoparticle-based delivery systems, microneedle patch, microspheres, beads, osmotic or mechanical pumps, and/or other mechanical means.

[00509] 205. The method of any one of embodiments 197 to 204, wherein the anti-inflammatory composition is administered in conjunction with another drug known to be effective in treating the chronic inflammatory condition that the subject is suffering from.

[00510] 206. The method of embodiment 205, wherein the anti-inflammatory composition is administered prior to, at the same time as, or after the administration of the other drug.

[00511] 207. A method of treating cancer in a subject, the method comprising administering an anti-inflammatory composition according to any one of embodiments 1 to 180 to the subject.

[00512] 208. The method of embodiment 207, wherein the cancer is selected from the group consisting of colon cancer, and breast cancer.

[00513] 209. The method of embodiment 207 or 208, wherein the anti-inflammatory composition is administered in conjunction with a chemotherapeutic agent or cell therapy.

[00514] 210. The method of embodiment 209, wherein the chemotherapeutic agent or cell therapy is selected from the group consisting of steroids, anthracyclines, thyroid hormone

replacement drugs, thymidylate-targeted drugs, checkpoint inhibitor drugs, Chimeric Antigen Receptor/T cell therapies, and other cell therapies.

**[00515]** 211. The method of embodiment 209, wherein the chemotherapeutic agent is selected from the group consisting of Gemcitabine, Docetaxel, Bleomycin, Erlotinib, Gefitinib, Lapatinib, Imatinib, Dasatinib, Nilotinib, Bosutinib, Crizotinib, Ceritinib, Trametinib, Bevacizumab, Sunitinib, Sorafenib, Trastuzumab, Ado-trastuzumab emtansine, Rituximab, Ipilimumab, Rapamycin, Temsirolimus, Everolimus, Methotrexate, Doxorubicin, Abraxane, Folfirinox, Cisplatin, Carboplatin, 5-fluorouracil, Teysumo, Paclitaxel, Prednisone, Levothyroxine, and Pemetrexed.

**[00516]** 212. The method of any one of embodiments 209 to 211, wherein the anti-inflammatory composition is administered prior to, at the same time as, or after the administration of the chemotherapeutic agent or cell therapy.

**[00517]** 213. The method of embodiment 207 or 208, wherein the anti-inflammatory composition is administered in conjunction with radiation therapy.

**[00518]** 214. The method of embodiment 213, wherein the anti-inflammatory composition is administered prior to, or after the administration of the radiation therapy.

**[00519]** 215. The method of any one of embodiments 207 to 214, wherein the subject is a mammal.

**[00520]** 216. The method of any one of embodiments 207 to 215, wherein the subject is a human.

**[00521]** 217. The method of any one of embodiments 207 to 216, wherein the anti-inflammatory composition is administered in a dosage that includes between about 1 mg and about 500 mg of peptide.

**[00522]** 218. The method of any one of embodiments 207 to 217, wherein the anti-inflammatory composition is administered intravenously, intraperitoneally, parenteral, orthotopically, subcutaneously, nasally, by means of an implantable depot, using nanoparticle-based delivery systems, microneedle patch, microspheres, beads, osmotic or mechanical pumps, and/or other mechanical means.



**What is claimed:**

1. An anti-inflammatory composition comprising a peptide, wherein the peptide is 3 to 24 amino acid residues in length and comprises a striapathic region consisting of alternating hydrophilic and hydrophobic modules,
  - wherein each hydrophilic module consists of from 1 to 5 hydrophilic amino acid residues;
  - wherein each hydrophobic module consists of from 1 to 5 hydrophobic amino acid residues; and
  - wherein the peptide binds to the dimerization site on a NFkB Class II protein.
2. The anti-inflammatory composition of claim 1, wherein the alternating hydrophilic and hydrophobic modules are defined as  $X_m$  and  $Y_n$  modules, respectively,
  - wherein m and n are positive integers that identify different modules,
  - wherein each  $X_m$  module consists of a sequence according to the formula  $X_{ma}-X_{mb}-X_{mc}-X_{md}-X_{me}$ ,
    - wherein  $X_{ma}$  is selected from the group consisting of a naturally occurring hydrophilic amino acid, a non-naturally occurring hydrophilic amino acid, and a hydrophilic amino acid mimetic, and
    - wherein  $X_{mb}$ ,  $X_{mc}$ ,  $X_{md}$  and  $X_{me}$  are each individually absent or selected from the group consisting of a naturally occurring hydrophilic amino acid, a non-naturally occurring hydrophilic amino acid, and a hydrophilic amino acid mimetic,
    - wherein each  $Y_n$  module consists of a sequence according to the formula  $Y_{na}-Y_{nb}-Y_{nc}-Y_{nd}-Y_{ne}$ ,
      - wherein  $Y_{na}$  is selected from the group consisting of a naturally occurring hydrophobic amino acid, a non-naturally occurring hydrophobic amino acid, and a hydrophobic amino acid mimetic, and
      - wherein  $Y_{nb}$ ,  $Y_{nc}$ ,  $Y_{nd}$ , and  $Y_{ne}$  are each individually absent or selected from the group consisting of a naturally occurring hydrophobic, a non-naturally occurring hydrophobic amino acid, and a hydrophobic amino acid mimetic.
  - 3. The anti-inflammatory composition of claim 1 or 2, wherein the peptide also binds to human serum albumin.

4. The anti-inflammatory composition of any one of claims 1 to 3, wherein the striapathic region of the peptide contains at least two  $X_m$  modules ( $X_1$  and  $X_2$ ) and at least two  $Y_n$  modules ( $Y_1$  and  $Y_2$ ).
5. The anti-inflammatory composition of any one of claims 1 to 4, wherein the striapathic region of the peptide has a length of 7 to 12 amino acid residues.
6. The anti-inflammatory composition of any one of claims 1 to 5, wherein the striapathic region of the peptide:
  - (i) has an amphipathic conformation under physiological conditions;
  - (ii) has an amphipathic  $3_{10}$ -helical conformation, an amphipathic  $\alpha$ -helical conformation, or an amphipathic  $\pi$ -helical conformation when bound to the NFkB Class II protein;
  - (iii) contains hydrophobic amino acid residues having a total volume of at least 650 cubic angstroms;
  - (iv) is characterized by a ratio of the sum of the volume of hydrophobic amino acid residues to the sum of the volume of hydrophilic amino acid residues, wherein the ratio is at least 0.75 or higher;
  - (v) comprises at least one proline residue and adopts an amphipathic conformation that includes a proline-rich helix; or
  - (vi) adopts an amphipathic beta-strand conformation.
7. The anti-inflammatory composition of claim 6, wherein the amphipathic  $3_{10}$ -helical,  $\alpha$ -helical, or  $\pi$ -helical conformation includes a hydrophobic portion having a facial arc of at least  $100^\circ$ .
8. The anti-inflammatory composition of any one of claims 1 to 7, wherein the striapathic region comprises a sequence defined by a Formula selected from the group consisting of:

$Y_{1a}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}$  (Formula VII);

$X_{1a}-Y_{1a}-X_{2a}-X_{2b}-Y_{2a}-Y_{2b}-X_{3a}-X_{3b}-Y_{3a}-Y_{3b}$  (Formula XI);

$Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}-X_{3a}$  (Formula X);

$Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}-Y_{3b}$  (Formula IX);


$Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}$  (Formula I);

$Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}-X_{2a}-Y_{3a}-X_{3a}$	(Formula II);
$X_{2a}-Y_{3a}-X_{3a}-Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-Y_{2a}-Y_{2b}-Y_{2c}$	(Formula III);
$X_{1a}-X_{1b}-X_{1c}-Y_{2a}-X_{2a}-X_{2b}-X_{2c}$	(Formula IV);
$Y_{1a}-X_{1a}-X_{1b}-X_{1c}-Y_{2a}-X_{2a}-X_{2b}-X_{2c}-Y_{3a}-X_{3a}$	(Formula V);
$X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}$	(Formula VI);
$Y_{1a}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}-Y_{3b}-X_{3a}$	(Formula VIII);
$X_{1a}-Y_{1a}-Y_{1b}-X_{2a}-X_{2b}-Y_{2a}-Y_{2b}-X_{3a}-X_{3b}-Y_{3a}$	(Formula XII);
$Y_{1a}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-X_{2c}-Y_{3a}-Y_{3b}$	(Formula XIII);
$X_{1a}-X_{1b}-X_{1c}-Y_{1a}-Y_{1b}-X_{2a}-X_{2b}-Y_{2a}-Y_{2b}-Y_{2c}$	(Formula XIV);
$Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-X_{2c}$	(Formula XV);
$Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-X_{1c}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}$	(Formula XVI);
$Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}$	(Formula XVII);
$X_{1a}-Y_{1a}-Y_{1b}-X_{2a}-X_{2b}-Y_{2a}-Y_{2b}-X_{3a}$	(Formula XVIII);
$Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-Y_{3a}-Y_{3b}-X_{3a}$	(Formula XIX);
$X_{1a}-Y_{1a}-Y_{1b}-X_{2a}-Y_{2a}-Y_{2b}-X_{3a}-X_{3b}-Y_{3a}-Y_{3b}$	(Formula XX);
$Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-X_{2a}-X_{2b}-Y_{3a}-Y_{3b}$	(Formula XXI);
$X_{1a}-Y_{1a}-Y_{1b}-X_{2a}-X_{2b}-X_{2c}-Y_{2a}-X_{3a}-Y_{3a}-Y_{3b}$	(Formula XXII);
$Y_{1a}-Y_{1b}-X_{1a}-Y_{2a}-X_{2a}-X_{2b}-X_{2c}-Y_{3a}-Y_{3b}-X_{3a}$	(Formula XXIII);
$X_{1a}-X_{1b}-Y_{1a}-X_{2a}-Y_{2a}-X_{3a}-X_{3b}$	(Formula XXIV);
$Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1b}-Y_{2a}-X_{2a}-Y_{3a}-X_{3a}-X_{3b}$	(Formula XXV);
$X_{1a}-X_{1b}-Y_{1a}-X_{2a}-Y_{2a}-X_{3a}-X_{3b}-Y_{3a}-Y_{3b}-Y_{3c}$	(Formula XXVI);
$X_{1a}-X_{1b}-X_{1c}-Y_{1a}-Y_{1b}-Y_{1c}$	(Formula XXVII);
$X_{1a}-X_{1b}-X_{1c}-X_{1d}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}$	(Formula XXVIII);
$Y_{1a}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-Y_{2a}-Y_{2b}-Y_{2c}-Y_{2d}-X_{2a}$	(Formula XXIX);
$X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}$	(Formula XXX);
$Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-X_{1c}-Y_{2a}-Y_{2b}-Y_{2c}-X_{2a}-X_{2b}$	(Formula XXXI);
$X_{1a}-Y_{1a}-X_{2a}-Y_{2a}-X_{3a}-X_{3b}-X_{3c}-Y_{3a}-Y_{3b}-Y_{3c}$	(Formula XXXII);
$Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1b}-X_{1c}$	(Formula XXXIII);
$Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-X_{1a}-X_{1b}-X_{1c}-X_{1d}$	(Formula XXXIV);
$X_{1a}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-X_{2a}-X_{2b}-X_{2c}-X_{2d}-Y_{2a}$	(Formula XXXV);
$Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}$	(Formula XXXVI);

- $X_{1a}-X_{1b}-Y_{1a}-Y_{1b}-Y_{1c}-X_{2a}-X_{2b}-X_{2c}-Y_{2a}-Y_{2b}$  (Formula XXXVII);  
 $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1b}-X_{1c}-Y_{2a}-X_{2a}-Y_{3a}-X_{3a}$  (Formula XXXVIII);  
 $Y_{1a}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}$  (Formula XXXIX);  
 $Y_{1a}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}-Y_{2b}-Y_{2c}-Y_{2d}$  (Formula XL);  
 $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}-Y_{2b}-Y_{2c}$  (Formula XLI);  
 $Y_{1a}-Y_{1b}-Y_{1c}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}-Y_{2b}$  (Formula XLII);  
 $Y_{1a}-Y_{1b}-Y_{1c}-Y_{1e}-X_{1a}-X_{1b}-X_{1c}-X_{1d}-X_{1e}-Y_{2a}$  (Formula XLIII);  
 $X_{1a}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{2a}$  (Formula XLIV);  
 $X_{1a}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{2a}-X_{2b}-X_{2c}-X_{2d}$  (Formula XLV);  
 $X_{1a}-X_{1b}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{2a}-X_{2b}-X_{2c}$  (Formula XLVI);  
 $X_{1a}-X_{1b}-X_{1c}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{2a}-X_{2b}$  (Formula XLVII);  
 $X_{1a}-X_{1b}-X_{1c}-X_{1d}-Y_{1a}-Y_{1b}-Y_{1c}-Y_{1d}-Y_{1e}-X_{2a}$  (Formula XLVIII); and  
 $Y_{1a}-Y_{1b}-X_{1a}-Y_{2a}-Y_{2b}-X_{2a}-Y_{3a}-Y_{3b}-X_{3a}-Y_{4a}$  (Formula L).

9. The anti-inflammatory composition of claim 8, wherein  $Y_{1a}$ ,  $Y_{1b}$ ,  $Y_{1c}$ ,  $Y_{2a}$ ,  $Y_{2b}$ ,  $Y_{2c}$ ,  $Y_{3a}$ ,  $Y_{3b}$ , and  $Y_{3c}$  are each individually selected from the group consisting of Phe (F), Trp (W), Tyr (Y), Leu (L), Cys (C), Met (M), Val (V), Ile (I), and Ala (A) and  $X_{1a}$ ,  $X_{1b}$ ,  $X_{1c}$ ,  $X_{2a}$ ,  $X_{2b}$ ,  $X_{2c}$ ,  $X_{3a}$ , and  $X_{3b}$  are each individually selected from the group consisting of Arg (R), Lys (K), His (H), Asn (N), Gln (Q), Asp (D), and Glu (E).

10. The anti-inflammatory composition of any one of claims 1 to 9, wherein the striapathic region comprises a sequence defined by Formula VII:



11. The anti-inflammatory composition of claim 10, wherein the striapathic region comprises a sequence defined by a Formula selected from the group consisting of:

- $X_{1a}-Y_{1a}-X_{2a}-X_{2b}-Y_{2a}-Y_{2b}-X_{3a}-X_{3b}-Y_{3a}-Y_{3b}$  (Formula XI);  
 $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}-X_{3a}$  (Formula X); or  
 $Y_{1a}-Y_{1b}-X_{1a}-X_{1b}-Y_{2a}-Y_{2b}-X_{2a}-X_{2b}-Y_{3a}-Y_{3b}$  (Formula IX).

12. The anti-inflammatory composition of claim 11, wherein the striapathic region comprises, consists essentially of, or consists of a sequence selected from the group consisting of RP182 (SEQ ID NO: 121), RP398 (SEQ ID NO: 155), RP183, RP185, RP186 (SEQ ID NOs: 122 to 124, respectively), RP233 (SEQ ID NO: 148), RP261 (SEQ ID NO: 217), RP124, RP132, RP134, RP142, RP147, RP151, RP166, RP167, RP168, RP169, RP170, RP171, RP172, RP175, RP177 (SEQ ID NOs: 106 to 120, respectively), RP424, RP190, RP194, RP198, RP199, RP200, RP201, RP202, RP204, RP206, RP207, RP209, RP210, RP212, RP213, RP214, RP215, RP216, RP218, RP219, RP425, RP225, RP227 (SEQ ID NOs: 125 to 147, respectively), RP234, RP235, RP236, RP237, RP238, RP239, RP241, RP242, RP243, RP244, RP245, RP246, RP247, RP250, RP251, RP252, RP253, RP254, RP255, RP256, RP426 (SEQ ID NOs: 149-170, respectively).

13. The anti-inflammatory composition of claim 12, wherein the peptide comprises a striapathic region having at least 70% identity with the sequence KFRKAFKRFF (RP182, SEQ ID NO: 121).

14. The anti-inflammatory composition of claim 13, wherein:

(i) the differences between the striapathic region of the peptide and the sequence KFRKAFKRFF (SEQ ID NO: 121) are limited to conservative or highly conservative amino acid substitutions;

(ii) the striapathic region of the peptide differs from the sequence KFRKAFKRFF (SEQ ID NO: 121) by substitution of one or more of the phenylalanine (F) residues with an amino acid residue selected from the group consisting of Trp (W), Tyr (Y), and Leu (L);

(iii) the striapathic region of the peptide differs from the sequence KFRKAFKRFF (SEQ ID NO: 121) by the deletion of one, two, or three amino acids.

15. The anti-inflammatory composition of any one of claims 1 to 14, wherein the peptide binds to the dimerization site on Rel B (SEQ ID NO: 367) and wherein:

(i) the peptide binds with a binding energy of at least -650 kcal/mol;

(ii) the peptide directly contacts at least one amino acid residue of Rel B selected from the group consisting of Glu 298, Tyr-300, Leu-301, Leu-302, Asp-330, His-332, and Leu-371; or

(iii) the peptide, when bound to the dimerization site on Rel B, forms an ionic bond with Asp-330, forms an ionic bond with His-332, and/or makes a hydrophobic contact with Leu-371.

16. The anti-inflammatory composition of any one of claims 1 to 15, wherein the peptide binds to CD206 (SEQ ID NO: 379) and wherein:

(i) the peptide binds to the mannose-binding site on CD206 and/or interferes with or blocks the binding of SIRP-mannose to CD206;

(ii) the peptide binds with a binding energy of at least -650 kcal/mol; or

(iii) the peptide directly contacts at least one amino acid residue of CD206 selected from the group consisting of Phe-708, Thr-709, Trp-710, Pro-714, Glu-719, Asn-720, Trp-721, Ala-722, Glu-725, Tyr-729, Glu-733, Asn-747, Asp-748, Ser-1691, Cys-1693, Phe-1694, and Phe-1703.

17. The anti-inflammatory composition of any one of claims 1 to 15, wherein the peptide binds to at least one signaling molecule selected from the group consisting of TGF $\beta$  (SEQ ID NO: 368), Notch1 (SEQ ID NO: 369), Wnt8R (SEQ ID NO: 370), TRAIL (SEQ ID NO: 371), IL6R (SEQ ID NO: 372), IL10R (SEQ ID NO: 373), EGFR (SEQ ID NO: 374), CDK6 (SEQ ID NO: 375), Histone Methyl Transferase (HMT) (SEQ ID NO: 376), CD47 (SEQ ID NO: 377), SIRP- $\alpha$  (SEQ ID NO: 378), CD206 (SEQ ID NO: 379), TGM2 (SEQ ID NO: 380); LEGUMAIN (SEQ ID NO: 413), CD209 (SEQ ID NO: 414), FAS (SEQ ID NO: 415), PD-1 (SEQ ID NO: 416), MKK7 (SEQ ID NO: 417), and RNR (SEQ ID NO: 418).

18. The anti-inflammatory composition of any one of claims 1 to 17, wherein the composition further comprises a second peptide as defined in any one of claims 1 to 17, wherein the first and second peptides can have the same sequence or different sequences.

19. The anti-inflammatory composition of claim 18, wherein the first and second peptides are linked together by a peptide bond, a peptide linker, or a non-peptide linker.

20. The anti-inflammatory composition of any one of claims 1 to 19, wherein the composition is substantially free of protein other than (i) the peptide or (ii) the peptide and the second peptide.

21. A pharmaceutical composition comprising the anti-inflammatory composition of any one of claims 1 to 20 and a pharmaceutically acceptable carrier.

22. The pharmaceutical composition of claim 21, wherein the composition further comprises a chemotherapeutic agent or cell therapy.
23. The pharmaceutical composition of claim 22, wherein the chemotherapeutic agent or cell therapy is selected from the group consisting of steroids, anthracyclines, thyroid hormone replacement drugs, thymidylate-targeted drugs, checkpoint inhibitor drugs, Chimeric Antigen Receptor/T cell therapies, and other cell therapies.
24. The pharmaceutical composition of claim 23, wherein the chemotherapeutic agent is selected from the group consisting of Gemcitabine, Docetaxel, Bleomycin, Erlotinib, Gefitinib, Lapatinib, Imatinib, Dasatinib, Nilotinib, Bosutinib, Crizotinib, Ceritinib, Trametinib, Bevacizumab, Sunitinib, Sorafenib, Trastuzumab, Ado-trastuzumab emtansine, Rituximab, Ipilimumab, Rapamycin, Temsirolimus, Everolimus, Methotrexate, Doxorubicin, Abraxane, Folfirinox, Cisplatin, Carboplatin, 5-fluorouracil, Teysumo, Paclitaxel, Prednisone, Levothyroxine, and Pemetrexed.
25. A method of treating a condition associated with chronic inflammation, the method comprising administering a pharmaceutical composition according to any one of claims 21 to 24 to a subject suffering from the condition.
26. The method of claim 25, wherein the condition is selected from the group consisting of: irritable bowel disease, ulcerative colitis, colitis, Crohn's disease, idiopathic pulmonary fibrosis, asthma, keratitis, arthritis, osteoarthritis, rheumatoid arthritis, auto-immune diseases, a feline or human immunodeficiency virus (FIV or HIV) infection, cancer, pulmonary fibrosis, dermal fibrosis, hepatic fibrosis, renal fibrosis, and fibrosis caused by ionized radiation.
27. The method of claim 23 or 24, wherein the subject is a mammal.
28. The method of claim 27, wherein the subject is a human.
29. The method of any one of claims 25 to 28, wherein the method reduces the level of at least one pro-inflammatory cytokine selected from group consisting of TNF $\alpha$ , IL1, IL6, IL12, MMP-1, MMP-9, MCP-1, IL8, IL17, and IL23.

30. The method of claim 29, wherein the level of the at least one cytokine is reduced by at least 10%.
31. The method of any one of claims 25 to 30, wherein the anti-inflammatory composition is administered in conjunction with another drug known to be effective in treating the condition.
32. The method of claim 31, wherein the drug is a chemotherapeutic agent or cell therapy.
33. The method of claim 32, wherein the chemotherapeutic agent or cell therapy is selected from the group consisting of steroids, anthracyclines, thyroid hormone replacement drugs, thymidylate-targeted drugs, checkpoint inhibitor drugs, Chemeric Antigen Receptor/T cell therapies, and other cell therapies.
34. The method of claim 33, wherein the chemotherapeutic agent is selected from the group consisting of Gemcitabine, Docetaxel, Bleomycin, Erlotinib, Gefitinib, Lapatinib, Imatinib, Dasatinib, Nilotinib, Bosutinib, Crizotinib, Ceritinib, Trametinib, Bevacizumab, Sunitinib, Sorafenib, Trastuzumab, Ado-trastuzumab emtansine, Rituximab, Ipilimumab, Rapamycin, Temsirolimus, Everolimus, Methotrexate, Doxorubicin, Abraxane, Folfirinox, Cisplatin, Carboplatin, 5-fluorouracil, Teysumo, Paclitaxel, Prednisone, Levothyroxine, and Pemetrexed.



## DRAWING SHEET (1/14)

Figure 1





Figure 2



## DRAWING SHEET (2/14)

Figure 3





Figure 4



## DRAWING SHEET (3/14)

Figure 5





Figure 6



## DRAWING SHEET (4/14)

Figure 7






Figure 8




## DRAWING SHEET (5/14)

Figure 9



## DRAWING SHEET (6/14)

Figure 10



## DRAWING SHEET (7/14)

Figure 11





Figure 12



DRAWING SHEET (8/14)

Figure 13





Figure 14





DRAWING SHEET (9/14)

Figure 15






Figure 16




DRAWING SHEET (10/14)

**Figure 17**




**Figure 18**



DRAWING SHEET (11/14)


Figure 19



Anti-PD-1 antibody  
ABCAM ab 52587


# DRAWING SHEET (12/14)

## Figure 20




## DRAWING SHEET (13/14)

Figure 21



## DRAWING SHEET (14/14)

Figure 22



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US15/55380

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 38/08, 48/00; C07K 14/47 (2016.01)

CPC - A61K 38/08, 48/00; C07K 14/47

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): A61K 38/08, 48/00, 38/03; C07K 14/47 (2016.01)

CPC: A61K 38/08, 48/00; C07K 14/47

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatSeer (US, EP, WO, JP, DE, GB, CN, FR, KR, ES, AU, IN, CA, INPADOC Data); Google/Google Scholar, PubMed, EBSCO; striapathic, hydrophilic, hydrophobic, peptide, 'anti-inflammatory,' amphipatic, 'beta sheet,' 'NFkappaB,' 'NFkappaB Class II protein'

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WANG, YF et al. A Cell-Penetrating Peptide Suppresses Inflammation By Inhibiting NF-kappa-Beta Signaling. Molecular Therapy. 10 May 2011, Vol. 19, No. 10; pages 1849-1857; abstract; DOI:10.1038/mt.2011.82.	1, 2 ----- 3/1, 3/2
Y	WO 2005/046714 A2 (ARES TRADING S.A.) May 26, 2005; page 16, lines 25-29	3/1, 3/2
A	PARK, HJ et al. Melittin Inhibits Inflammatory Target Gene Expression and Mediator Generation Via Interaction With IkappaB Kinase. Biochemical Pharmacology. 29 September 2006, Vol. 73, No. 2; pages 237-247. DOI:10.1016/j.bcp.2006.09.023.	1-3

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

19 January 2016 (19.01.2016)

Date of mailing of the international search report

02 FEB 2016

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US15/55380

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 4-34  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.